

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07H 21/04, C07K 1/00, C12P 21/06	A2	(11) International Publication Number: WO 00/55177 (43) International Publication Date: 21 September 2000 (21.09.00)
(21) International Application Number: PCT/US00/06058 (22) International Filing Date: 9 March 2000 (09.03.00) (30) Priority Data: 60/124,145 12 March 1999 (12.03.99) US 60/168,654 3 December 1999 (03.12.99) US (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Laytonsville, MD 20882 (US). KOMAT-SOULIS, George [US/US]; 9518 Garwood Street, Silver Spring, MD 20901 (US). (74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With declaration under Article 17(2)(a); without abstract; title not checked by the International Searching Authority.</i>
(54) Title: 49 HUMAN SECRETED PROTEINS		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

49 Human Secreted Proteins

Field of the Invention

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

Background of the Invention

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of

the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using secreted proteins or the genes that encode them.

5

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders and conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such disorders and conditions. The invention further relates to screening methods for identifying binding partners of the polypeptides.

10

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

25
30

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released
5 into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000
10 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding
15 sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid
20 sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants
25 of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig
30 analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the

ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

- 5 A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC
10 (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

- Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions.
15 Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl;
20 0.2M NaH_2PO_4 ; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

- 25 Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking
30 reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of

ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Many proteins (and translated DNA sequences) contain regions where the amino acid composition is highly biased toward a small subset of the available

residues. For example, membrane spanning domains and signal peptides (which are also membrane spanning) typically contain long stretches where Leucine (L), Valine (V), Alanine (A), and Isoleucine (I) predominate. Poly-Adenosine tracts (polyA) at the end of cDNAs appear in forward translations as poly-Lysine (poly-K) and poly-Phenylalanine (poly-F) when the reverse complement is translated. These regions are often referred to as “low complexity” regions.

Such regions can cause database similarity search programs such as BLAST to find high-scoring sequence matches that do not imply true homology. The problem is exacerbated by the fact that most weight matrices (used to score the alignments generated by BLAST) give a match between any of a group of hydrophobic amino acids (L,V and I) that are commonly found in certain low complexity regions almost as high a score as for exact matches.

In order to compensate for this, BLASTX.2 (version 2.0a5MP-WashU) employs two filters (“seg” and “xnu”) which “mask” the low complexity regions in a particular sequence. These filters parse the sequence for such regions, and create a new sequence in which the amino acids in the low complexity region have been replaced with the character “X”. This is then used as the input sequence (sometimes referred to herein as “Query” and/or “Q”) to the BLASTX program. While this regime helps to ensure that high-scoring matches represent true homology, there is a negative consequence in that the BLASTX program uses the query sequence that has been masked by the filters to draw alignments.

Thus, a stretch of “X”s in an alignment shown in the following application does not necessarily indicate that either the underlying DNA sequence or the translated protein sequence is unknown or uncertain. Nor is the presence of such stretches meant to indicate that the sequence is identical or not identical to the sequence disclosed in the alignment of the present invention. Such stretches may simply indicate that the BLASTX program masked amino acids in that region due to the detection of a low complexity region, as defined above. In all cases, the reference sequence(s) (sometimes referred to herein as “Subject”, “Sbjct”, and/or “S”) indicated in the specification, sequence table (Table 1), and/or the deposited clone is (are) the definitive embodiment(s) of the present invention, and should not be construed as

limiting the present invention to the partial sequence shown in an alignment, unless specifically noted otherwise herein.

Polynucleotides and Polypeptides of the Invention

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

It has been discovered that this gene is expressed primarily in the following tissues: Soares fetal liver spleen 1NFLS and to a lesser extent in Soares placenta Nb2HP, Hepatocellular Tumor; re-excision, Human Placenta, Human Osteoclastoma, 10 Soares_multiple_sclerosis_2NbHMSP, Soares_placenta_8to9weeks_2NbHP8to9W, Human Amygdala, Soares_fetal_lung_NbHL19W, Adrenal Gland,normal, Soares adult brain N2b4HB55Y, Hepatocellular Tumor, Human Stomach;re-excision, Salivary Gland, Lib 2, Human Activated T-Cells, Pancreas Islet Cell Tumor, Gessler Wilms tumor, Human adult lung 3' directed MboI cDNA, Fetal Heart, 15 NCI_CGAP_AA1, NCI_CGAP_Br2, NCI_CGAP_Lu5, NCI_CGAP_Kid5, Nine Week Old Early Stage Human.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of 20 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1191 of SEQ ID NO:11, b 25 is an integer of 15 to 1205, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

30 It has been discovered that this gene is expressed primarily in the following tissues: Synovial Fibroblasts (III/TNF), subt and to a lesser extent in Soares_multiple_sclerosis_2NbHMSP, 12 Week Old Early Stage Human, II,

Soares_pregnant_uterus_NbHPU, Human Amygdala, Human Fetal Brain, normalized
 50021F, normalized A5002F, Human White Fat, Human Frontal Cortex,
 Schizophrenia, Human Osteoclastoma, re-excision, Ulcerative Colitis,
 Soares_NhHMPu_S1, Human Thymus Stromal Cells, Bone Marrow Stromal Cell,
 5 untreated, H. Frontal cortex,epileptic;re-excision, 12 Week Old Early Stage Human,
 Human Eosinophils, Human Bone Marrow, treated, Nine Week Old Early Stage
 Human.

Many polynucleotide sequences, such as EST sequences, are publicly
 available and accessible through sequence databases. Some of these sequences are
 10 related to SEQ ID NO:12 and may have been publicly available prior to conception of
 the present invention. Preferably, such related polynucleotides are specifically
 excluded from the scope of the present invention. To list every related sequence
 would be cumbersome. Accordingly, preferably excluded from the present invention
 are one or more polynucleotides comprising a nucleotide sequence described by the
 15 general formula of a-b, where a is any integer between 1 to 1830 of SEQ ID NO:12, b
 is an integer of 15 to 1844, where both a and b correspond to the positions of
 nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a
 + 14.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 3

It has been discovered that this gene is expressed primarily in Human
 Amygdala.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.
 62 as residues: Asn-34 to Gly-39.

25 Many polynucleotide sequences, such as EST sequences, are publicly
 available and accessible through sequence databases. Some of these sequences are
 related to SEQ ID NO:13 and may have been publicly available prior to conception of
 the present invention. Preferably, such related polynucleotides are specifically
 excluded from the scope of the present invention. To list every related sequence
 30 would be cumbersome. Accordingly, preferably excluded from the present invention
 are one or more polynucleotides comprising a nucleotide sequence described by the
 general formula of a-b, where a is any integer between 1 to 1256 of SEQ ID NO:13, b

is an integer of 15 to 1270, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 4

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. bbsl129340 (all information available through the recited accession number is
10 incorporated herein by reference) which is described therein as "X-linked retinopathy protein." A partial alignment demonstrating the observed homology is shown immediately below.

```

15 >bbsl129340 X-linked retinopathy protein (C-terminal, clone XEH.8c)
(human, Peptide Partial, 100 aa) [Homo sapiens] >pir|A46010|A46010 X-
linked retinopathy protein (C-terminal, clone XEH.8c) - human
(fragment) Length = 100
20 Minus Strand HSPs:
Score = 168 (59.1 bits), Expect = 2.4e-11, P = 2.4e-11
25 Identities = 39/71 (54%), Positives = 47/71 (66%), Frame = -2
Query: 1236 FFFFETESHVPAQAGVQWHDLGSLQSLPPRFKRFPNLSLPSS*QYKCAHHNRVIFVFLV
1057
      FFFFETES VA+AGVQW DLGSL+S PP      P + +      HH ++IFVFLV
30 Sbct: 2 FFFFETESCSVAEAGVQWCDLGSLKSPPGSSDSPASASRVAGITGMHHHTQLIFVFLV
61
Query: 1056 ETGFSHVGQAD 1024
      ETG SH+ +D
35 Sbct: 62 ETG-SHMLSD 71

```

The segment of bbsl129340 that is shown as "Sbct" above is set out as sequence(s) SEQ ID NO. 109. Based on the structural similarity these homologous
40 polypeptides are expected to share at least some biological activities. Such activities are known in the art and described elsewhere herein. Assays for determining such activities are also known in the art some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise polypeptides having the amino acid sequence(s) set out as SEQ ID NO. 110 which correspond to the Query

sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues: KMH2, L428. When tested against both Jurkat T-cells and U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates both T-cells and myeloid cells, and to a lesser extent other immune cells, through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 63 as residues: Leu-33 to Asp-38.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1223 of SEQ ID NO: 14, b is an integer of 15 to 1237, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 14, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 5

It has been discovered that this gene is expressed primarily in L428 cells, which are derived from Hodgkin's lymphoma cells.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2168 of SEQ ID NO:15, b is an integer of 15 to 2182, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 6

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil1872200 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "MYB PROTO-ONCOGENE PROTEIN." A partial alignment demonstrating the observed homology is shown immediately below.

```

>gi|1872200 alternatively spliced product using exon 13A [Homo sapiens]
>sp|P78525|P78525 MYB PROTO-ONCOGENE PROTEIN (C-MYB).
Length = 666

Plus Strand HSPs:

Score = 265 (93.3 bits), Expect = 1.1e-19, P = 1.1e-19
Identities = 61/95 (64%), Positives = 64/95 (67%), Frame = +3

Query:   843 TESCSVAQA--GVQWHDLSSLQAPPPGFMPFSCLSLPSSWDYRLPLPYLANFFVVLVEMG
1016
      T++ VA A GVQWHD SLQ PPGF FSCLSLP SWDYR P P ANF LVE G
Sbjct:   557 TQTSPVADAPTGVQWHDGSLQPLPPGFKRFSCLSLPRSWDYRHPPRPANF-EFLVETG
615

Query:   1017 FHHISQDGLNLLTS*SARL-ASQSAGITGVSHLARP 1121
      F H+ Q GL LLTS ASQSA ITGVSH ARP
Sbjct:   616 FLHVGQAGLELLTSGDLPASASQSARITGVSHRARP 651

```

The segment of gil1872200 that is shown as "Sbjct" above is set out as sequence(s) SEQ ID NO. 111. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities

are known in the art and described elsewhere herein. Assays for determining such activities are also known in the art some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise polypeptides having the amino acid sequence(s) set out as SEQ ID NO. 112 which correspond to the Query
 5 sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues: Human Adult Pulmonary.

Many polynucleotide sequences, such as EST sequences, are publicly
 10 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
 15 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1571 of SEQ ID NO:16, b is an integer of 15 to 1585, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 7

It has been discovered that this gene is expressed primarily in the following tissues: Soares fetal liver spleen INFLS and to a lesser extent in Soares placenta Nb2HP, Human Endometrial Tumor, Keratinocyte, Primary Dendritic Cells, lib 1,
 25 Stratagene placenta (#937225), Stratagene NT2 neuronal precursor 937230, Endothelial-induced, Activated T-cell(12h)/Thiouridine-re-excision, Amniotic Cells - TNF induced, Breast Lymph node cDNA library, Amniotic Cells - Primary Culture, H. Lymph node breast Cancer, Macrophage-oxLDL, Stratagene NT2 neuronal precursor 937230, Soares breast 2NbHBst, Macrophage (GM-CSF treated),
 30 Macrophage-oxLDL; re-excision, Human Placenta, Soares melanocyte 2NbHM, human tonsils, Endothelial cells-control, Monocyte activated, Human Pancreatic Langerhans, Normal trachea, Tongue Normal, Prostate, A1-CELL LINE, L1 Cell line,

Stratagene neuroepithelium (#937231). Human Umbilical Vein Endothelial Cells, fract. A, Aorta endothelial cells + TNF- α . Human adult small intestine.re-excision, Hepatocellular Tumor, pBMC stimulated w/ poly I/C, NTERA2 + retinoic acid, 14 days, Human Stomach;re-excision, Healing groin wound, 6.5 hours post incision,

5 NCI_CGAP_Co3, NCI_CGAP_GC2, NCI_CGAP_Pr1, Human Umbilical Vein; Reexcision, Prostate BPH, Stratagene colon (#937204), Stratagene NT2 neuronal precursor 937230, Human Thymus, Human Fetal Dura Mater, Human Uterine Cancer, Merkel Cells, Human Hypothalamus, Schizophrenia, Human Pancreas Tumor; Reexcision, Liver, Hepatoma, Soares adult brain N2b5HB55Y, Epithelial-TNF α and

10 INF induced, Human Testes Tumor, re-excision, Stratagene colon (#937204), Human Whole Six Week Old Embryo, Stratagene liver (#937224), PC3 Prostate cell line, Soares_total_fetus_Nb2HF8_9w, Fetal Heart, Resting T-Cell Library, II, Colon Carcinoma, NCI_CGAP_GCB1, Breast Lymph node cDNA library, H Macrophage (GM-CSF treated), re-excision, Dendritic cells, pooled, Primary Dendritic cells, frac 2,

15 Human Fetal Lung III, Human Placenta, Bone marrow, Human Fetal Heart, Human Adult Pulmonary;re-excision, Human Bone Marrow, treated, Human 8 Week Whole Embryo, Soares_fetal_heart_NbHH19W.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

20 related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

25 general formula of a-b, where a is any integer between 1 to 1874 of SEQ ID NO:17, b is an integer of 15 to 1888, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

30 **FEATURES OF PROTEIN ENCODED BY GENE NO: 8**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting

example, the sequence accessible through the following database accession no. gil288145 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "put. ORF [Homo sapiens]." A partial alignment demonstrating the observed homology is shown
 5 immediately below.

```

    >gi|288145 put. ORF [Homo sapiens] >pir|I38022|I38022 hypothetical protein
    -
    human >sp|Q29976|Q29976 MAHLAVU HEPATOCELLULAR CARCINOMA HHC(M)
10  DNA.
        Length = 196

        Minus Strand HSPs:
15  Score = 267 (94.0 bits), Expect = 4.5e-22, P = 4.5e-22
        Identities = 55/80 (68%), Positives = 60/80 (75%), Frame = -2

        Query:   245 HLRSGVQDQLGQHG*SPSLKLVQKLAWHGGMHL*FQLLGRLRQENCLSPGGEGCSEPRSH
20  66          HLRSGVQD  GQHG  PSLK+Q+LA HGG  L  QLL RLRQEN L+ GG GCSEP+SH
        Sbjct:   3  HLRSGVQDYPGQHGKIPSLKIQELAGHGGRCLQSQLLRRLRQENHLNSGGRGCEPKSH
        62

        Query:   65 RCTPAWATE*DSVTK*NINK 6
25          C PAW TE DSV+K N K
        Sbjct:   63 LCIPAWVTEGDSVSKQNKTK 82
  
```

The segment of gil288145 that is shown as "Sbjct" above is set out as sequence(s) SEQ ID NO. 113. Preferred polypeptides of the invention comprise
 30 polypeptides having the amino acid sequence(s) set out as SEQ ID NO. 114 which correspond to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in Human Adult Pulmonary;re-excision.

35 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence
 40 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1366 of SEQ ID NO:18, b

is an integer of 15 to 1380, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 9

It has been discovered that this gene is expressed primarily in the following tissues: Amniotic Cells - Primary Culture and to a lesser extent in breast lymph node CDNA library, Smooth muscle, control; re-excision, Myeloid Progenitor Cell Line, Macrophage-oxLDL, PERM TF274, Hemangiopericytoma, NCI_CGAP_Pr5,
10 NCI_CGAP_Pr22, Human Testes, Reexcision, Soares placenta Nb2HP.

When tested against fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates fibroblast cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various
15 tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 68 as residues: Trp-10 to Lys-18, Val-32 to Cys-38, Asp-41 to Thr-47.

Many polynucleotide sequences, such as EST sequences, are publicly
20 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
25 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1034 of SEQ ID NO:19, b is an integer of 15 to 1048, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

30

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnllPID|d1035484 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "KIAA0783 protein." A partial alignment demonstrating the observed homology is shown immediately below.

```
10 >gnl|PID|d1035484 (AB018326) KIAA0783 protein [Homo sapiens]
    >sp|D1035484|D1035484 KIAA0783 PROTEIN.
    Length = 888

    Plus Strand HSPs:

15 Score = 1950 (686.4 bits), Expect = 4.5e-265, Sum P(2) = 4.5e-265
    Identities = 374/393 (95%), Positives = 374/393 (95%), Frame = +1

    Query:   361 AYCKQHADRDRKWKRNLYLALQSYCKMSLQEREKQLSPEAQARINARLQQYRAKAELAR
540
20           AYCKQHADRDRKWKRNLYLALQSYCKMSLQEREKQLSPEAQARINARLQQYRAKAELAR
    Sbjet:   493 AYCKQHADRDRKWKRNLYLALQSYCKMSLQEREKQLSPEAQARINARLQQYRAKAELAR
552

    Query:   541 STRPQAWVPREKLPRPLTSSASAIRKLMRKAELMGISTDIFPVDNSDTSSSVDRGRKHQ
25 720
           STRPQAWVPREKLPRPLTSSASAIRKLMRKAELMGISTDIFPVDNSDTSSSVDRGRKHQ
    Sbjet:   553 STRPQAWVPREKLPRPLTSSASAIRKLMRKAELMGISTDIFPVDNSDTSSSVDRGRKHQ
612

    Query:   721 PALTADFNYYFERNMRMIQIQENMAEQKNIKDKLENEQEKLHVEYNKLCESLEELQNLN
30 900
           PALTADFNYYFERNMRMIQIQENMAEQKNIKDKLENEQEKLHVEYNKLCESLEELQNLN
    Sbjet:   613 PALTADFNYYFERNMRMIQIQENMAEQKNIKDKLENEQEKLHVEYNKLCESLEELQNLN
35 672

    Query:   901 GKLRSEGQGIWALLGRITGQKLNIPAILRAPKERKPSKKEGGTQKTSTLPAVLYSCGICK
40 1080
           GKLRSEGQGIWALLGRITGQKLNIPAILRAPKERKPSKKEGGTQKTSTLPAVLYSCGICK
    Sbjet:   673 GKLRSEGQGIWALLGRITGQKLNIPAILRAPKERKPSKKEGGTQKTSTLPAVLYSCGICK
732

    Query:   1081 KNHDQHLLLLCDTCKLHYHLGCLDPPLTRMPRKTKNSYWQCSECDQAGSSDMEADMAMET
1260
           KNHDQHLLLLCDTCKLHYHLGCLDPPLTRMPRKTKNSYWQCSECDQAGSSDMEADMAMET
45 Sbjet:   733 KNHDQHLLLLCDTCKLHYHLGCLDPPLTRMPRKTKNSYWQCSECDQAGSSDMEADMAMET
792

    Query:   1261 LPDGTKRSRRQIKEPVKFVPQDVPPEPKKIPINRTRTRGRKRSFXXXXXXXXXXXXXXXXXX
50 1440
           LPDGTKRSRRQIKEPVKFVPQDVPPEPKKIPINRTRTRGRKRSF
    Sbjet:   793 LPDGTKRSRRQIKEPVKFVPQDVPPEPKKIPINRTRTRGRKRSFVPEEEKHEERVPRERR
852

    Query:   1441 XXXSVLQKKPKAEDLRTECATCKGTGDNENLVR 1539
55           SVLQKKPKAEDLRTECATCKGTGDNENLVR
    Sbjet:   853 QRQSVLQKKPKAEDLRTECATCKGTGDNENLVR 885
```

```

5      Query:      17 KCGVSPSCELCPNQDGIFKETDAGRWHIVCALYVPGVAFGDIKLRPVTLTEMNYSKYG
      196
      KCGVSPSCELCPNQDGIFKETDAGRWHIVCALYVPGVAFGDIKLRPVTLTEMNYSKYG
      Sbjct:      378 KCGVSPSCELCPNQDGIFKETDAGRWHIVCALYVPGVAFGDIKLRPVTLTEMNYSKYG
      437

10     Query:      197 AKECSFCEDPRFARTGVCISCDAGMCRAVFHVTCQAQKEGLLSEAAAEEDIADPF 358
      AKECSFCEDPRFARTGVCISCDAGMCRAVFHVTCQAQKEGLLSEAAAEEDIADPF
      Sbjct:      438 AKECSFCEDPRFARTGVCISCDAGMCRAVFHVTCQAQKEGLLSEAAAEEDIADPF 491

      Score = 157 (55.3 bits), Expect = 1.4e-75, Sum P(2) = 1.4e-75
      Identities = 28/79 (35%), Positives = 41/79 (51%), Frame = +1

15     Query:      1495 CATCKGTGDNENLVRCDCECLCYHFGCLDPPLKSPKQTGYG-WICQECDSSSSSKEDENE
      1671
      C CK D L+ CD C+L YH GCLDPPL + P++T W C ECD + S + E +
20     Sbjct:      728 CGICKKNHNDQHLLLLCDTCKLHYHLGCLDPPLTRMPRKTKNSYWQCSECDQAGSSDMEAD
      787

      Query:      1672 AERKNISQELNMEQKNPKK 1728
      + + ++ K+
25     Sbjct:      788 MAMETLDPDGTKRSRRIQKE 806

```

The segment of gnl|PID|1035484 that is shown as "Sbjct" above is set out as sequence(s) SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID NO. 119. Preferred polypeptides of the invention comprise polypeptides having the amino acid sequence(s) set out as SEQ ID NO. 116, SEQ ID NO. 118, SEQ ID NO. 120 which correspond to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues: Soares_fetal_liver_spleen_1NFLS_S1, NCI_CGAP_Pr12 and to a lesser extent in Morton Fetal Cochlea, Soares_pregnant_uterus_NbHPU, Stratagene pancreas (#937208), HEL cell line, Human Synovium, Human Prostate Cancer, Stage C fraction, Amniotic Cells - Primary Culture, Healing groin wound, 6.5 hours post incision, Soares_NhHMPu_S1, Synovial hypoxia, NTERA2, control, Human adult (K.Okubo), NCI_CGAP_Lu6, NCI_CGAP_GCB1, NCI_CGAP_Pr22, Colon Carcinoma, Colon Normal II, Human Placenta, Nine Week Old Early Stage Human, Soares infant brain 1NIB.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1868 of SEQ ID NO:20, b is an integer of 15 to 1882, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 11

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. bbsl129340 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "X-linked retinopathy protein." A partial alignment demonstrating the observed homology is shown immediately below.

```

>bbsl129340 X-linked retinopathy protein (C-terminal, clone XEH.8c)
[human,
Peptide Partial, 100 aa] [Homo sapiens] >pir|A46010|A46010 X-
linked
retinopathy protein (C-terminal, clone XEH.8c) - human
(fragment)
Length = 100

Plus Strand HSPs:

Score = 99 (34.8 bits), Expect = 2.3e-12, Sum P(3) = 2.3e-12
Identities = 19/26 (73%), Positives = 22/26 (84%), Frame = +2

Query: 44 ETESHVVQAGVQWRNLGSLQPPPPG 121
      ETES SV +AGVQW +LGSL+ PPPG
Sbjct: 7 ETESCSVAEAGVQWCDLGSLKSPPPG 32

Score = 61 (21.5 bits), Expect = 2.3e-12, Sum P(3) = 2.3e-12
Identities = 13/17 (76%), Positives = 14/17 (82%), Frame = +3

Query: 120 GSSDSPASXF*VAGVTG 170
      GSSDSPAS VAG+TG
Sbjct: 32 GSSDSPASASRVAGITG 48

Score = 60 (21.1 bits), Expect = 3.7e-08, Sum P(2) = 3.7e-08
Identities = 14/26 (53%), Positives = 16/26 (61%), Frame = +1

Query: 265 DLPTSASPSAGITGVSHCARLTVSFL 342
      D P SAS AGITG+ H +L FL
Sbjct: 35 DSPASASRVAGITGMHHHTQLIFVFL 60

```

Score = 55 (19.4 bits), Expect = 2.3e-12, Sum P(3) = 2.3e-12
 Identities = 11/16 (68%), Positives = 12/16 (75%), Frame = +1

5 Query: 178 HHTRLIFVFLVGMRFH 225
 HHT+LIFVFLV H
 Sbjct: 51 HHTQLIFVFLVETGSH 66

The segment of bbsl129340 that is shown as "Sbjct" above is set out as
 10 sequence(s) SEQ ID NO. 121,SEQ ID NO. 123,SEQ ID NO. 125,SEQ ID NO. 127.
 Based on the structural similarity these homologous polypeptides are expected to
 share at least some biological activities. Such activities are known in the art and
 described elsewhere herein. Assays for determining such activities are also known in
 the art some of which have been described elsewhere herein. Preferred polypeptides
 15 of the invention comprise polypeptides having the amino acid sequence(s) set out as
 SEQ ID NO. 122,SEQ ID NO. 124,SEQ ID NO. 126,SEQ ID NO. 128 which
 correspond to the Query sequence in the alignment shown above (gaps introduced in
 the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in Human Adult
 20 Retina.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.
 70 as residues: Pro-52 to Cys-57.

Many polynucleotide sequences, such as EST sequences, are publicly
 available and accessible through sequence databases. Some of these sequences are
 25 related to SEQ ID NO:21 and may have been publicly available prior to conception of
 the present invention. Preferably, such related polynucleotides are specifically
 excluded from the scope of the present invention. To list every related sequence
 would be cumbersome. Accordingly, preferably excluded from the present invention
 are one or more polynucleotides comprising a nucleotide sequence described by the
 30 general formula of a-b, where a is any integer between 1 to 1231 of SEQ ID NO:21, b
 is an integer of 15 to 1245, where both a and b correspond to the positions of
 nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a
 + 14.

35 **FEATURES OF PROTEIN ENCODED BY GENE NO: 12**

It has been discovered that this gene is expressed primarily in Human Amygdala.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 796 of SEQ ID NO:22, b is an integer of 15 to 810, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 13**

It has been discovered that this gene is expressed primarily in the following tissues: Human Amygdala.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1661 of SEQ ID NO:23, b is an integer of 15 to 1675, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

30 **FEATURES OF PROTEIN ENCODED BY GENE NO: 14**

It has been discovered that this gene is expressed primarily in the following tissues: Soares_NhHMPu_S1, Human Amygdala.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 73 as residues: Pro-20 to Cys-30.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1055 of SEQ ID NO:24, b is an integer of 15 to 1069, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 15**

It has been discovered that this gene is expressed primarily in the following tissues: Human Fetal Brain, Infant brain, Bento Soares and to a lesser extent in Soares infant brain 1NIB, Soares adult brain N2b4HB55Y, H. Kidney Cortex, subtracted, re-rescue, random primed, Frontal Lobe, Dementia, Human Cerebellum, subtracted, Human Amygdala;re-excision, NCI_CGAP_GC3, Stratagene NT2 neuronal precursor 937230, normalized infant brain cDNA, Human Hypothalamus,schizophrenia, re-excision, NTERA2 + retinoic acid, 14 days, Human Manic Depression Tissue, Brain frontal cortex, Endothelial cells-control, Human Amygdala, Smooth muscle,control.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1461 of SEQ ID NO:25, b is an integer of 15 to 1475, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

5 It has been discovered that this gene is expressed primarily in the following tissues: Glioblastoma, Endothelial cells-control, Human Amygdala, Soares infant brain INIB.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 917 of SEQ ID NO:26, b is an integer of 15 to 931, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 17

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil2197085 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "ORF2-like protein." A partial alignment demonstrating the observed homology is shown immediately below.

30 >gi|2197085 (AF003535) ORF2-like protein [Homo sapiens]
Length = 573

Plus Strand HSPs:

35 Score = 187 (65.8 bits), Expect = 6.1e-24, Sum P(3) = 6.1e-24
Identities = 34/48 (70%), Positives = 39/48 (81%), Frame = +2

5 Query: 605 KRSIHHDQVRFIPGXQGWFNINKSINVINHTSKVKGKNHMIITDAKK 748
 K+ IHHDQV FIPG QGWFNI KSINVI H ++ K KNHMII+ DA+K
 Sbjct: 70 KKLIHHDQVGFIPGMQGWFNIRKSINVIQHINRAKDKNHMIISIDAEK 117

 Score = 81 (28.5 bits), Expect = 6.1e-24, Sum P(3) = 6.1e-24
 Identities = 15/23 (65%), Positives = 18/23 (78%), Frame = +3

10 Query: 459 LPNSFYDVGITLIPKRDKDTTRK 527
 LPNSFY+ I LIPK +DTT+K
 Sbjct: 19 LPNSFYEASII LIPKPGRDTTKK 41

 Score = 77 (27.1 bits), Expect = 6.1e-24, Sum P(3) = 6.1e-24
 Identities = 17/26 (65%), Positives = 20/26 (76%), Frame = +1

15 Query: 514 TLQENYRSISLMNXYAKILXKILTNO 591
 T +EN+R ISLMN AKIL KIL N+
 Sbjct: 39 TKKENFRPISLMNIDAKILNKILANR 64

20 The segment of gil2197085 that is shown as "Sbjct" above is set out as
 sequence(s) SEQ ID NO. 129, SEQ ID NO. 131, SEQ ID NO. 133. Preferred
 polypeptides of the invention comprise polypeptides having the amino acid
 sequence(s) set out as SEQ ID NO. 130, SEQ ID NO. 132, SEQ ID NO. 134 which
 correspond to the Query sequence in the alignment shown above (gaps introduced in
 25 the sequence by the computer are, of course, removed).

 It has been discovered that this gene is expressed primarily in Human
 Amygdala.

 Many polynucleotide sequences, such as EST sequences, are publicly
 available and accessible through sequence databases. Some of these sequences are
 30 related to SEQ ID NO:27 and may have been publicly available prior to conception of
 the present invention. Preferably, such related polynucleotides are specifically
 excluded from the scope of the present invention. To list every related sequence
 would be cumbersome. Accordingly, preferably excluded from the present invention
 are one or more polynucleotides comprising a nucleotide sequence described by the
 35 general formula of a-b, where a is any integer between 1 to 897 of SEQ ID NO:27, b
 is an integer of 15 to 911, where both a and b correspond to the positions of
 nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a
 + 14.

40 FEATURES OF PROTEIN ENCODED BY GENE NO: 18

It has been discovered that this gene is expressed primarily in the following tissues: Human Amygdala;re-excision. Endothelial cells-control.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1683 of SEQ ID NO:28, b is an integer of 15 to 1697, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 19**

It has been discovered that this gene is expressed primarily in Human Amygdala;re-excision.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1128 of SEQ ID NO:29, b is an integer of 15 to 1142, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

30 **FEATURES OF PROTEIN ENCODED BY GENE NO: 20**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting

example, the sequence accessible through the following database accession no. gil347314 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "hnRNP H [Homo sapiens]." A partial alignment demonstrating the observed homology is shown

5 immediately below.

```

10      >gi|347314 hnRNP H [Homo sapiens] >pir|I39358|I39358 49K protein - human
      >sp|P31943|ROH1_HUMAN HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN H
      (HNRNP H).
      Length = 449

      Plus Strand HSPs:

15      Score = 464 (163.3 bits), Expect = 6.8e-78, Sum P(3) = 6.8e-78
      Identities = 88/113 (77%), Positives = 99/113 (87%), Frame = +2

      Query:   140 QAFKSNNGIEMDWMKHNGPND---ASDGTVRLRGLPFGCSKEEIVQFFQGLEIVPNGITL
310
      + FKSN +EMDWV+KH GPN      A+DG VRLRGLPFGCSKEEIVQFF GLEIVPNGITL
20      Sbjct:   84 EVFKSNNVEMDWVLKHTGPNSPDTANDGFVRLRGLPFGCSKEEIVQFFSGLEIVPNGITL
143

      Query:   311 TMDYQGRSTGEAFVQFASKEIAENALGKHKERIGHRYIEIFRSSRSEIKGFYD 469
      +D+QGRSTGEAFVQFAS+EIAE AL KHKERIGHRYIEIF+SSR+E++ YD
25      Sbjct:  144 PVDFQGRSTGEAFVQFASQEIAEKALKKKKERIGHRYIEIFKSSRAEVRTHYD 196

```

The segment of gil347314 that is shown as "Sbjct" above is set out as sequence(s) SEQ ID NO. 135. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art and described elsewhere herein. Assays for determining such activities are also known in the art some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise polypeptides having the amino acid sequence(s) set out as SEQ ID NO. 136 which correspond to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues: Soares fetal liver spleen 1NFLS and to a lesser extent in Nine Week Old Early Stage Human, Stromal cell TF274, Stratagene colon (#937204), Osteoblasts, Human 8 Week Whole Embryo, Resting T-Cell Library,II, Primary Dendritic Cells, lib 1, Soares_NhHMPu_S1, Stratagene muscle 937209, Stratagene HeLa cell s3

- 937216, Human Ovarian Cancer Reexcision, Macrophage (GM-CSF treated), 12 Week Old Early Stage Human, Stratagene colon (#937204), Stratagene fibroblast (#937212), Smooth muscle, control, Human Testes, Soares_NhHMPu_S1, Stratagene HeLa cell s3 937216, Soares_parathyroid_tumor_NbHPA,
- 5 Soares_multiple_sclerosis_2NbHMSP. Soares_NhHMPu_S1, Soares infant brain INIB, H. Kidney Pyramid, subtracted. Human Bone Marrow, Human B Cell 8866, Human Fibrosarcoma. A1-CELL LINE. Human White Adipose, Healing Abdomen wound; 70&90 min post incision, Human stomach, Frontal lobe, dementia; re-excision, Activated T-cells, Human Adult Heart; re-excision, Smooth Muscle- HASTE
- 10 normalized, Stomach cancer (human); re-excision, pBMC stimulated w/ poly I/C, NTERA2 + retinoic acid, 14 days, Glioblastoma, Human Stomach; re-excision, Human Frontal Cortex, Schizophrenia. Jurkat T-Cell, S phase, Spinal Cord, re-excision, Temporal cortex-Alzheimer: subtracted, Human Brain, Striatum, 12 Week Old Early Stage Human, II, Human Jurkat membrane bound polysomes, Human
- 15 Uterine Cancer, T-Cell PHA 24 hrs, Human Hippocampus, Ulcerative Colitis, Hemangiopericytoma, PC3 Prostate cell line, T Cell helper I, Soares_placenta_8to9weeks_2NbHP8to9W, Colon Normal II, Dendritic cells, pooled, Human Fetal Lung III, Soares_multiple_sclerosis_2NbHMSP, Human Placenta, human tonsils, Human Adult Pulmonary; re-excision, Anergic T-cell, Human
- 20 Amygdala, Monocyte activated, Neutrophils IL-1 and LPS induced, Hodgkin's Lymphoma II, Stratagene endothelial cell 937223, Keratinocyte, Soares placenta Nb2HP.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

25 related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

30 general formula of a-b, where a is any integer between 1 to 2308 of SEQ ID NO:30, b is an integer of 15 to 2322, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 21

5 It has been discovered that this gene is expressed primarily in Human Adult Heart;re-excision.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of
10 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 644 of SEQ ID NO:31, b
15 is an integer of 15 to 658, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 22

20 It has been discovered that this gene is expressed primarily in the following tissues: Soares_total_fetus_Nb2HF8_9w, Epithelial-TNF α and INF induced.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of
25 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1423 of SEQ ID NO:32, b
30 is an integer of 15 to 1437, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 23

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnl|PID|e1249651 (all information available through the recited accession number is incorporated herein by reference) which is described therein as an Arabidopsis putative protein. A partial alignment demonstrating the observed homology is shown immediately below.

10

```
>gnl|PID|e1249651 (AL021711) putative protein [Arabidopsis thaliana]
>gnl|PID|e1248930 (AL021687) putative protein [Arabidopsis
thaliana] >sp|O50052|O50052 HYPOTHETICAL 160.5 KD PROTEIN.
Length = 1405
```

15

Minus Strand HSPs:

Score = 787 (277.0 bits), Expect = 1.5e-76, P = 1.5e-76
Identities = 138/203 (67%), Positives = 165/203 (81%), Frame = -2

20

```
Query: 1742 SSKTFKPKKNIPEGSHQYELLKHAEATLGSGNLRQAVMLPEGEDLNEWIAVNTVDFFNQI
1563
```

25

```
+ KTF+PKK+ P G+ EL KH +ATLGSGNLR+AV LP GEDLNEW+AVNTVDFFNQ+
Sbjct: 1199 NQKTFRPKKSAPSGTKGAELRKHIDATLGSGNLRQAVMLPEGEDLNEWIAVNTVDFFNQV
1258
```

30

```
Query: 1562 NMLYGTITEFCTEASCPVMSAGPRYEHYHWDGNTIKKPIKCSAPKYIDYLMTWVQDQLDD
1383
```

```
N+L+GT+TEFCT +C M+AGP+YEHYHWDG IKKPI+ SAPKY++YLM W++ QLDD
Sbjct: 1259 NLLFGTLTEFCTPENCSTMTAGPKYEHYHWDGVIKKPIEVSAPKYVEYLMDWIETQLDD
1318
```

35

```
Query: 1382 ETLFPSKIGVFPKFNFSVAKTILKRLFRVYAHYHSHFDSVMQLQEEAHLNTSFKHFIF
1203
```

```
ET+FP K+G FP NF V KTI KRLFRVYAHYH HF ++ L+EEAHLNT FKHF I
Sbjct: 1319 ETIFPQKLGAAPFPNFKEVVKTIKRLFRVYAHYHSHFQKIVSLKEEAHLNTCFKHFIL
1378
```

40

```
Query: 1202 FVQEFNLIDRRELAPLQELIEKL 1134
```

```
F EF LID++ELAPLQELIE +
Sbjct: 1379 FTHEFVLIDKKELAPLQELIESI 1401
```

The segment of gnl|PID|e1249651 that is shown as "Sbjct" above is set out as sequence(s) SEQ ID NO. 137. Preferred polypeptides of the invention comprise polypeptides having the amino acid sequence(s) set out as SEQ ID NO. 138 which correspond to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

45

It has been discovered that this gene is expressed primarily in the following tissues: Primary Dendritic Cells, lib 1 and to a lesser extent in Human Osteoclastoma, re-excision, NCI_CGAP_GCB1, Human Fetal Heart, Differential (Fetal-Specific), B Cell lymphoma, Dendritic cells, pooled. NCI_CGAP_Br2, Soares_NhHMPu_S1,

5 Activated T-Cell (12hs)/Thiouridine labelledEco, Human Osteoclastoma, Spleen, Chronic lymphocytic leukemia, Osteoblasts, Human Prostate,differential expression, Kidney medulla, pBMC stimulated w/ poly I/C, Jurkat T-Cell, S phase, Synovial Fibroblasts (Il1/TNF), subt, Human Adult Small Intestine, Human Prostate, T-Cell PHA 16 hrs, NCI_CGAP_Lu5, NCI_CGAP_GCB1, NCI_CGAP_Kid3,

10 NCI_CGAP_Brn23, Monocyte activated: re-excision, Human Pancreas Tumor, T-Cell PHA 24 hrs, Human Heart, Human Thymus Stromal Cells, Epithelial-TNF α and INF induced, T Cell helper I, Human T-Cell Lymphoma, Human Testes Tumor, Colon Tumor II, Soares melanocyte 2NbHM, Soares_fetal_lung_NbHL19W, Primary Dendritic cells,frac 2, Human Placenta, human tonsils, Human Adult Pulmonary;re-

15 excision, Human adult (K.Okubo), HUMAN B CELL LYMPHOMA, Activated T-cell(12h)/Thiouridine-re-excision, Bone Marrow Cell Line (RS4;11), Hodgkin's Lymphoma II, NCI_CGAP_GCB1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

20 related to SEQ ID NO:33 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

25 general formula of a-b, where a is any integer between 1 to 1954 of SEQ ID NO:33, b is an integer of 15 to 1968, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

30 **FEATURES OF PROTEIN ENCODED BY GENE NO: 24**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting

example, the sequence accessible through the following database accession no. gnllPIDle206544 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "pval [Plasmodium vivax]." A partial alignment demonstrating the observed homology is shown immediately below.

```

>gnl|PID|e206544 pval [Plasmodium vivax] >sp|Q26195|Q26195 PVA1 GENE.
      Length = 200

10      Minus Strand HSPs:

      Score = 169 (59.5 bits), Expect = 4.3e-12, P = 4.3e-12
      Identities = 40/74 (54%), Positives = 45/74 (60%), Frame = -1

15      Query:   715 DRVWLCHPGWSAVVQSWLTAASTSW-GQAILLSLPPSSWDYRHMPPQSTTFFYL*RG-GF
542
                DRV LCHPGWSAVVQS  T AST   Q+  L LP SSWDYR +PP    F +  R
      Sbjct:   114 DRVLLCHPGWSAVVQSLFTVASTFLVKQSSCLGLP-SSWDYRRIPPHLANFSFFCRNKSL
172

20      Query:   541 AM*PRLVSSS*AQAI 497
                M PRL+ +S  Q I
      Sbjct:   173 TMLPRLILNSWPQVI 187

```

The segment of gnllPIDle206544 that is shown as "Sbjct" above is set out as sequence(s) SEQ ID NO. 139. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art and described elsewhere herein. Assays for determining such activities are also known in the art some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise polypeptides having the amino acid sequence(s) set out as SEQ ID NO. 140 which correspond to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues: Soares placenta Nb2HP and to a lesser extent in Epithelial-TNF α and INF induced, Activated T-Cell labeled with 4-thioluri, Human Fetal Bone, Human Heart, Stratagene lung (#937210), Primary Dendritic cells, frac 2.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the
 5 general formula of a-b, where a is any integer between 1 to 740 of SEQ ID NO:34, b is an integer of 15 to 754, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 25

It has been discovered that this gene is expressed primarily in the following tissues: Human Endometrial Tumor and to a lesser extent in Soares infant brain 1NIB, Soares melanocyte 2NbHM, Soares fetal liver spleen 1NFLS, Salivary Gland, Lib 2, H. Kidney Medulla, re-excision, Human Adrenal Gland Tumor, Human Placenta,
 15 Soares_pregnant_uterus_NbHPU, Human T-cell lymphoma;re-excision, Stratagene ovarian cancer (#937219), Synovial Fibroblasts (II1/TNF), subt, NCI_CGAP_GCB1, Soares_fetal_liver_spleen_1NFLS_S1, Human Thymus, Stratagene fetal spleen (#937205), Human Pancreas Tumor, Human Heart, Rejected Kidney, lib 4, Hepatocellular Tumor; re-excision, Human Substantia Nigra, Early Stage Human
 20 Brain, Pancreatic Islet, Soares_fetal_heart_NbHH19W, Soares_multiple_sclerosis_2NbHMSP, Endothelial-induced, Human 8 Week Whole Embryo, Soares placenta Nb2HP, Messangial cell, frac 1, Human epithelioid sarcoma, Human Colon, subtraction, Human Umbilical Vein Endothelial Cells, fract. A, Adipocytes;re-excision, Soares retina N2b4HR, Human adult small intestine,re-
 25 excision, Smooth Muscle- HASTE normalized, Human Colon Cancer;re-excision, Synovial IL-1/TNF stimulated, Stratagene fetal retina 937202, Synovial hypoxia-RSF subtracted, Glioblastoma, Human Stomach;re-excision, Synovial hypoxia, Human Manic Depression Tissue, KMH2, Spinal Cord, re-excision, Fetal Liver, subtraction II, Human Prostate, Human Bone Marrow, re-excision, Human Uterine Cancer,
 30 Stromal cell TF274, Human Rhabdomyosarcoma, Ulcerative Colitis, Human Thymus Stromal Cells, Epithelial-TNF α and INF induced, Bone Marrow Stromal Cell, untreated, Human T-Cell Lymphoma, Soares breast 3NbHBst, Human Testes Tumor,

Human Testes, Reexcision, Human Adult Pulmonary:re-excision, Endothelial cells-control, Colon Normal III, Human Osteoclastoma, Human Microvascular Endothelial Cells, fract. A, Keratinocyte, Nine Week Old Early Stage Human.

Many polynucleotide sequences, such as EST sequences, are publicly
5 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
10 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1310 of SEQ ID NO:35, b is an integer of 15 to 1324, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 26

It has been discovered that this gene is expressed primarily in the following tissues: Soares_multiple_sclerosis_2NbHMSP and to a lesser extent in Human Lung Cancer;re-excision, Healing groin wound; 7.5 hours post incision, L428, Stratagene
20 neuroepithelium NT2RAMI 937234, Human Adipose, Soares_senescent_fibroblasts_NbHSF, HUMAN B CELL LYMPHOMA, Soares placenta Nb2HP.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
25 related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the
30 general formula of a-b, where a is any integer between 1 to 1085 of SEQ ID NO:36, b is an integer of 15 to 1099, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 27

5 It has been discovered that this gene is expressed primarily in the following tissues: NCI_CGAP_GCB1 and to a lesser extent in Soares_fetal_liver_spleen_1NFLS_S1, Human Tonsil, Lib 3, KMH2, T cell helper II, Hodgkin's Lymphoma II, Human 8 Week Whole Embryo, Soares infant brain 1NIB.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.
10 86 as residues: Val-34 to Glu-39.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
15 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1365 of SEQ ID NO:37, b is an integer of 15 to 1379, where both a and b correspond to the positions of
20 nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 28

It has been discovered that this gene is expressed primarily in the following
25 tissues: Soares infant brain 1NIB and to a lesser extent in Morton Fetal Cochlea, NCI_CGAP_GCB1, Soares fetal liver spleen 1NFLS, Soares_NhHMPu_S1, Aorta endothelial cells + TNF-a, Healing groin wound, 6.5 hours post incision, KMH2, Apoptotic T-cell, Synovial Fibroblasts (control), Human Liver, normal, NCI_CGAP_Ew1, NCI_CGAP_GC3, NCI_CGAP_GC4, NCI_CGAP_GCB1, Colon
30 Tumor II, NCI_CGAP_Br2, Soares melanocyte 2NbHM, Bone marrow, Human Adult Pulmonary;re-excision, T cell helper II, Hodgkin's Lymphoma II.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 87 as residues: Thr-22 to Lys-30.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 567 of SEQ ID NO:38, b is an integer of 15 to 581, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 29**

It has been discovered that this gene is expressed primarily in the following tissues: Nine Week Old Early Stage Human and to a lesser extent in NCI_CGAP_GCB1, Soares_NhHMPu_S1, Soares melanocyte 2NbHM, HPAS (human pancreas, subtracted), Human Pituitary, re-excision, Human Primary Breast Cancer;re-excision, human colon cancer, HSA 172 Cells, Raji Cells, cyclohexamide treated, Human Osteosarcoma, KMH2, Breast Cancer Cell line, angiogenic, L428, Apoptotic T-cell, Human Primary Breast Cancer Reexcision, Soares_pregnant_uterus_NbHPU, Stratagene neuroepithelium (#937231), Human Whole Six Week Old Embryo, Soares_parathyroid_tumor_NbHPA, Human Synovial Sarcoma, Human Microvascular Endothelial Cells, fract. A, Activated T-cell(12h)/Thiouridine-re-excision, Soares infant brain 1NIB.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1270 of SEQ ID NO:39, b is an integer of 15 to 1284, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 30

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnllPIDle1283869 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "neuropathy target esterase." A partial alignment demonstrating the observed homology is shown immediately below.

```

15      >gnl|PID|e1283869 (AJ004832) neuropathy target esterase [Homo sapiens]
          Length = 1327

20      Plus Strand HSPs:

          Score = 955 (336.2 bits), Expect = 1.9e-95, P = 1.9e-95
          Identities = 181/181 (100%), Positives = 181/181 (100%), Frame = +3

25      Query:      3 DMAEIQSRLAYVSCVRQLEVVKSSSYCEYL RPPIDCFKTMDFGKFDQIYDVGYQYGKAVF
182
          DMAEIQSRLAYVSCVRQLEVVKSSSYCEYL RPPIDCFKTMDFGKFDQIYDVGYQYGKAVF
          Sbjct: 1147 DMAEIQSRLAYVSCVRQLEVVKSSSYCEYL RPPIDCFKTMDFGKFDQIYDVGYQYGKAVF
1206

30      Query:      183 GGWSRGNVIEKMLTDRRSTDLNESRRADVLAFPSSGFTDLAEIVSRIEPPTSIVSDGCAD
362
          GGWSRGNVIEKMLTDRRSTDLNESRRADVLAFPSSGFTDLAEIVSRIEPPTSIVSDGCAD
          Sbjct: 1207 GGWSRGNVIEKMLTDRRSTDLNESRRADVLAFPSSGFTDLAEIVSRIEPPTSIVSDGCAD
1266

35      Query:      363 GEESDCLTEYEEDAGPDCSRDEGGSPEGASPSTASEMEEKSILRQRRCLPQEPPGSATD
542
          GEESDCLTEYEEDAGPDCSRDEGGSPEGASPSTASEMEEKSILRQRRCLPQEPPGSATD
          Sbjct: 1267 GEESDCLTEYEEDAGPDCSRDEGGSPEGASPSTASEMEEKSILRQRRCLPQEPPGSATD
40      1326

          Query:      543 A 545
          A
          Sbjct: 1327 A 1327
45

```

The segment of gnllPIDle1283869 that is shown as "Sbjct" above is set out as sequence(s) SEQ ID NO. 141. Based on the structural similarity these homologous

polypeptides are expected to share at least some biological activities. Such activities are known in the art and described elsewhere herein. Assays for determining such activities are also known in the art some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise polypeptides having the amino acid sequence(s) set out as SEQ ID NO. 142 which correspond to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues: Soares infant brain 1NIB and to a lesser extent in Primary Dendritic Cells, lib 1, Human adult testis, large inserts, Human Adult Testes, Large Inserts, Reexcision, Soares breast 2NbHBst, Soares fetal liver spleen 1NFLS, breast lymph node CDNA library, NCI_CGAP_GC4, HEL cell line, Stratagene HeLa cell s3 937216, Macrophage (GM-CSF treated), Smooth muscle, serum induced, re-exc, Human Eosinophils, Monocyte activated, Bone Marrow Cell Line (RS4;11), Nine Week Old Early Stage Human, Human frontal cortex, CHME Cell Line, untreated, Larynx Tumour, NCI_CGAP_Lu1, NCI_CGAP_GCB1, NCI_CGAP_Pr23, Ku 812F Basophils Line, HL-60, PMA 4H, Human Adult Pulmonary, eosinophil-IL5 induced, Human Skin Tumor, Healing groin wound - zero hr post-incision (control), Soares adult brain N2b4HB55Y, NTERA2 + retinoic acid, 14 days, Glioblastoma, Human Adipose Tissue, re-excision, Human Colon; re-excision, Myeloid Progenitor Cell Line, Spleen metastatic melanoma, Human Infant Brain, Human Thymus, Human Brain, Striatum, Human Fetal Dura Mater, Spinal cord, PERM TF274, Epithelial-TNF α and INF induced, Human Thymus, Hemangiopericytoma, H. Frontal cortex, epileptic; re-excision, Pancreas Islet Cell Tumor, Human T-Cell Lymphoma, Primary Dendritic cells, frac 2, Hodgkin's Lymphoma II, Human 8 Week Whole Embryo, Human Cerebellum.

The tissue distribution in infant brain tissue suggests that the protein product of this clone is useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance,

and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 778 of SEQ ID NO:40, b is an integer of 15 to 792, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 31

It has been discovered that this gene is expressed primarily in the following tissues: Soares infant brain 1NIB and to a lesser extent in Human Prostate Cancer, Stage B2 fraction, Human Adult Pulmonary, Human Pancreatic Carcinoma, wilm's tumor, Pancreas Islet Cell Tumor, Soares_pregnant_uterus_NbHPU, Soares_parathyroid_tumor_NbHPA.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 90 as residues: Ser-20 to Asp-25.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 1337 of SEQ ID NO:41, b is an integer of 15 to 1351, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 32

It has been discovered that this gene is expressed primarily in the following tissues: Soares_fetal_heart_NbHH19W, Stratagene endothelial cell 937223, Stratagene lung (#937210), Stratagene muscle 937209, Human B-cell lymphoma and
 10 to a lesser extent in Human Fetal Lung, Human colon carcinoma (HCC) cell line, remake, Soares retina N2b4HR, HEL cell line, Stromal-Osteoclastoma, Human Manic Depression Tissue, Prostate BPH, Soares_multiple_sclerosis_2NbHMSP, T-Cell PHA 16 hrs, human ovarian cancer, Human Fetal Dura Mater, Rejected Kidney, lib 4, Soares_NhHMPu_S1, H. Frontal cortex.epileptic;re-excision, Pancreas Islet Cell
 15 Tumor, Human T-Cell Lymphoma, Human Placenta, Dendritic cells, pooled, Human Fetal Lung III, Human Adult Pulmonary;re-excision, Human Microvascular Endothelial Cells, fract. A, CD34 positive cells (Cord Blood), T cell helper II, Nine Week Old Early Stage Human, Soares placenta Nb2HP.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.
 20 91 as residues: Glu-45 to Thr-63.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
 25 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2798 of SEQ ID NO:42, b is an integer of 15 to 2812, where both a and b correspond to the positions of
 30 nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 33

It has been discovered that this gene is expressed primarily in the following tissues: NCI_CGAP_Kid6, Soares_fetal_heart_NbHH19W and to a lesser extent in Human Epididymus, NCI_CGAP_Kid3, Colon Tumor II, Human Fetal Lung III,
 5 HUMAN B CELL LYMPHOMA, Human Testes, Smooth Muscle Serum Treated, Norm, human colon cancer, Aorta endothelial cells + TNF-a, NCI_CGAP_Co9, NCI_CGAP_GC4, Human Lung Cancer;re-excision, Human Osteosarcoma, Jurkat T-Cell, S phase, Soares_fetal_lung_NbHL19W, Soares_senescent_fibroblasts_NbHSF, Human Umbilical Vein Endothelial Cells, uninduced, Soares breast 2NbHBst,
 10 NCI_CGAP_Kid5, NCI_CGAP_Kid6, Human Adult Pulmonary;re-excision, Activated T-Cell (12hs)/Thiouridine labelledEco.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of
 15 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1131 of SEQ ID NO:43, b
 20 is an integer of 15 to 1145, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 34

25 It has been discovered that this gene is expressed primarily in the following tissues: Human Osteoclastoma and to a lesser extent in Soares infant brain 1NIB, Soares placenta Nb2HP, Morton Fetal Cochlea, STRATAGENE Human skeletal muscle cDNA library, cat. #936215., Colon Carcinoma, NCI_CGAP_Kid5, Primary Dendritic Cells, lib 1, Soares_parathyroid_tumor_NbHPA, Myeloid Progenitor Cell
 30 Line, Stratagene muscle 937209, Spinal Cord, re-excision, Mo7e Cell Line GM-CSF treated (1ng/ml), TF-1 Cell Line GM-CSF Treated, Clontech human aorta polyA+ mRNA (#6572), Human Ovarian Cancer Reexcision, Bone Marrow Stromal Cell,

- untreated, Colon Tumor, Soares_pregnant_uterus_NbHPU, Human Adult Pulmonary;re-excision, Colon Normal III, NCI_CGAP_Lu5, NCI_CGAP_GCB1, Human Astrocyte, Soares ovary tumor NbHOT, Osteoclastoma-normalized A, Larynx Normal, Human OB HOS treated (1 nM E2) fraction I,
- 5 Soares_multiple_sclerosis_2NbHMSP, Soares_placenta_8to9weeks_2NbHP8to9W, Human Adult Retina, Human Pituitary, subtracted, HUMAN STOMACH, Human Lung, Morton Fetal, STROMAL -OSTEOCLASTOMA, NTERA2 + retinoic acid, 14 days, H. Kidney Cortex, subtracted, KMH2, Human Prostate, Human promyelocyte, normalized infant brain cDNA, Normalized infant brain, Bento Soares,
- 10 STRATAGENE Human skeletal muscle cDNA library, cat. #936215.. Stratagene NT2 neuronal precursor 937230, Macrophage-oxLDL, Human Adrenal Gland Tumor, NTERA2, control, Gessler Wilms tumor, Soares_parathyroid_tumor_NbHPA, Stratagene lung (#937210), Pancreas Islet Cell Tumor, 12 Week Old Early Stage Human, Colon Tumor II, Primary Dendritic cells,frac 2, NCI_CGAP_GCB1, Human
- 15 fetal brain (TFujiwara), NCI_CGAP_AA1, NCI_CGAP_Co8, NCI_CGAP_Co9, NCI_CGAP_Pr2, NCI_CGAP_GCB1, NCI_CGAP_Pr12, Soares_total_fetus_Nb2HF8_9w, Stratagene lung carcinoma 937218, Monocyte activated, Human Testes, NCI_CGAP_Pr2, Hodgkin's Lymphoma II, Human 8 Week Whole Embryo, Nine Week Old Early Stage Human,
- 20 Soares_total_fetus_Nb2HF8_9w.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

25 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1495 of SEQ ID NO:44, b is an integer of 15 to 1509, where both a and b correspond to the positions of

30 nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 35

It has been discovered that this gene is expressed primarily in the following tissues: Soares placenta Nb2HP and to a lesser extent in Soares retina N2b4HR, NCI_CGAP_GCB1, Stratagene ovarian cancer (#937219), Human Chondrosarcoma, 5 Stratagene lung (#937210), Human T-Cell Lymphoma, Human Placenta, Morton Fetal Cochlea, HSC172 cells, Stratagene fetal retina 937202, Human adult small intestine, re-excision, NTERA2 teratocarcinoma cell line+retinoic acid (14 days), Human endometrial stromal cells-treated with estradiol, H Female Bladder, Adult, KMH2, Soares_total_fetus_Nb2HF8_9w, Mo7e Cell Line GM-CSF treated (1ng/ml), 10 Apoptotic T-cell, Human Uterine Cancer, Soares_NFL_T_GBC_S1, Human Activated T-Cells, re-excision, Human Thymus Stromal Cells, 12 Week Old Early Stage Human, Human fetal brain (TFujiwara), NCI_CGAP_Kid3, NCI_CGAP_Br1.1, Stratagene hNT neuron (#937233), Human Testes Tumor, Human Adult Pulmonary; re-excision, Human 8 Week Whole Embryo, Primary Dendritic Cells, lib 15 1, Soares infant brain 1NIB.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically 20 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1843 of SEQ ID NO:45, b is an integer of 15 to 1857, where both a and b correspond to the positions of 25 nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 36

It has been discovered that this gene is expressed primarily in the following 30 tissues: Human Adult Pulmonary; re-excision, Human Endometrial Tumor.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the
5 general formula of a-b, where a is any integer between 1 to 1796 of SEQ ID NO:46, b is an integer of 15 to 1810, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 37

It has been discovered that this gene is expressed primarily in the following tissues: Human Adult Pulmonary;re-excision, Human Adult Pulmonary and to a lesser extent in Human Fetal Lung III, Kidney Pyramids, Soares ovary tumor
15 NbHOT, Human Tonsil, Lib 3, Human Endometrial Tumor.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 96 as residues: Pro-28 to Ser-35.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are
20 related to SEQ ID NO:47 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the
25 general formula of a-b, where a is any integer between 1 to 1865 of SEQ ID NO:47, b is an integer of 15 to 1879, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

30 FEATURES OF PROTEIN ENCODED BY GENE NO: 38

It has been discovered that this gene is expressed primarily in the following tissues: Human Adult Pulmonary;re-excision, Soares_pregnant_uterus_NbHPU, Soares fetal liver spleen 1NFLS.

Many polynucleotide sequences, such as EST sequences, are publicly
5 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
10 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 542 of SEQ ID NO:48, b is an integer of 15 to 556, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 39

It has been discovered that this gene is expressed primarily in the following tissues: Human Primary Breast Cancer;re-excision, Soares breast 3NbHBst and to a lesser extent in Namalwa Cells, Amniotic Cells - Primary Culture, NTERA2 +
20 retinoic acid, 14 days, Human Whole Six Week Old Embryo, Soares fetal liver spleen 1NFLS.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of
25 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 593 of SEQ ID NO:49, b
30 is an integer of 15 to 607, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 40

It has been discovered that this gene is expressed primarily in the following tissues: Amniotic Cells - Primary Culture.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence
10 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 582 of SEQ ID NO:50, b is an integer of 15 to 596, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a
15 + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 41

It has been discovered that this gene is expressed primarily in the following tissues: Amniotic Cells - Primary Culture, Human B cell Lymphoma.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence
25 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 270 of SEQ ID NO:51, b is an integer of 15 to 284, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a
30 + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 42

It has been discovered that this gene is expressed primarily in the following tissues: Smooth muscle, control; re-excision, Smooth muscle-ILb induced, HSA 172 Cells, Amniotic Cells - Primary Culture, Spleen metastatic melanoma, H. Kidney Medulla, re-excision, CD34 depleted Buffy Coat (Cord Blood), Stromal cell TF274, Spinal cord. Human Rhabdomyosarcoma, Smooth muscle, serum induced, re-exc, Human Gall Bladder, Activated T-Cell (12hs)/Thiouridine labelled Eco, CD34 depleted Buffy Coat (Cord Blood), re-excision, Anergic T-cell, Activated T-cell (12h)/Thiouridine-re-excision, Soares placenta Nb2HP, Soares fetal liver spleen 1NFLS.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1601 of SEQ ID NO:52, b is an integer of 15 to 1615, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 43

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnl|PID|e1291654 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "rna helicase", which is thought to function by unwinding double-stranded RNA in a 3' to 5' direction. A partial alignment demonstrating the observed homology is shown immediately below.

```
>gnl|PID|e1291654 (AL023290) rna helicase [Schizosaccharomyces pombe]
      Length = 1428
```

Plus Strand HSPs:

Score = 435 (153.1 bits), Expect = 1.1e-37, P = 1.1e-37

Identities = 122/429 (28%), Positives = 229/429 (53%), Frame = +2

5
Query: 2 GKMKEKRYDASKGMESLEDTFVSQANALQRKGRAGVVASGVCFLFTSHHYNHQLLKQQL
181
Sbjct: 986 GVHREMRYNSRRHLSRLTDTFVSKANAKQRSGRAGRVQEGICYHLFSKFKHDTQFLSYQT
10 1045

Query: 182 PEIQRVPLEQLCLRIKILEMFSAHNLQSVFSRLIEPPH-TDSL RASKIRLRDLGALTPDE
358
Sbjct: 1046 PEILRLNLQEVVLRVKMCQM---GDVQDVLGKALDPPSSTNIIRALE-KLHQVGALSENE
15 1101

Query: 359 RLTPLGHYHLASLPVDVRIGKLMFLGSI FRCLDPALTIAASLAFKSPFVSPWDKKEEANQK
538
Sbjct: 1102 KLTKLGKFLSQLPVDANLGKILVLGCFYKCVDAASSIVAMLTIGSPFRKSVDNEFSANKA
20 1161

Query: 539 KLEFAFAN--SDYLALLQAYKGWQLSTKEGVRASYN-YCRQNFLSGRVLQEMASLKRQFT
709
Sbjct: 1162 RLSFAKENTRSDLVLMYAYCAWREICLSPLGPDEDSFAKEKYNLEALSMTESLKIQLL
25 1221

Query: 710 ELLSDIGF--AREGLRAREIEKRAQGGDGVLDATGEEANSNAENPKLISAMLCALYPNV
883
Sbjct: 1222 SELKDMKLLGASDVDTCKSLKRSICRRFAVIP---KEHDINSNGAEILCGVIAASLYPNI
30 1278

Query: 884 VQVKSPEGKFQKTSTGAVRMQPKSAELKFVTKNDGYVHIHPSSVNYQVRHFDSPYLLYHE
1063
Sbjct: 1279 LRYDYEKQWSTLSTN-----KRVRI LDVSVNN-----RSELPNMPSKFVAYTN
35 1322

Query: 1064 KIKTSRV--FIRDCSMVSVYPLVLFGGGQVNVQLQRGEFVVSLDDGWIRF--VAASHQVA
1231
Sbjct: 1323 MMSSTRASEYVNETTMVTLRQLLMCGLKVENRVSVGQ--AKLDNFTVYFENVVVSASLS
45 1380

Query: 1232 ELVKELRCELDQLLQDKIK 1288
L + + L++ + K
50 Sbjct: 1381 ILRRFIETSLNEFFAEPDK 1399

The segment of gnlIPIDle1291654 that is shown as "Sbjct" above is set out as
55 sequence(s) SEQ ID NO. 143. Based on the structural similarity these homologous
polypeptides are expected to share at least some biological activities. Such activities
are known in the art and described elsewhere herein. Assays for determining such
activities are also known in the art some of which have been described elsewhere

herein. Preferred polypeptides of the invention comprise polypeptides having the amino acid sequence(s) set out as SEQ ID NO. 144 which correspond to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

5 It has been discovered that this gene is expressed primarily in the following tissues: Synovial hypoxia-RSF subtracted and to a lesser extent in Soares infant brain 1NIB, HL-60, PMA 4H, re-excision, Nine Week Old Early Stage Human, Human Lung Cancer, Supt cells, cyclohexamide treated, subtracted, Human Adult Retina, Synovial hypoxia, Stratagene fetal spleen (#937205), Stratagene lung (#937210),
10 Brain frontal cortex, Adipocytes, Human Microvascular Endothelial Cells, fract. A, Monocyte activated, Human Bone Marrow, treated, Human Testes, Stratagene endothelial cell 937223.

 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 102 as residues: Pro-29 to Lys-40, Glu-66 to Phe-79, Arg-112 to Gly-121, Thr-128 to
15 Lys-140, Lys-158 to Ser-168.

 The expression of this gene product in synovium suggests a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or
20 treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial arthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the
25 protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of
30 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1947 of SEQ ID NO:53, b is an integer of 15 to 1961, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 44

It has been discovered that this gene is expressed primarily in the following tissues: Soares_NhHMPu_S1 and to a lesser extent in Human Brain, Human Adult Liver, subtracted, Human Adult Spleen, Human Heart, Human Gall Bladder, Human Adult Pulmonary;re-excision, Human Osteoclastoma.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1343 of SEQ ID NO:54, b is an integer of 15 to 1357, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 45

It has been discovered that this gene is expressed primarily in the following tissues: Soares retina N2b4HR, Soares_fetal_heart_NbHH19W, Soares infant brain 1NIB and to a lesser extent in Human Adult Retina, NCI_CGAP_Lu5, Human Stomach;re-excision, Human Infant Brain, Soares adult brain N2b5HB55Y, Human Amygdala, Human Cerebellum.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the
 5 general formula of a-b, where a is any integer between 1 to 771 of SEQ ID NO:55, b is an integer of 15 to 785, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 46

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil3115348 (all information available through the recited accession number is
 15 incorporated herein by reference) which is described therein as "mitochondrial processing peptidase beta subunit precursor", which is thought to function as a peptidase which cleaves the leader sequence from mitochondrial proteins following translocation. A partial alignment demonstrating the observed homology is shown immediately below.

20

```
>gi|3115348 (AC004668) mitochondrial processing peptidase beta subunit
precursor; similar to Q03346 (PID:g1171010) [Homo sapiens]
Length = 489
```

25

Plus Strand HSPs:

Score = 2357 (829.7 bits), Expect = 5.3e-244, P = 5.3e-244
 Identities = 456/462 (98%), Positives = 457/462 (98%), Frame = +2

30

```
Query:      65 VVIRGA--RRLWGFSESLIRGAAGRSLYFGENRLRSTQAATQVVLNVPETRVTCLESGL
238
```

```
VV+  A  RRLWGFSESLIRGAAGRSLYFGENRLRSTQAATQVVLNVPETRVTCLESGL
Sbjct:      8 VVLSSAARRRLWGFSESLIRGAAGRSLYFGENRLRSTQAATQVVLNVPETRVTCLESGL
67
```

35

```
Query:     239 RVASEDSGLSTCTVGLWIDAGSRYENEKNNGTAHFLEHMAFKGTTKRSQLDLELEIENMG
418
```

```
RVASEDSGLSTCTVGLWIDAGSRYENEKNNGTAHFLEHMAFKGTTKRSQLDLELEIENMG
Sbjct:     68 RVASEDSGLSTCTVGLWIDAGSRYENEKNNGTAHFLEHMAFKGTTKRSQLDLELEIENMG
40 127
```

```
Query:     419 AHLNAYTSREQTVYYAKAFSKDLPRAVEILADIIQNSTLGEAEIERERGVILREMQEVET
598
AHLNAYTSREQTVYYAKAFSKDLPRAVEILADIIQNSTLGEAEIERERGVILREMQEVET
```


5 Sbjct: 128 AHLNAYTSREQTVYYAKAFSKDLPRAVEILADI IQNSTLGEAEIERERGVILREMQUEVET
 187
 Query: 599 NLQEVVFDYLHATAYQNTALGRTLGP TENIKSISRKDLVDYITTHYKGPRIVLAAAGGV
 778
 NLQEVVFDYLHATAYQNTALGRTLGP TENIKSISRKDLVDYITTHYKGPRIVLAAAGGV
 Sbjct: 128 NLQEVVFDYLHATAYQNTALGRTLGP TENIKSISRKDLVDYITTHYKGPRIVLAAAGGV
 247
 10 Query: 779 SHDELLDLAKFHFGDSLCTHKGEIPALPPCKFTGSEIRVRDDKMPLAHLAIAVEAVGWAH
 958
 SHDELLDLAKFHFGDSLCTHKGEIPALPPCKFTGSEIRVRDDKMPLAHLAIAVEAVGWAH
 Sbjct: 248 SHDELLDLAKFHFGDSLCTHKGEIPALPPCKFTGSEIRVRDDKMPLAHLAIAVEAVGWAH
 307
 15 Query: 959 PDTICLMVANTLIGNWDRSFGGGMNLSSKLAQLTCHGNLCHSFQSFNTSYTDTGLWGGLYM
 1138
 PDTICLMVANTLIGNWDRSFGGGMNLSSKLAQLTCHGNLCHSFQSFNTSYTDTGLWGGLYM
 Sbjct: 308 PDTICLMVANTLIGNWDRSFGGGMNLSSKLAQLTCHGNLCHSFQSFNTSYTDTGLWGGLYM
 367
 20 Query: 1139 VCESSTVADMLHVQKEWMRLCTSVTESEVARARNLLKTNMMLQLDGGSTPICEDIGRQML
 1318
 VCESSTVADMLHVQKEWMRLCTSVTESEVARARNLLKTNMMLQLDGGSTPICEDIGRQML
 Sbjct: 368 VCESSTVADMLHVQKEWMRLCTSVTESEVARARNLLKTNMMLQLDGGSTPICEDIGRQML
 427
 25 Query: 1319 CYNRRIPPELEARIDAVNAEXIREVCTKYIYNRSPAIAAVG 1444
 CYNRRIPPELEARIDAVNAE IREVCTKYIYNRSPAIAAVG
 Sbjct: 428 CYNRRIPPELEARIDAVNAETIREVCTKYIYNRSPAIAAVG 469
 30

The segment of gil3115348 that is shown as "Sbjct" above is set out as
 sequence(s) SEQ ID NO. 145. Based on the structural similarity these homologous
 polypeptides are expected to share at least some biological activities. Such activities
 35 are known in the art and described elsewhere herein. Assays for determining such
 activities are also known in the art some of which have been described elsewhere
 herein. Preferred polypeptides of the invention comprise polypeptides having the
 amino acid sequence(s) set out as SEQ ID NO. 146 which correspond to the Query
 sequence in the alignment shown above (gaps introduced in the sequence by the
 40 computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following
 tissues: Primary Dendritic Cells, lib 1 and to a lesser extent in Human Adrenal Gland
 Tumor, Soares_pregnant_uterus_NbHPU, Human Adult Small Intestine, Human T-
 Cell Lymphoma, Human Testes Tumor, Keratinocyte, Nine Week Old Early Stage
 45 Human, Namalwa Cells, Liver Normal Met5No, Human Prostate, subtracted, Human
 Colon, subtraction, Human Thyroid, Human Soleus, Human adult small intestine, re-
 excision, Human Amygdala; re-excision, B Cell lymphoma, Human Synovium,

Stratagene NT2 neuronal precursor 937230, Human Adipose Tissue. re-excision, Human Osteosarcoma, Human Osteoclastoma, re-excision, Human Manic Depression Tissue, KMH2, Human Dermal Endothelial Cells, untreated, L428, Human Fetal Dura Mater, T-Cell PHA 24 hrs. Merkel Cells, Stratagene liver (#937224).

- 5 Soares_fetal_lung_NbHL19W, Soares_multiple_sclerosis_2NbHMSP, Soares_senescent_fibroblasts_NbHSF, Resting T-Cell Library, II, 12 Week Old Early Stage Human, Smooth muscle, serum treated, Normal colon, Endothelial cells-control, Human Osteoclastoma, Human Amygdala, Human Bone Marrow, treated, Human Testes, Soares_NhHMPu_S1, T cell helper II, Human Endometrial Tumor, 10 Hodgkin's Lymphoma II, Soares infant brain 1NIB.

- The homology to mitochondrial processing peptidase beta subunit protein suggests that the translation product of this gene is useful for the detection and/or treatment of disorders involving the post-translational processing of proteins, and/or disorders involving aberrant transport of mitochondrial proteins. Furthermore, the tissue distribution in primary dendritic cells suggests that the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in tonsils suggests a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. 15 Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. 20 25 30

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
5 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2426 of SEQ ID NO:56, b is an integer of 15 to 2440, where both a and b correspond to the positions of
10 nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 47

It has been discovered that this gene is expressed primarily in the following
15 tissues: Human Adult Spleen, Human placenta cDNA (TFujiwara), Resting T-Cell; re-excision, Macrophage-oxLDL.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of
20 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 796 of SEQ ID NO:57, b
25 is an integer of 15 to 810, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 48

30 The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

gnl|PID|e206544 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "pva1 [Plasmodium vivax]." A partial alignment demonstrating the observed homology is shown immediately below.

5

```
>gnl|PID|e206544 pva1 [Plasmodium vivax] >sp|Q26195|Q26195 PVA1 GENE.
      Length = 200
```

10

Minus Strand HSPs:

Score = 139 (48.9 bits), Expect = 6.8e-09, P = 6.8e-09
Identities = 28/53 (52%), Positives = 31/53 (58%), Frame = -1

15

```
Query:   484 FFFFRDGVLIICPGWS*TPSS-----KRSSCFGIPKCWDYRHEPPH 356
          FF FFRD VL+C PGWS      S          K+SSC G+P WDYR  PPH
Sbjct:   107 FFIFFRDRVLLCHPGWSAVVQSLFTVASTFLVKQSSCLGLPSSWDYRRIPPH 159
```

The segment of gnl|PID|e206544 that is shown as "Sbjct" above is set out as sequence(s) SEQ ID NO. 147. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art and described elsewhere herein. Assays for determining such activities are also known in the art some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise polypeptides having the amino acid sequence(s) set out as SEQ ID NO. 148 which correspond to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues: Human Amygdala.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 107 as residues: Ser-33 to Leu-38.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 470 of SEQ ID NO:58, b is an integer of 15 to 484, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 49

It has been discovered that this gene is expressed primarily in the following tissues: Activated Monocytes and to a lesser extent in Human Normal Cartilage, Fraction I, Human Normal Cartilage Fraction II, Human Brain, Striatum, Stratagene colon (#937204), Monocyte activated; re-excision, Human Hippocampus, Hepatocellular Tumor; re-excision, Colon Tumor, Human Substantia Nigra, Colon Normal II, NCI_CGAP_Co3, NCI_CGAP_Kid3, NCI_CGAP_Pr10, Colon Tumor II, Stratagene colon (#937204), Soares fetal liver spleen 1NFLS.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 108 as residues: Ala-17 to Gln-23.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 417 of SEQ ID NO:59, b is an integer of 15 to 431, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.

Table 1

Gene No.	cDNA Clone ID	ATCC Deposit NO: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HAGEQ67	203917 4/8/99	Uni-ZAP XR	11	1205	1	1205	226	226	60	1	22	23	37
2	HAGFF43	203917 4/8/99	Uni-ZAP XR	12	1844	1	1844	266	266	61	1			5
3	HAGFU31	203917 4/8/99	Uni-ZAP XR	13	1270	1	1270	105	105	62	1	21	22	44
4	HAJAA47	203917 4/8/99	pCMVSPORT 3.0	14	1237	1	1237		192	63	1	15	16	38
5	HAJCH70	203917 4/8/99	pCMVSPORT 3.0	15	2182	1	2182	284	284	64	1	32	33	38
6	HAPBR13	203917 4/8/99	Uni-ZAP XR	16	1585	1	1585	125	125	65	1	22	23	52
7	HKACA25	203917 4/8/99	pCMVSPORT 2.0	17	1888	145	1813		213	66	1	12	13	18
8	HAPRK55	203917 4/8/99	Uni-ZAP XR	18	1380	1	1380	172	172	67	1	28	29	38
9	HAQBG57	203917 4/8/99	Uni-ZAP XR	19	1048	1	1031		170	68	1	16	17	56
10	HAQBY85	203917 4/8/99	Uni-ZAP XR	20	1882	1	1882	192	192	69	1	22	23	33

Gene No.	cDNA Clone ID	ATCC Deposit NO: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
11	HARAE26	203917 4/8/99	pBluescript SK-	21	1245	1	1245	225	225	70	1	32	33	97
12	HAGEP30	203917 4/8/99	Uni-ZAP XR	22	810	1	810	120	120	71	1	18	19	35
13	HAGEQ58	203917 4/8/99	Uni-ZAP XR	23	1675	1	1675	162	162	72	1			17
14	HAGEW83	203917 4/8/99	Uni-ZAP XR	24	1069	1	1069	18	18	73	1	24	25	31
15	HAGEX49	203917 4/8/99	Uni-ZAP XR	25	1475	373	1434	606	606	74	1			16
16	HAGFM58	203917 4/8/99	Uni-ZAP XR	26	931	1	931	243	243	75	1			11
17	HAGFW13	203917 4/8/99	Uni-ZAP XR	27	911	1	911	183	183	76	1	20	21	34
18	HAGHE85	203917 4/8/99	Uni-ZAP XR	28	1697	1	1697		342	77	1			5
19	HAGHR18	203917 4/8/99	Uni-ZAP XR	29	1142	1	1142	28	28	78	1	22	23	32
20	HOEBI94	203917 4/8/99	Uni-ZAP XR	30	2322	439	2241		558	79	1	15	16	24
21	HAHEM51	203917 4/8/99	Uni-ZAP XR	31	658	1	658	185	185	80	1	31	32	39

Gene No.	cDNA Clone ID	ATCC Deposit NO: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Peptide	AA SEQ ID NO: Y	First AA of Signal Peptide	Last AA of Signal Peptide	First AA of Secreted Portion	Last AA of ORF
22	HAIBT20	203917 4/8/99	Uni-ZAP XR	32	1437	1	1437	286	286	81	1	25	26	35
23	HAICE62	203917 4/8/99	Uni-ZAP XR	33	1968	38	1361	363	363	82	1			5
24	HAICL90	203917 4/8/99	Uni-ZAP XR	34	754	1	754	140	140	83	1	23	24	39
25	HAICV44	203917 4/8/99	Uni-ZAP XR	35	1324	1	1324	232	232	84	1	23	24	26
26	HAAJAZ56	203917 4/8/99	pCMVSPORT 3.0	36	1099	267	1099	300	300	85	1	19	20	35
27	HAMFC67	203917 4/8/99	pCMVSPORT 3.0	37	1379	1	1379	282	282	86	1	29	30	72
28	HAMFQ38	203917 4/8/99	pCMVSPORT 3.0	38	581	1	581	90	90	87	1	25	26	37
29	HAMGG01	203917 4/8/99	pCMVSPORT 3.0	39	1284	323	1259	644	644	88	1			17
30	HAPBU09	203917 4/8/99	Uni-ZAP XR	40	792	1	792	247	247	89	1	20	21	45
31	HAPBU86	203917 4/8/99	Uni-ZAP XR	41	1351	255	1351	403	403	90	1	23	24	35
32	HAPNL62	203917 4/8/99	Uni-ZAP XR	42	2812	433	2239	701	701	91	1	41	42	102

Gene No.	cDNA Clone ID	ATCC Deposit NO: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
33	HAPNO50	203917 4/8/99	Uni-ZAP XR	43	1145	1	1134	205	205	92	1	20	21	36
34	HAPNY10	203917 4/8/99	Uni-ZAP XR	44	1509	1	1509		33	93	1	41	42	44
35	HAPQJ73	203917 4/8/99	Uni-ZAP XR	45	1857	1	1857		286	94	1			16
36	HAPQK26	203917 4/8/99	Uni-ZAP XR	46	1810	1	1810		300	95	1			12
37	HAPQU71	203917 4/8/99	Uni-ZAP XR	47	1879	1264	1807	1324	1324	96	1	20	21	53
38	HAPQW18	203917 4/8/99	Uni-ZAP XR	48	556	1	556	20	20	97	1	29	30	37
39	HAQA192	203917 4/8/99	Uni-ZAP XR	49	607	1	602	250	250	98	1	15	16	23
40	HAQCE11	203917 4/8/99	Uni-ZAP XR	50	596	1	596		262	99	1			3
41	HAQCE18	203917 4/8/99	Uni-ZAP XR	51	284	1	284	79	79	100	1			10
42	HAQCF94	203917 4/8/99	Uni-ZAP XR	52	1615	7	1495	89	89	101	1			25
43	HARAT69	203917 4/8/99	pBluescript SK-	53	1961	189	1961	422	422	102	1	21	22	334

Gene No.	cDNA Clone ID	ATCC Deposit NO: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
44	HASAX57	203917 4/8/99	Uni-ZAP XR	54	1357	1	1357	136	136	103	1	30	31	38
45	HAGEQ79	203917 4/8/99	Uni-ZAP XR	55	785	1	785	515	515	104	1			11
46	HAGHN57	203917 4/8/99	Uni-ZAP XR	56	2440	843	2440	900	900	105	1			10
47	HASAY07	203917 4/8/99	Uni-ZAP XR	57	810	1	810		699	106	1			5
48	HAGEU26	203917 4/8/99	Uni-ZAP XR	58	484	1	484	175	175	107	1	20	21	53
49	HANGB24	203917 4/8/99	pSport1	59	431	1	431	199	199	108	1	21	22	66

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently

accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also

5 hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1.

10 Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the

15 actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the

20 generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods.

25 The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

30 The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed

herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained in ATCC deposit Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA contained in ATCC deposit Z are also encompassed by the invention.

10 **Signal Sequences**

The present invention also encompasses mature forms of the polypeptide having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of

predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, supra.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

5 In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis
10 of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence
15 shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present
20 invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of
25 directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present
30 invention.

Polynucleotide and Polypeptide Variants

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA sequence contained in a deposited clone.

The present invention also encompasses variants of the polypeptide sequence
5 disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

10 The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the
15 complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein). Polynucleotides which hybridize to these nucleic acid molecules under stringent
20 hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence
25 shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended
30 that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In

other words, to obtain a nucleic acid having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using

the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10
5 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100
10 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not
15 matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter
20 the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host
25 (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These
30 allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions,

inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies
5 for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions
10 where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes
15 at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

20 As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains
25 are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr,
30 and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues,

where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for
5 example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of
10 charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev.
15 Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid
20 substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3,
25 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

30

Polynucleotide and Polypeptide Fragments

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in
5 a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt,
10 and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger
15 or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the
20 invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500,
25 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini.
30 Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under

stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 301 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are

specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily
5 identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Preferably, the polynucleotide fragments of the invention encode a
10 polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a
15 polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

The functional activity of polypeptides of the invention, and fragments,
20 variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using
25 techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays,
30 hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another

embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

5 In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel chromatography, protein affinity chromatography, and affinity blotting. See
10 generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the
15 invention and fragments, variants derivatives and analogs thereof to elicit related biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope of the invention.

20 **Epitopes and Antibodies**

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that
25 hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X),
30 polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize

to the complementary strand under stringent hybridization conditions or lower stringency hybridization conditions defined supra.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described infra. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985), further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in

immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe
5 et al., supra; Wilson et al., supra; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for
10 eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very
15 least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., supra; Wilson et al., supra, and Bittle et al., J. Gen. Virol., 66:2347-
20 2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS),
25 while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an
30 immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid

surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

5 As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination
10 thereof and portions thereof) resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., *Nature*,
15 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be
20 more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., *J. Biochem.*, 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For
25 example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine
30 residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni²⁺

nitrioloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

25 Antibodies

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a

Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules
5 that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.

Most preferably the antibodies are human antigen-binding antibody fragments
10 of the present invention and include, but are not limited to, Fab, Fab' and F(ab')₂, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region,
15 CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or
20 chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

25 The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO
30 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in
5 contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in
10 terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described
15 herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%,
20 less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific
25 antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide
30 of the invention. Preferred binding affinities include those with a dissociation constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9}

M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, or 10^{-15} M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described
5 herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the
10 polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The
15 invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by
20 immunoprecipitation followed by western blot analysis (for example, as described supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

25 The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as
30 well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor

agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No. 5,811,097; Deng et al., *Blood* 92(6):1981-1988 (1998); Chen et al., *Cancer Res.* 58(16):3668-3678 (1998); Harrop et al., *J. Immunol.* 161(4):1786-1794 (1998); Zhu et al., *Cancer Res.* 58(15):3209-3214 (1998); Yoon et al., *J. Immunol.* 160(7):3170-3179 (1998); Prat et al., *J. Cell. Sci.* 111(Pt2):237-247 (1998); Pitard et al., *J. Immunol. Methods* 205(2):177-190 (1997); Liautard et al., *Cytokine* 9(4):233-241 (1997); Carlson et al., *J. Biol. Chem.* 272(17):11295-11301 (1997); Taryman et al., *Neuron* 14(4):755-762 (1995); Muller et al., *Structure* 6(9):1153-1167 (1998); Bartunek et al., *Cytokine* 8(1):14-20 (1996) (which are all incorporated by reference herein in their entirety).

Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include

5 antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation,

10 metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest can be produced by various procedures well known in the art. For example, a polypeptide of

15 the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum

20 hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques

25 known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and*

30 *T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term

“monoclonal antibody” refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma
5 technology are routine and well known in the art and are discussed in detail in the Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The
10 splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of
15 antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized
20 with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')₂ fragments of the invention may be
25 produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). F(ab')₂ fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated
30 using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such

phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')₂ fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., BioTechniques 12(6):864-869 (1992); and Sawai et al., AJRI 34:26-34 (1995); and Better et al., Science 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology 203:46-88 (1991); Shu et al., PNAS 90:7995-7999 (1993); and Skerra et al., Science 240:1038-1040 (1988). For some uses, including

in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal

5 antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., (1989) J. Immunol. Methods 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are

10 antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve,

15 antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988),

20 which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al.,

25 Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody

30 libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO

98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can
5 express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes.
10 The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce
15 chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human
20 immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, Int. Rev. Immunol. 13:65-93 (1995). For a
25 detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are
30 incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to

provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a
5 selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using
10 techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or
15 binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

20

Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower
25 stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the
30 polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described

in Kutmeier et al., *BioTechniques* 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

5 Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library
10 generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a
15 cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

 Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated
20 using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John
25 Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

 In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the
30 complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using

routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423-42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038-1041 (1988)).

Methods of Producing Antibodies

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably,
5 by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a
10 polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by
15 expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo
20 genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT
25 Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an
30 antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous

promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the

generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the E. coli expression vector pUR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding
5 sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such
10 fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

15 In an insect system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin
20 promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric
25 gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for
30 efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure

translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al.,
5 Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein.
10 Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript,
15 glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

20 For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences,
25 transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to
30 form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule.

Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

- A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., *Cell* 11:223 (1977)),
- 5 hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, *Proc. Natl. Acad. Sci. USA* 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., *Cell* 22:817 (1980)) genes can be employed in tk-, hgp^rt- or ap^rt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., *Natl. Acad. Sci. USA* 77:357 (1980); O'Hare et al., *Proc. Natl. Acad. Sci. USA* 78:1527 (1981)); gpt,
- 10 which confers resistance to mycophenolic acid (Mulligan & Berg, *Proc. Natl. Acad. Sci. USA* 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 (*Clinical Pharmacy* 12:488-505; Wu and Wu, *Biotherapy* 3:87-95 (1991); Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, 1993, *TIB TECH* 11(5):155-215); and hyg^r, which confers resistance to hygromycin (Santerre et al., *Gene* 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al.
- 20 (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), *Current Protocols in Human Genetics*, John Wiley & Sons, NY (1994); Colberre-Garapin et al., *J. Mol. Biol.* 150:1 (1981), which are incorporated by reference herein in their entireties.
- 25 The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, *The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning*, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in
- 30 culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., *Mol. Cell. Biol.* 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g.,

Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS 89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entireties.

5 The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant
10 region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be
15 made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991);
20 Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337- 11341(1992) (said references incorporated by reference in their entireties).

 As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to
25 the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various
30 domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having

disulfide- linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995)).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment

thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish
5 peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material
10 includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ¹¹¹In or ⁹⁹Tc.

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or
15 a radioactive metal ion, e.g., alpha-emitters such as, for example, ²¹³Bi. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-
20 dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU),
25 cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

30 The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein

or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, α -interferon, β -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- α , TNF- β , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon *et al.*, "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld *et al.* (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom *et al.*, "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson *et al.* (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera *et al.* (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin *et al.* (eds.), pp. 303-16 (Academic Press 1985), and Thorpe *et al.*, "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

5 Immunophenotyping

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or
10 maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with
15 antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to
20 prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

Assays For Antibody Binding

25 The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions,
30 gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well

known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

5 Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell
10 lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the
15 art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

20 Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-
25 fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or
30 alkaline phosphatase) or radioactive molecule (e.g., ³²P or ¹²⁵I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can

be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

5 ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be
10 conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the
15 coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

20 The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., ^3H or ^{125}I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the
25 antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., ^3H or ^{125}I) in the presence of
30 increasing amounts of an unlabeled second antibody.

Therapeutic Uses

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of

products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

- 5 It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will
- 10 preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities include those with a dissociation constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, and 10^{-15} M.
- 15

Gene Therapy

- In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or
- 20 prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

- 25 Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

- For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science
- 30 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al.

(eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences
5 encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue- specific. In another particular embodiment,
10 nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific
15 embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or
20 indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be
25 accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun;
30 Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by

administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); Zijlstra et al., *Nature* 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., *Meth. Enzymol.* 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., *J. Clin. Invest.* 93:644-651 (1994); Kiem et al., *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current*

Opinion in Genetics and Development 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., Human Gene Therapy 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143-155 (1992); Mastrangeli et al., J. Clin. Invest. 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., Gene Therapy 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth. Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be
5 determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages,
10 neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

15 In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and
20 maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

In a specific embodiment, the nucleic acid to be introduced for purposes of
25 gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription. Demonstration of Therapeutic or Prophylactic Activity

The compounds or pharmaceutical compositions of the invention are
30 preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition

include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

10 Therapeutic/Prophylactic Administration and Composition

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In

addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter. for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J.Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose

(see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).

5 In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered in vivo to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by
10 use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g., Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA
15 for expression, by homologous recombination.

 The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term
"pharmaceutically acceptable" means approved by a regulatory agency of the Federal
20 or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as
25 peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel,
30 sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering

agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as
5 pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier
10 so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous
15 administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such
20 as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

25 The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol,
30 histidine, procaine, etc.

The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant

expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. **Diagnosis and Imaging**

Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases and/or disorders associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an

increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium (^{99}Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for

unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of ^{99m}Tc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body

scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI). Kits

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the

kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may
5 also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The
10 diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled
15 monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing
20 unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by
25 incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include
30 non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group.

Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound
5 recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

Fusion Proteins

Any polypeptide of the present invention can be used to generate fusion
10 proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target
15 cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics
20 of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the
25 polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of
30 immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an

increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).)

- 5 Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

- Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion
10 proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified,
15 would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol.
20 Chem. 270:9459-9471 (1995).)

- Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue,
25 Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767
30 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech,
5 Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated
10 transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

15 A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most
20 preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical
25 synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also
30 include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency

from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

5 In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide
10 sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit
15 (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of
20 which are incorporated by reference in their entireties).

 In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a
25 polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, α -amino isobutyric acid, 4-
30 aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-

butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoro-amino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

5 The invention encompasses polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not
10 limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH_4 ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

 Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of
15 N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and
20 isolation of the protein.

 Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for
25 derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

30 The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of

polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., Exp. Hematol. 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different

types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

5 The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, *Therapeutics*) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or
10 tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

 Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA
15 contained in a deposited clone (including fragments, variants, splice variants, and fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another
20 specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (e.g., containing polypeptides having identical or different amino acid sequences) or a homotrimer (e.g., containing polypeptides having identical and/or different amino acid sequences). In additional
25 embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

 As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (i.e., polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the
30 invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the

invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker

molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues
5 located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers
10 containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its
15 entirety).

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent
20 Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse
25 orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal
30 peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes
5 known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present
10 invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of
15 somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per
20 day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved
25 using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon
30 Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for

marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

- 5 Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and
10 one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

- Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.
15 First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide
20 and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

- Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using
25 polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

- Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the
30 present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression

level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test
5 subject. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand
10 containing a 31' mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present
15 invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the
20 polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard
25 being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

30 By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the polypeptide of the present invention or mRNA. As indicated, biological samples

include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art.

- 5 Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a
10 "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying
15 disease loci for many disorders, including cancerous diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or
20 according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine, thymine and cytosine are available commercially (Perceptive Biosystems). Certain
25 components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, Science 254, 1497 (1991); and M. Egholm, O. Buchardt, L.Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, Nature 365, 666 (1993), PNAs bind specifically and
30 tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide

backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined
5 with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point (T.sub.m) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

10 The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic
15 leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative disorders are often associated with inappropriate
20 activation of proto-oncogenes. (Germann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in Neoplastic Diseases of the Blood, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the
25 chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Germann et al., supra) It is likely that mutated or altered expression of specific genes is involved in the pathogenesis of some leukemias, among other tissues and cell types. (Germann et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal
30 neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Germann et al., supra)

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of HL-60 cells to a DNA
5 construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However,
10 the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative disorders of hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

In addition to the foregoing, a polynucleotide can be used to control gene
15 expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and
20 Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456
25 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into
30 polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an

identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (¹²⁵I, ¹²¹I), carbon (¹⁴C), sulfur (³⁵S), tritium (³H), indium (¹¹²In), and technetium (^{99m}Tc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which
5 emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with
10 an appropriate detectable imaging moiety, such as a radioisotope (for example, ^{131}I , ^{112}In , $^{99\text{m}}\text{Tc}$), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety
15 needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of $^{99\text{m}}\text{Tc}$. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics
20 of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells
25 or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a
30 predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ

preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

Gene Therapy Methods

Another aspect of the present invention is to gene therapy methods for treating disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into
5 an animal to achieve expression of a polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein
10 incorporated by reference.

Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the
15 art. For example, see Belldegrün et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255
20 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be
25 delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked
30 polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations,

lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and
5 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene;
10 pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of polynucleotide sequence of the invention. Suitable promoters
15 include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters,
20 such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the
25 polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver,
30 spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular,

fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph
5 fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated
10 cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked *nucleic acid* sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20
15 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

20 The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the
25 procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

30 The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a
5 tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated
10 by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are
15 particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

20 Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc.
25 Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily
30 available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP

starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC),
dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine
5 (DOPE) can be used in various combinations to make conventional liposomes, with or
without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be
prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas
into a sonication vial. The sample is placed under a vacuum pump overnight and is
hydrated the following day with deionized water. The sample is then sonicated for 2
10 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an
inverted cup (bath type) probe at the maximum setting while the bath is circulated at
15EC. Alternatively, negatively charged vesicles can be prepared without sonication
to produce multilamellar vesicles or by extrusion through nucleopore membranes to
produce unilamellar vesicles of discrete size. Other methods are known and available
15 to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar
vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred.
The various liposome-nucleic acid complexes are prepared using methods well known
in the art. See, e.g., Straubinger et al., *Methods of Immunology*, 101:512-527 (1983),
20 which is herein incorporated by reference. For example, MLVs containing nucleic
acid can be prepared by depositing a thin film of phospholipid on the walls of a glass
tube and subsequently hydrating with a solution of the material to be encapsulated.
SUVs are prepared by extended sonication of MLVs to produce a homogeneous
population of unilamellar liposomes. The material to be entrapped is added to a
25 suspension of preformed MLVs and then sonicated. When using liposomes containing
cationic lipids, the dried lipid film is resuspended in an appropriate solution such as
sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and
then the preformed liposomes are mixed directly with the DNA. The liposome and
DNA form a very stable complex due to binding of the positively charged liposomes
30 to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are
prepared by a number of methods, well known in the art. Commonly used methods
include Ca^{2+} -EDTA chelation (Papahadjopoulos et al., *Biochim. Biophys. Acta*,

394:483 (1975); Wilson et al., Cell , 17:77 (1979)); ether injection (Deamer et al., Biochim. Biophys. Acta, 443:629 (1976); Ostro et al., Biochem. Biophys. Res. Commun., 76:836 (1977); Fraley et al., Proc. Natl. Acad. Sci. USA, 76:3348 (1979)); detergent dialysis (Enoch et al., Proc. Natl. Acad. Sci. USA , 76:145 (1979)); and
5 reverse-phase evaporation (REV) (Fraley et al., J. Biol. Chem., 255:10431 (1980); Szoka et al., Proc. Natl. Acad. Sci. USA , 75:145 (1978); Schaefer-Ridder et al., Science, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the
10 ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469
15 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

20 In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis
25 virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-
30 19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy , 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any

means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO_4 precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

5 The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding polypeptides of the invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

 In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with
10 polynucleotides of the invention contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses polypeptides of the invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional
15 mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis., 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science, 252:431-434 (1991);
20 Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al. Proc. Natl. Acad. Sci. USA, 76:6606 (1979)).

 Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993);
25 Rosenfeld et al., Cell, 68:143-155 (1992); Engelhardt et al., Human Genet. Ther., 4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature, 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and
30 constitutively express Ela and Elb, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other

varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr. Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention. These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express the desired gene product.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 5 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

10 Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting 15 sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same 20 restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

25 The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, 30 topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

5 The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth
10 factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein.
15 Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

20 Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available
25 depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the
30 rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is

administered by direct injection into or locally within the area of arteries.

Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide
5 construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

Therapeutic compositions useful in systemic administration, include
10 recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a particular site.

Preferred methods of systemic administration, include intravenous injection,
15 aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA , 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present
20 invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

25 Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of
30 polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of

the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

5 **Biological Activities**

 The polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological
10 activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

Immune Activity

 The polynucleotides or polypeptides, or agonists or antagonists of the present
15 invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells.
20 The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

25 A polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. A polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those
30 disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia

telangiectasia, common variable immunodeficiency, DiGeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary

Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a
5 polynucleotides or polypeptides, or agonists or antagonists of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host
10 disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response,
15 particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide or agonists
20 or antagonist may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-
25 mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

30 A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat or detect hyperproliferative disorders, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention

may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

5 For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an
10 immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

 Examples of hyperproliferative disorders that can be treated or detected by a polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast,
15 digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

 Similarly, other hyperproliferative disorders can also be treated or detected by
20 a polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia,
25 located in an organ system listed above.

 One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

 Thus, the present invention provides a method for treating cell proliferative
30 disorders by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

Another embodiment of the present invention provides a method of treating cell-proliferative disorders in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA
5 construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the polynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is
10 hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic,
15 specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

20 Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational
25 modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of
30 cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not

limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating one or more of the described disorders. Methods for producing anti-polypeptides and anti-polynucleotide
5 antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the
10 present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without
15 undue experimentation.

In particular, the antibodies, fragments and derivatives of the present invention are useful for treating a subject having or developing cell proliferative and/or differentiation disorders as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate
20 thereof.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

25 It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will
30 preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those with a dissociation constant or K_d less than $5 \times 10^{-6}M$, $10^{-6}M$, $5 \times 10^{-7}M$, $10^{-7}M$, $5 \times 10^{-8}M$, $10^{-8}M$, $5 \times 10^{-9}M$, $10^{-9}M$, $5 \times 10^{-10}M$.

10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, and 10^{-15} M.

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference).

Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al., Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference).

Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues.

Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby
5 incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous
10 polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

15 Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to
20 enhance the immune response (e.g. chemokines), to said antigens and immunogens.

Cardiovascular Disorders

Polynucleotides or polypeptides, or agonists or antagonists of the invention may be used to treat cardiovascular disorders, including peripheral artery disease,
25 such as limb ischemia.

Cardiovascular disorders include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart,
30 dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus,

and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilog y of Fallot, ventricular heart septal defects.

Cardiovascular disorders also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve disease include aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, 5 angiodyplasia, angiomas, bacillary angiomas, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular disorders, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, 10 hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, ataxia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous 15 insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, 20 carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular disorders include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral 25 arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, 30 migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and

thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment
5 syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

10 Polynucleotides or polypeptides, or agonists or antagonists of the invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous
15 injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides of the invention may be administered as part of a *Therapeutic*,
20 described in more detail below. Methods of delivering polynucleotides of the invention are described in more detail herein.

Anti-Angiogenesis Activity

The naturally occurring balance between endogenous stimulators and
25 inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally
30 delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases.

A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye disorders, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

The present invention provides for treatment of diseases or disorders associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat a cancer or tumor. Cancers which may be treated with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically,

in order to treat cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating other disorders, besides cancers, which involve angiogenesis. These disorders include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably

initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

Moreover, Ocular disorders associated with neovascularization which can be treated with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalmol.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalmol.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of disorders can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and

administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the

compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

Additionally, disorders which can be treated with the polynucleotides, polypeptides, agonists and/or antagonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, disorders and/or states, which can be treated with the polynucleotides, polypeptides, agonists and/or antagonists include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb

angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophilic joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have
5 angiogenesis as a pathologic consequence such as cat scratch disease (Rochele minalia quintosa), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and
10 fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

15 Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present
20 invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat
25 tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti-angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized
30 during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl

complexes include. for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten
5 oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its
10 hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and
15 sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan
20 Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin;
25 Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum;
30 alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-

316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole; and metalloproteinase inhibitors such as BB94.

Diseases at the Cellular Level

- 5 Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated or detected by the polynucleotides or polypeptides and/or antagonists or agonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer,
- 10 melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary
- 15 cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or agonists or antagonists of
- 20 the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

- Additional diseases or conditions associated with increased cell survival that could be treated or detected by the polynucleotides or polypeptides, or agonists or antagonists of the invention, include, but are not limited to, progression, and/or
- 25 metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and
- 30 non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma,

osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal
5 cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder
10 carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated or detected by the polynucleotides or polypeptides, and/or agonists or antagonists of the
15 invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus
20 erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by
25 alcohol), septic shock, cachexia and anorexia.

Wound Healing and Epithelial Cell Proliferation

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists
30 or antagonists of the invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds.

Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal
5 ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of
10 the invention, could be used to promote dermal reestablishment subsequent to dermal loss

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are a non-
15 exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists of the invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepidermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft,
20 homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omentop graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, can be used to promote skin strength and to improve the appearance of aged skin.

25 It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could promote proliferation of epithelial cells such as
30 sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists

or antagonists of the invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may have a cytoprotective effect on the small intestine mucosa. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention,

could be used to treat diseases associate with the under expression of the polynucleotides of the invention.

Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and brochiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated using the polynucleotides or polypeptides, and/or agonists or antagonists of the invention. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary displasia, in premature infants.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetraholoride and other hepatotoxins known in the art).

In addition, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

Neurological Diseases

Nervous system disorders, which can be treated with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian patients) according to the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to,

multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

In a preferred embodiment, the polypeptides, polynucleotides, or agonists or
5 antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat or prevent neural cell injury associated with cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury
10 associated with cerebral ischemia. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a stroke.
15 In a further aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a heart attack.

The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in
20 promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or
25 acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (J. Neurosci.
30 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (Exp. Neurol. 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981));

increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron disorders that may be treated according to the invention include, but are not limited to, disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

Infectious Disease

A polypeptide or polynucleotide and/or agonist or antagonist of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polypeptide or polynucleotide and/or agonist or antagonist of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae,

Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papilloma virus, Papovaviridae, Parvoviridae, 5 Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue 10 syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and 15 viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists 20 or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and 25 that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Nocardia), Cryptococcus neoformans, Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), 30 Bacteroidaceae, Blastomycosis, Bordetella, Borrelia (e.g., Borrelia burgdorferi), Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, E. coli (e.g., Enterotoxigenic E. coli and Enterohemorrhagic E.

coli), Enterobacteriaceae (Klebsiella, Salmonella (e.g., Salmonella typhi, and Salmonella paratyphi), Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Mycobacterium leprae, Vibrio cholerae, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal),

5 Meisseria meningitidis, Pasteurellacea Infections (e.g., Actinobacillus, Heamophilus (e.g., Heamophilus influenza type B), Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, Shigella spp., Staphylococcal, Meningiococcal, Pneumococcal and Streptococcal (e.g., Streptococcus pneumoniae and Group B Streptococcus). These bacterial or fungal families can cause the following diseases or

10 symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning,

15 Typhoid, pneumonia, Gonorrhea, meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. Polynucleotides or polypeptides, agonists or

20 antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, Ppolynucleotides, polypeptides, agonists or antagonists of the invention are used to treat: tetanus, Diphtheria, botulism, and/or meningitis type B.

Moreover, parasitic agents causing disease or symptoms that can be treated or

25 detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax,

30 Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis),

liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or
5 agonists or antagonists of the invention are used to treat malaria.

Preferably, treatment using a polypeptide or polynucleotide and/or agonist or antagonist of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the
10 engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

15 A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis,
20 osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic,
25 and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage.
30 A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or

ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide and/or agonist or antagonist of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

Chemotaxis

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may inhibit chemotactic activity. These molecules

could also be used to treat disorders. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention could be used as an inhibitor of chemotaxis.

5

Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit
10 (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural
15 or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

20 Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially
25 containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the
30 candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product

mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

5 Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

 Additionally, the receptor to which a polypeptide of the invention binds can be
10 identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF
15 family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition
20 site for a site-specific protein kinase.

 Following fixation and incubation, the slides are subjected to auto-radiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

25 As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein
30 microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of polypeptides of the invention thereby effectively generating agonists and antagonists of polypeptides of the invention. See
5 generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, L. O., et al., *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. *Biotechniques* 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated
10 by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide sequence of the invention molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides of the
15 invention may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptides of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more
20 heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B,
25 decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the
30 polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The

biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention.

5 An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and 3[H] thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the
10 compound to determine if the compound stimulates proliferation by determining the uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of 3[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.

15 In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following
20 interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

25 All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from
30 suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and

(b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with the polypeptide, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

5 Also, one could identify molecules bind a polypeptide of the invention experimentally by using the beta-pleated sheet regions contained in the polypeptide sequence of the protein. Accordingly, specific embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed
10 polypeptide sequence. Additional embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, any combination or all of contained in the polypeptide sequences of the invention. Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta
15 pleated sheet regions in one of the polypeptide sequences of the invention. Additional embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions in one of the polypeptide sequences of the invention.

20 **Targeted Delivery**

In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be
25 associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic
30 acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double

stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

Drug Screening

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any

of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids
5 expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any
10 other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically
15 labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present
20 invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and
25 washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays
30 in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of

any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

Antisense And Ribozyme (Antagonists)

5 In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered
10 (see, for example, O'Connor, Neurochem., 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense
15 Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., Nucleic Acids Research, 6:3073 (1979); Cooney et al., Science, 241:456 (1988); and Dervan et al., Science, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

20 For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of
25 oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl₂, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then
30 ligated to the EcoRI/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA

oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, *Nature*, 29:304-310 (1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell*, 22:787-797 (1980)), the herpes thymidine promoter (Wagner et al., *Proc. Natl. Acad. Sci. U.S.A.*, 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster et al., *Nature*, 296:39-42 (1982)), etc.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA sequence of the

invention it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, *e.g.*,
5 the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' -
10 non- translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but
15 could be used in accordance with the invention. Whether designed to hybridize to the 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

20 The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (*e.g.*,
25 for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger et al., *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556 (1989); Lemaitre et al., *Proc. Natl. Acad. Sci.*, 84:648-652 (1987); PCT Publication NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, *e.g.*, PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, *e.g.*, Krol et al., *BioTechniques*, 6:958-976 (1988))
30 or intercalating agents. (See, *e.g.*, Zon, *Pharm. Res.*, 5:539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide,

hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil,
 5 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine,
 10 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,
 15 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose,
 20 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl
 25 phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)).
 30 The oligonucleotide is a 2-0-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215:327-330 (1987)).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al.
5 (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated
10 region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs
15 corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5' -UG-3' . The construction and production of hammerhead ribozymes is well
20 known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to
25 increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo.
30 DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the

ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular
5 concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation
10 or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirable in cases such as restenosis after balloon
15 angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

The antagonist/agonist may also be employed to treat the diseases described herein.

20 Thus, the invention provides a method of treating disorders or diseases, including but not limited to the disorders or diseases listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present
25 invention

Other Activities

The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as
30 thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide

may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells
5 of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat and prevent neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease,
10 Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

The polypeptide of the present invention may be also be employed to prevent
15 skin aging due to sunburn by stimulating keratinocyte growth.

The polypeptide of the invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone
20 marrow cells when used in combination with other cytokines.

The polypeptide of the invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues.

The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.
25

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

The polypeptide or polynucleotides and/or agonist or antagonists of the
30 present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or

polynucleotides and/or agonist or antagonists of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

Polypeptide or polynucleotides and/or agonist or antagonists of the present
5 invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

10 Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

15 **Other Preferred Embodiments**

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

20 Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

25 Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

30 Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the

range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

5 Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

 Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500
10 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

 A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about
15 the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

20 Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

25 Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

30 Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA

Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the
5 complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule
10 comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete
15 nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X
20 wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and
25 determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence
30 selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected

from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said
5 cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit
10 with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the
15 deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA
20 clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as
25 defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a
30 polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as

defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid

sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone

identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred
5 is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is
10 expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of
15 SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA
20 clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to
25 increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit,
30 goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 2, preferably excluded are one or more polynucleotides comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 2 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 2. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences referred to in the fifth column of Table 2. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 2

Gene No.	cDNA Clone ID	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
2	HAGFF43	12	821316	N48187, N49746, N52675, AA115107
7	HKACA25	17	824087	T71107, R07491, R07544, R02367, R02473, R12602, R74032, R74123, R79290, R81173, R81277, R86952, H49320, N54909, AA196897
9	HAQBG57	19	837545	R69327, AA507216, AA593594
10	HAQBY85	20	832384	T64857, H88471, W89023, W89024, AA036826, AA158032, AA253382, AA688389, AA748991, AA837024, AA888418, AA935978, C21449
14	HAGEW83	24	617111	AA424534, AA424600
15	HAGEX49	25	834502	T89093, R60840, H16750, H51569, H51939, AI005611
16	HAGFM58	26	604536	H05533
20	HOEBI94	30	795312	T77192, R02068, R39545, H03581, R83018, R92004, H57629, H57730, N30564, N63606, N73133, N79282, N94803, W32888, W35158, AA053126, AA064861, AA065119, AA081354, AA088706, AA088774, AA088775, AA088772, AA101806, AA182658, AA196568, AA196670, AA233292, AA236666, AA256263, AA256359, AA425103, AA429324
22	HAIBT20	32	741086	AA461563
23	HAICE62	33	834523	N35973, N70484, AA236276, AA234286, AA417589, AA482028, AA488888, AA554535, AA633532, AA715033, AA765790, AA923504, AA987966, AI027570, C00553
26	HAJAZ56	36	716168	R69788, N62743, N79684, W52081, AA084615
29	HAMGG01	39	783864	R55333, N24631, N35833, W63691, AA070411,

				AA147489, AA253000, AA252999, AA255718, AA262075
31	HAPBU86	41	789544	T77303, R20876, R38187, R42056, W56173, AA030021
32	HAPNL62	42	790340	T92717, T92796, R22380, N77136, AA018552, AA037814, AA037815, AA146872, AA146873, AA192996, AA193047, AA424312
33	HAPNO50	43	834384	R52145, N80724, W52200, W56688, W56696, W76539, AA588352, AA593340, AA593332, AA742572, AA865071, AA977531, AA988767, AI002202, AI081543
37	HAPQU71	47	752580	AA459527
42	HAQCF94	52	795993	R23565, H52947
43	HARAT69	53	769389	T50337, T61914, T79997, R37580, H29047, H29149, AA100250
45	HAGEQ79	55	828055	T72606, R55798, H46138, H91757, W73069, W92767, AA044775, AA975324
46	HAGHN57	56	773286	T60588, H16095, N58884, W01852, W31025, AA101864, AA134574, AA151047, AA182513, AA227675
47	HASAY07	57	834511	C18262

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
	<u>Plasmid</u>	
	Lambda Zap	pBluescript (pBS)
20	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
25	pCMVSPORT 3.0	pCMVSPORT 3.0
	pCR [®] 2.1	pCR [®] 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Altling-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Altling-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey

30

Pines Road, La Jolla, CA. 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS-. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

10 Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, 15 NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., 20 Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

 The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional 25 plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample 30 may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

- 5 Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P - γ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).)
- 10 The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate.
- 15 These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

- Alternatively, two primers of 17-20 nucleotides derived from both ends of the
- 20 SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μl of reaction mixture with 0.5 μg of the above cDNA template. A convenient reaction mixture is
- 25 1.5-5 mM MgCl_2 , 0.01% (w/v) gelatin, 20 μM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and
- 30 the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

Example 3: Tissue Distribution of Polypeptide

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from

QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or

Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

5

Example 6: Purification of a Polypeptide from an Inclusion Body

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

10 Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution
15 containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

 The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by
20 centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

 The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree
25 C overnight to allow further GuHCl extraction.

 Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C
30 without mixing for 12 hours prior to further purification steps.

 To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 um membrane filter with appropriate surface area

(e.g., Filtron). equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a
5 stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak
10 anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are
15 collected under constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified
20 protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus

25 Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as
30 BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the

plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to
5 generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as
10 required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally
15 occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555
20 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

25 The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4
30 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified

by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0
5 ug of a commercially available linearized baculovirus DNA ("BaculoGold™
baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method
described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug
of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a
microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies
10 Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are
added, mixed and incubated for 15 minutes at room temperature. Then the
transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded
in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is
then incubated for 5 hours at 27 degrees C. The transfection solution is then removed
15 from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf
serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed,
as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life
Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of
20 gal-expressing clones, which produce blue-stained plaques. (A detailed description of
a "plaque assay" of this type can also be found in the user's guide for insect cell
culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page
9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a
micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then
25 resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the
suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded
in 35 mm dishes. Four days later the supernatants of these culture dishes are
harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's
30 medium supplemented with 10% heat-inactivated FBS. The cells are infected with
the recombinant baculovirus containing the polynucleotide at a multiplicity of
infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the

medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of ^{35}S -methionine and 5 uCi ^{35}S -cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation.

- 5 The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

10 **Example 8: Expression of a Polypeptide in Mammalian Cells**

- The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIV and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).
- 15
20

- Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.
- 25

- Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.
- 30

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene. and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment

then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μ g of the expression plasmid pC6 a pC4 is cotransfected with 0.5 μ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

25 **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a

specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by
5 modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These
10 primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with
15 BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted
20 protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

25 GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGC
CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA
CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
30 CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA
ACCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC

CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT
CCCGTGCTGGACTCCGACGGCTCCTTCTCCTCTACAGCAAGCTCACCGTG
5 GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG
GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

Example 10: Production of an Antibody from a Polypeptide

10 The antibodies of the present invention can be prepared by a variety of
methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells
expressing a polypeptide of the present invention is administered to an animal to
induce the production of sera containing polyclonal antibodies. In a preferred
method, a preparation of the secreted protein is prepared and purified to render it
15 substantially free of natural contaminants. Such a preparation is then introduced into
an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are
monoclonal antibodies (or protein binding fragments thereof). Such monoclonal
antibodies can be prepared using hybridoma technology. (Köhler et al., Nature
20 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J.
Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell
Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures
involve immunizing an animal (preferably a mouse) with polypeptide or, more
preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in
25 any suitable tissue culture medium; however, it is preferable to culture cells in Earle's
modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at
about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids,
about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma
30 cell line. Any suitable myeloma cell line may be employed in accordance with the
present invention; however, it is preferable to employ the parent myeloma cell line
(SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are

selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

5 Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a
10 mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of
15 further protein-specific antibodies.

 It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂
20 fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

 For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced
25 using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson
30 et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening Assays

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in

5 Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each
10 well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml
15 DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate.
20 With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45
25 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too
30 much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other

channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

- While cells are incubating, prepare appropriate media, either 1%BSA in
- 5 DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl₂ (anhyd); 0.00130 mg/L CuSO₄·5H₂O; 0.050 mg/L of Fe(NO₃)₃·9H₂O; 0.417 mg/L of FeSO₄·7H₂O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄·H₂O; 71.02 mg/L of Na₂HPO₄; .4320 mg/L of ZnSO₄·7H₂O; .002 mg/L of Arachidonic Acid ; 1.022 mg/L
 - 10 of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml
 - 15 of L-Asparagine-H₂O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H₂O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H₂O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0
 - 20 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H₂O; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319
 - 25 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of
 - 30 Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L

DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person
5 B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

10 It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant
15 characterized by an activity in a particular assay.

Example 12: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the
20 Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six
25 members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at
30 higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are
5 generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, *Ann. Rev. Biochem.* 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-
10 12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN- α , IFN- γ , and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn
15 activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines
20 are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

	<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u> <u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>	<u>STATs</u>	<u>GAS(elements) or ISRE</u>
	<u>IFN family</u>						
5	IFN-a/B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
	Il-10	+	?	?	-	1,3	
	<u>gp130 family</u>						
10	IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	Il-11(Pleiotrophic)	?	+	?	?	1,3	
	OnM(Pleiotrophic)	?	+	+	?	1,3	
	LIF(Pleiotrophic)	?	+	+	?	1,3	
	CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
15	G-CSF(Pleiotrophic)	?	+	?	?	1,3	
	IL-12(Pleiotrophic)	+	-	+	+	1,3	
	<u>g-C family</u>						
	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
20	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
	IL-15	?	+	?	+	5	GAS
25	<u>gp140 family</u>						
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5	GAS
	GM-CSF (myeloid)	-	-	+	-	5	GAS
30	<u>Growth hormone family</u>						
	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
	EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
35	<u>Receptor Tyrosine Kinases</u>						
	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	
	CSF-1	?	+	+	-	1,3	GAS (not IRF1)
40							

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

10 5':GCGCCTCGAGATTTCCCGAAATCTAGATTTCCCGAAATGATTTCCCG
GAAATGATTTCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

15 PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

20 5':CTCGAGATTTCCCGAAATCTAGATTTCCCGAAATGATTTCCCGAAA
TGATTTCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCG
CCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCT
CCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC
TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCT
25 AGGCTTTTGCAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter
30 molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately
5 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells
10 containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1% Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

15 During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

20 The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptides of the invention and/or induced polypeptides of the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and
25 resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells
30 into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100,000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the
5 assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophane covers) and
10 stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the
15 positive control wells.

The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

20 The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is
25 U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing
30 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM Na₂HPO₄·7H₂O, 1 mM MgCl₂, and 675 uM CaCl₂. Incubate at 37 degrees C for 45 min.

- 5 Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

- 10 These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example

- 15 11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

20 **Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

- When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the
- 25 EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).

- 30 The EGR1 gene expression is activated during this treatment. Thus, by stably

transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene
5 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified
10 product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30
15 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-
20 inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine
25 protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80%
30 confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

- 5 Add 200 μ l of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 μ l supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ μ l of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the
10 supernatant according to Example 17.

Example 16: High-Throughput Screening Assay for T-cell Activity

- NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and
15 CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

- 20 In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

- 25 Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid
30 arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTCCGGGGACTTTCCGGGAC
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

10 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)

Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTCCGGGGACTTCCGGGACTTTCC
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC
ATCCCGCCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA
20 CTAATTTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGAGCTA
TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA
GCTT:3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2- promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5

19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used

instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for
5 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO₂ incubator for 60 min. The plate is washed four
10 times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are
15 washed twice with HBSS, resuspended to 1x10⁶ cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as
20 fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm;
25 and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca⁺⁺ concentration.

Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase

Activity

30 The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine

Kinase RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also

5 membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and

10 non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of

15 activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from

20 Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or

25 calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen

30 Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in

5 Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a

10 vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4

15 degrees C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by

20 determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

25 The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂⁺ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the

30 components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any

of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degrees C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal
5 medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in
10 place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing
15 reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

20 RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for
25 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and
30 genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

5 Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is
10 carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology,
15 Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of
20 the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a
25 **Biological Sample**

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their
30 particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with

specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

- 5 The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

- 10 Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

- 15 Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

20

Example 23: Formulation

- 25 The invention also provides methods of treatment and/or prevention of diseases or disorders (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

- 30 The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other

factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about
5 1ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per
10 day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be administered orally, rectally, parenterally,
15 intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include
20 intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracisternally, intravaginally,
25 intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal,
30 intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable

polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

- 5 Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., *Biopolymers* 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., *Id.*) or poly-D- (-)-3-hydroxybutyric
10 acid (EP 133,988).

Sustained-release Therapeutics also include liposomally entrapped Therapeutics of the invention (*see generally*, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)).

- 15 Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. (USA)* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci.(USA)* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small
20 (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

- In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see Langer, supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.*
25 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

- For parenteral administration, in one embodiment, the Therapeutic is
30 formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and

concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic
5 uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl
10 oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts;
15 antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose
20 or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will
25 be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container
30 having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered

separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in
5 combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either
10 concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination"
15 further includes the separate administration of one of the compounds or agents given first, followed by the second.

In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include,
20 but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6
25 (International Publication No. WO 98/30694), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication
30 No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202),

312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

- In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors.
- Nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine).
- Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz).
- Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir).
- In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.
- In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICLOVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF).
- In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™,

- DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or
- 5 ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific
- 10 embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to
- 15 prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with
- 20 PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.
- 25 In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.
- In a further embodiment, the Therapeutics of the invention are administered
- 30 in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin,

beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-
5 sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other
10 immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™
15 (cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucocorticosteroids, and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered
20 alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in
25 combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention
30 include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives,

pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, 5 pifoxime, proquazone, proxazole, and tenidap.

In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and 10 dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); 15 hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephalen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., 20 dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).

In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another 25 embodiment, Therapeutics of the invention are administered in combination with Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP.

In an additional embodiment, the Therapeutics of the invention are 30 administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-

alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

5 In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European
10 Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PlGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PlGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication
15 Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO
20 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by
25 reference herein.

 In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and
30 NEUPOGEN™ (FILGRASTIM™).

 In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth

Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in
5 combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

Example 24: Method of Treating Decreased Levels of the Polypeptide

The present invention relates to a method for treating an individual in need of
10 an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be
15 treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

20 For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

25 **Example 25: Method of Treating Increased Levels of the Polypeptide**

The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and
30 antibodies of the invention).

In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

10 **Example 26: Method of Treatment Using Gene Therapy-Ex Vivo**

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine

sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto
5 agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the
10 gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media,
15 containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no
20 selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or
25 after having been grown to confluence on cytodex 3 microcarrier beads.

Example 27: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention

Another method of gene therapy according to the present invention involves
30 operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411,

published September 26, 1996; International Publication NO: WO 94/12650,
published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935
(1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the
activation of a gene which is present in the target cells, but which is not expressed in
5 the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting
sequences, which are homologous to the 5' non-coding sequence of endogenous
polynucleotide sequence, flanking the promoter. The targeting sequence will be
sufficiently near the 5' end of the polynucleotide sequence so the promoter will be
10 operably linked to the endogenous sequence upon homologous recombination. The
promoter and the targeting sequences can be amplified using PCR. Preferably, the
amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends.
Preferably, the 3' end of the first targeting sequence contains the same restriction
enzyme site as the 5' end of the amplified promoter and the 5' end of the second
15 targeting sequence contains the same restriction site as the 3' end of the amplified
promoter.

The amplified promoter and the amplified targeting sequences are digested
with the appropriate restriction enzymes and subsequently treated with calf intestinal
phosphatase. The digested promoter and digested targeting sequences are added
20 together in the presence of T4 DNA ligase. The resulting mixture is maintained under
conditions appropriate for ligation of the two fragments. The construct is size
fractionated on an agarose gel then purified by phenol extraction and ethanol
precipitation.

In this Example, the polynucleotide constructs are administered as naked
25 polynucleotides via electroporation. However, the polynucleotide constructs may also
be administered with transfection-facilitating agents, such as liposomes, viral
sequences, viral particles, precipitating agents, etc. Such methods of delivery are
known in the art.

Once the cells are transfected, homologous recombination will take place
30 which results in the promoter being operably linked to the endogenous polynucleotide
sequence. This results in the expression of polynucleotide corresponding to the

polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary
5 phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na₂ HPO₄, 6 mM dextrose). The cells are recentrifuged, the
10 supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately 3×10^6 cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to
15 construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3' end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an
20 Xba site at the 3' end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5' end and a HindIII site at the 3' end. The CMV promoter and the fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-
25 digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120 µg/ml. 0.5 ml of the cell suspension (containing approximately 1.5×10^6 cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is
30 performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 µF and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their

genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer
5 pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after
10 having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

Example 28: Method of Treatment Using Gene Therapy - In Vivo

15 Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter
20 or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al., Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318
25 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation 94(12):3281-3290 (1996) (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The
30 polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are

free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in
5 Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain
10 sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to
15 provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and
20 connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of
25 the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely
30 differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after

preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

5

Example 29: Transgenic Animals.

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*,
10 baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (*i.e.*,
15 polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus
20 mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science
25 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

30 Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to

quiescence (Campbell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate
5 lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to
10 produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of
15 polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 30: Knock-Out Animals.

20 Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*, see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional
25 polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in
30 the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in

research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly
5 administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are
10 administered to a patient *in vivo*. Such cells may be obtained from the patient (*i.e.*, animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (*e.g.*, lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the
15 invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, *e.g.*, by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.
20 The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, *e.g.*, in the circulation, or
25 intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, *e.g.*, genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and
30 Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing
5 for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders
10 associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 31: Production of an Antibody

a) Hybridoma Technology

15 The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide(s) of the invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide(s) of the invention is prepared and purified to render it
20 substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for polypeptide(s) of the invention are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976);
25 Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide(s) of the invention or, more preferably, with a secreted polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with
30 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are
5 selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide(s) of the invention.

Alternatively, additional antibodies capable of binding to polypeptide(s) of the
10 invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to
15 produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by polypeptide(s) of the invention. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and are used to immunize an animal to induce formation of further protein-specific antibodies.

20 For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214
25 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

30 b) Isolation Of Antibody Fragments Directed Against
 Polypeptide(s) From A Library Of scFvs

Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide(s) of the invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

5 Rescue of the Library.

A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 109 E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and
10 grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10⁸ TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY
15 containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III
20 particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-
25 AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10¹³ transducing units/ml (ampicillin-resistant clones).

30 Panning of the Library.

Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with

2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 1013 TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with
5 PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100
10 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

15 Characterization of Binders.

Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 µg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones
20 positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or
25 antagonistic activity.

Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation

30 Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed

development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed Staphylococcus aureus Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added 10^5 B-cells suspended in culture medium (RPMI 1640 containing 10% FBS, 5×10^{-5} M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and 10^{-5} dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse

(1uCi/well) with 3H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

Example 33: T Cell Proliferation Assay

A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of ³H-thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 µl/well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 degrees C (1 µg/ml in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from

human peripheral blood and added to quadruplicate wells (5×10^4 /well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of polypeptides of the invention (total volume 200 μ l). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37 degrees C, plates are spun for 2 min. at 1000 rpm and 100 μ l of supernatant is removed and stored -20 degrees C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 μ l of medium containing 0.5 μ Ci of 3 H-thymidine and cultured at 37 degrees C for 18-24 hr. Wells are harvested and incorporation of 3 H-thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of polypeptides of the invention.

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells

Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- α , causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC γ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of polypeptides of the invention or LPS (positive

control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

5

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells (10^6 /ml) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

15

Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

30

Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be

applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American
5 Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from
10 internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying
15 concentrations of the compound to be tested. Cells are suspended at a concentration of 2×10^6 /ml in PBS containing PI at a final concentration of 5 μ g/ml, and then incubated at room temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is
20 their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of 5×10^5 cells/ml with increasing concentrations of the a polypeptide of the invention and under the same
25 conditions, but in the absence of the polypeptide. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g., R & D Systems (Minneapolis, MN)) and applying
30 the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at 2×10^5 cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20 μ l 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of H_2O_2 produced by the macrophages, a standard curve of a H_2O_2 solution of known molarity is performed for each experiment.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 35: Biological Effects of Polypeptides of the Invention

Astrocyte and Neuronal Assays:

Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl.*

Acad. Sci. USA 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

Fibroblast and endothelial cell assays

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE₂ assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1 α for 24 hours. The supernatants are collected and assayed for PGE₂ by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 α for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth

of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

Parkinson Models.

5 The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized
10 by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP⁺) and released. Subsequently, MPP⁺ is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP⁺ is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and
15 eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic
20 neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

Based on the data with FGF-2, polypeptides of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic
25 neurons in the striatum from the damage associated with MPTP treatment. The potential effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm² on polyorthinine-laminin coated glass coverslips.
30 The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for

dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 36: The Effect of Polypeptides of the Invention on the Growth of Vascular Endothelial Cells

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at $2-5 \times 10^4$ cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells

For evaluation of mitogenic activity of growth factors, the colorimetric MTS
5 (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF₁₆₅ or a
10 polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al.*
15 *In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

20

Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect

HAoSMC proliferation can be measured, for example, by BrdUrd incorporation.
25 Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6 mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and
30 then incubated with the streptavidin-peroxidase and diaminobenzidine. After counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the

BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for individual cells by the concomitant use of bright field illumination and dark field-UV fluorescent illumination. See, Hayashida et al., J. Biol. Chem. 6:271(36):21985-21992 (1996).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 39: Stimulation of Endothelial Migration

This example will be used to explore the possibility that a polypeptide of the invention may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 μ m (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25 μ l of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber, 2.5×10^5 cells suspended in 50 μ l M199 containing 1% FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO₂ to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.


5

Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells

Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be
10 assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in
15 the medium is determined by use of the Griess reagent to measure total nitrite after reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision
20 Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



The standard calibration curve is obtained by adding graded concentrations of KNO_2 (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing
25 KI and H_2SO_4 . The specificity of the Iso-NO electrode to NO is previously determined by measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C.
30 The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions. S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of

released NO is expressed as picomoles per 1×10^6 endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

The studies described in this example tested activity of polypeptides of the
5 invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10 **Example 41: Effect of Polypeptides of the Invention on Cord Formation in Angiogenesis**

Another step in angiogenesis is cord formation, marked by differentiation of endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

15 CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 μ l/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500
20 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 μ l Cell Applications' Chord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in
25 triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. b-esteradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also utilized as a control.

The studies described in this example tested activity of a polypeptide of the
30 invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese quail (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old quail embryos is studied with the following methods.

On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cello tape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse

In vivo angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After 7 days, the solid "plug" of Matrigel is removed and examined for the presence of new

blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold
5 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde,
10 embedded in paraffin and used to produce sections for histological examination after staining with Masson's Trichrome. Cross sections from 3 different regions of each plug are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

15 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

20 **Example 44: Rescue of Ischemia in Rabbit Lower Limb Model**

To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660
25 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.* *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10
30 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid

containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen *et al. Hum Gene Ther.* 4:749-758 (1993); Leclerc *et al. J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or
5 control is delivered into the internal iliac artery of the ischemic limb over a period of 1 min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow during undilated condition and Max FL: the blood flow during fully dilated condition (also
10 an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic
15 sections taken from hindlimbs.

The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

20 **Example 45: Effect of Polypeptides of the Invention on Vasodilation**

Since dilation of vascular endothelium is important in reducing blood pressure, the ability of polypeptides of the invention to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900
25 mg/kg) of the polypeptides of the invention are administered to 13-14 week old spontaneously hypertensive rats (SHR). Data are expressed as the mean +/- SEM. Statistical analysis are performed with a paired t-test and statistical significance is defined as $p < 0.05$ vs. the response to buffer alone.

The studies described in this example tested activity of a polypeptide of the
30 invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 46: Rat Ischemic Skin Flap Model

5 The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of polypeptides of the invention, during the skin ischemia, is studied using in situ hybridization.

The study in this model is divided into three parts as follows:

- a) Ischemic skin
- 10 b) Ischemic skin wounds
- c) Normal wounds

The experimental protocol includes:

- a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).
- 15 b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).
- c) Topical treatment with a polypeptide of the invention of the excisional wounds (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.
- d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

20 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

25 **Example 47: Peripheral Arterial Disease Model**

Angiogenic therapy using a polypeptide of the invention is a novel therapeutic strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

- a) One side of the femoral artery is ligated to create ischemic muscle of
- 30 the hindlimb, the other side of hindlimb serves as a control.

b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.

c) The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the contralateral hindlimb.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 48: Ischemic Myocardial Disease Model

A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

a) The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.

b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.

c) Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 49: Rat Corneal Wound Healing Model

This animal model shows the effect of a polypeptide of the invention on neovascularization. The experimental protocol includes:

- a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.
- 5 b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.
- c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).
- d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention, within the pocket.
- 10 e) Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the
15 invention.

Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models

A. *Diabetic db+/db+ Mouse Model.*

To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is
25 dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal
30 heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria.

Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and
5 microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*, *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to
10 human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic
15 (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional
20 Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01
25 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The
30 wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

B. Steroid Impaired Rat Model

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahlet *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *An. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

To demonstrate that a polypeptide of the invention can accelerate the healing process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

5 Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad*
10 *libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

 The wounding protocol is followed according to section A, above. On the day of
15 wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the
20 testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

 Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement
25 on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

 The polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups
30 received 50mL of vehicle solution.

 Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for

histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch.

Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 51: Lymphadema Animal Model

or The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system

in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

- 5 Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws
- 10 after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

- Using the knee joint as a landmark, a mid-leg inguinal incision is made
- 15 circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated suture ligated.

- Using a microscope, muscles in back of the leg (near the semitendinosus and
- 20 adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

- Care is taken to control any mild bleeding resulting from this procedure. After
- 25 lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

- To avoid infection, animals are housed individually with mesh (no bedding).
- 30 Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated

places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

5 Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

 Volumetric Measurements: On the day of surgery, animals are anesthetized with
10 Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the
15 limb to marked area.

 Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca²⁺ comparison.

 Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control
20 legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

 Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon
25 sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 52: Suppression of TNF alpha-induced adhesion molecule expression by a Polypeptide of the Invention

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Tumor necrosis factor alpha (TNF- α), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF- α induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- α treated ECs when co-stimulated with a member of the FGF family of proteins.

To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO₂.

HUVECs are seeded in 96-well plates at concentrations of 1×10^4 cells/well in EGM medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 ul of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 ul volumes). Plates are incubated at 37 degree C for
5 either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 µl of 0.1% paraformaldehyde-PBS(with Ca++ and Mg++) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10 µl of
10 diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 µg/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20 µl of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to
15 each well and incubated at 37°C for 30 min. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: $1:5,000 (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$.
20 5 µl of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The
25 template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to
30 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

- 5 The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both
- 10 incorporated herein by reference in their entireties.

Applicant's or agent's file reference number	PF503PCT	International application No.	UNASSIGNED
-------------------------------------------------	----------	-------------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>56</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>08 April 1999</u>	Accession Number <u>203917</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
<u>Europe</u> In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input type="checkbox"/> This sheet was received with the international application Authorized officer	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer

ATCC Deposit No.: 203917

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

ATCC Deposit No.: 203917

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- 5 consisting of:
- (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - 10 (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - 15 (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;
 - (f) a polynucleotide which is a variant of SEQ ID NO:X;
 - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
 - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
 - 20 (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
 - 25

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.
- 5 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
- 10 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
- 15 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide
20 sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
- 25 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
9. A recombinant host cell produced by the method of claim 8.
- 30 10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

5 (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included
10 in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

15 (g) a variant of SEQ ID NO:Y;

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-
20 terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

25 14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 14 under conditions such that
30 said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount
5 of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of
10 claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to
15 a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
20

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the
25 polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the
30 method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Komatsoulis et al.

<120> 49 Human Secreted Proteins

<130> PS503PCT

<140> Unassigned

<141> 2000-03-09

<150> 60/124,145

<151> 1999-03-12

<150> 60/168,654

<151> 1999-12-03

<160> 148

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gcccaaatct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgacccgtca	gtcttctctt	tcccccaaaa	acccaaggac	accctcatga	120
tctcccggac	tcctgaggtc	acatgcgtgg	tggtggacgt	aagccacgaa	gaccctgagg	180
tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgcaagg	tctccaacaa	agccctccca	acccccatcg	360
agaaaacccat	ctccaaagcc	aaagggcagc	cccgagaacc	acaggtgtac	accctgcccc	420
catcccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgggaga	gcaatgggca	gccggagAAC	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttctt	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaagagtg	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser

1

5

<210> 3

<211> 86

<212> DNA

<213> Homo sapiens

<400> 3

gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60
cccgaaatat ctgccatctc aattag 86

<210> 4

<211> 27

<212> DNA

<213> Homo sapiens

<400> 4

gcggcaagct ttttgcaaag cctaggc 27

<210> 5

<211> 271

<212> DNA

<213> Homo sapiens

<400> 5

ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60
aaatatctgc catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc 120
gccctaact cgcgccagtt cgcgccattc tccgccccat ggctgactaa ttttttttat 180
ttatgcagag gccgaggccg cctcggcctc tgagctatc cagaagtagt gaggagggtt 240
ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 6

<211> 32

<212> DNA

<213> Homo sapiens

<400> 6

gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7

<211> 31

<212> DNA

<213> Homo sapiens

<400> 7

gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8

<211> 12

<212> DNA

<213> Homo sapiens

<400> 8

ggggactttc cc 12

<210> 9

<211> 73

<212> DNA

<213> Homo sapiens

<400> 9

gcggcctcga	ggggactttc	ccggggactt	tccggggact	ttccgggact	ttccatcctg	60
ccatctcaat	tag					73

<210> 10

<211> 256

<212> DNA

<213> Homo sapiens

<400> 10

ctcgaggga	ctttcccggg	gactttccgg	ggactttccg	ggactttcca	tctgccatct	60
caattagtca	gcaaccatag	tcccggccct	aactccgccc	atcccggccc	taactccgcc	120
cagttccgcc	cattctccgc	cccatggctg	actaattttt	tttatttatg	cagaggccga	180
ggccgcctcg	gcctctgagc	tattccagaa	gtagttagga	ggcttttttg	gaggcctagg	240
cttttgcaaa	aagctt					256

<210> 11

<211> 1205

<212> DNA

<213> Homo sapiens

<400> 11

tgcaggaatt	cggcaccgagc	ccgagtggtc	gccaacagtg	gctttgatgt	gctttgccat	60
gccctggagt	catacaccac	cctgccctac	cacctgcgga	cccctgccct	tcaaatccca	120
tcacacggcc	tgcgtaccag	ggcagcaacc	caatcagtga	catttgggct	atccacgcgc	180
tgcggatcgt	ggctaagtat	ctgaagaggg	ctgtcagaaa	tcccgatgat	cttgaagcaa	240
ggtctcatat	gcacttggca	agtgcctttg	ctggcatcgg	ctttggaaat	gctgggtgtt	300
atctgtgcca	tggaaatgtct	tacccaattt	caggttttagt	gaagatgtat	aaagcaaagg	360
attacaatgt	ggatcaccca	ctggtgcccc	atggcctttc	tgtggtgctc	acgtccccag	420
cgggtgttcac	tttctcggcc	cagatgtttc	cagagcgaca	cctggagatg	gcagaaatac	480
tgggagccga	caccgcact	gccaggatcc	aagatgcagg	gctgggtgtg	gcagacacgc	540
tccggaaatt	cttattcgat	ctggatgttg	atgatggcct	agcagctgtt	ggttactcca	600
aagctgatat	ccccgcacta	gtgaaaggaa	cgctgccccca	ggaaagggtc	accaagcttg	660
caccocgtgc	ccagtcagaa	gaggatctgg	ctgctctgtt	tgaagcttca	atgaaactgt	720
attaattgtc	attttaactg	aaagaattac	cgctggccat	tgtagtgtctg	agagcaagag	780
ctgatctagc	tagggctttg	tcttttcatac	tttgtgcata	acttacctgt	taccagtata	840
ggtgggatat	acatttatct	tgcaggaaat	tcccaaaagc	tcagagtcca	gttccttcca	900
taaaacaggc	tggacaaatg	accactatgt	tagacccccca	ggctcgactt	caggggtcag	960
tgttcctgtc	ccaaaccccc	cacagaatac	tctgcctctg	cttcattgtag	caaatagagca	1020
aaaactcagt	atctatcaaa	agtgtaaatt	atatttcccta	tgcctagtaa	ttcacttcat	1080
gtctaaaaat	ttatctgata	gaaacactag	caccagtaca	tacagaagca	tggcaaggat	1140
gtttctggca	gcactttttct	aataataaaa	gatttgaaac	aaaaaaaaaa	aaaaaaaaac	1200
tcgag						1205

<210> 12

<211> 1844

<212> DNA

<213> Homo sapiens

<400> 12

gactaactgt	aataaatgta	tgacattatt	ttgattgata	cattaaaaaa	gagtttttag	60
aacaaatag	gcatttagct	ttattattta	tttgctttta	agaaatattc	tttgtggaat	120
tgttgaataa	actataaaat	attattttgt	attgcagctt	taaagtggca	cactccataa	180
taatctactt	actagaaata	gtgggtgctac	cacaaaaaat	gttaaccatc	agtaccattg	240

tttgggagaa	agaaacagat	caagaatgca	tattattcag	tgaccgcttt	cctagagtta	300
aaatacctcc	tctttgtaag	gtttgtaggt	aaattgaggt	ataaactatg	gatgaaccaa	360
ataattagtt	caaagtgttg	tcatgattcc	aaatttggtg	agtctggtgt	ttttaccata	420
gaatgtggac	agaagtacag	tcatagctca	gtagctatat	gtatttcctt	ttatgttaga	480
agagactttc	ttgagtgaac	tttttaata	gaggaggtat	tcactatgtt	tttctgtatc	540
acagcagcat	tcctagtcct	taggccctcg	gacagagtga	aatcatgagt	atztatgagt	600
tcaatattgt	caaataaggc	tacagtattt	gcttttttgt	gtgaatgtat	tgcataatat	660
gttcaagtag	atgattttac	atztatggac	atataaaatg	tctgattacc	ccattttatc	720
agtcctgact	gtacaagatt	gttgcathtt	cagaaatagca	gttttataaa	ttgattttatc	780
ttttaatcta	taacaatttg	tgttagctgt	tcatttcagg	attatathtt	ctacaagtgc	840
cacttggtgg	actccttttg	ttgcccctat	ttttttttta	agaaggaaga	aagaaaaata	900
agtagcagtt	taaaaatgag	aatggagaga	aaagaaaaag	aatgaaaagg	aaaggcagta	960
aagagggaaa	aaaaaggaag	gatggaagga	atgaaggaag	gaagggagga	aggggagaag	1020
gtaggaagaa	agaaaggatg	agaggggaag	aagaatcaga	gtattagggg	agttaactta	1080
cacattttgca	ttccttagttt	aactgcaagt	ggtgttaacta	tgtttttcaa	tgatcgcat	1140
tgaacataaa	gtcctattat	accatttaagt	tcctattatg	cagcaattat	ataataaaaa	1200
gtactgcccc	agttatagta	atgtgggtgt	ttttgagaca	ctaaaagatt	tgagagggag	1260
aatttcaaac	ttaaagccac	ttttgggggg	tttataactt	aactgaaaaa	ttaatgcttc	1320
atcataacat	ttaagctata	tctagaaagt	agactggaga	actgagaaaa	ttaccagggt	1380
aattcagggg	aaaaaaaaaa	tatatatata	tataaatacc	cctacatttg	aagtcagaaa	1440
actctgaaaa	actgaattat	caaagtcagt	catctataat	gatcaaat	actgaacaat	1500
tgtaatttta	tccattgtgc	ttagctttgt	gacacagcca	aaagttacct	atttaactct	1560
ttcaataaaa	attgtttttt	gaaatccaga	aatgatttaa	aaagaggtca	ggttttttaac	1620
tatttattga	agtatgtgga	tgtacagtat	ttcaatagat	atgaatatga	ataaatggta	1680
tgccctaaga	ttctttgaat	atgtattttac	tttaaaagact	ggaaaaagct	cttcctgtct	1740
tttagtaaaa	catccatatt	tcataacctg	atgtaaaata	tgttgtactg	tttacaatag	1800
gtgaatataa	actcagttta	tcaatttaaaa	aaaaaaaaaa	aaaa		1844

<210> 13

<211> 1270

<212> DNA

<213> Homo sapiens

<400> 13

aggaattcgg	cacgagcaga	attcctttct	catatttcaa	gtgtccctgt	gaattatgag	60
gggaaaaaaaa	tctttattaa	agaaaaaagt	gaaaaataat	atgcatggat	acttggattt	120
ttcttttagt	aacaaagata	tttaaatat	ttgtatacac	acacacacac	acacacacac	180
acacacacgt	atctgtacct	agaaatgttt	ataggggagg	tcagttttct	gaagattaaa	240
tgcagcccta	atgtcagatt	aatgttataa	acacatcggt	taatcacaa	ttttcagaga	300
gcagggtcca	cagatagtct	ctaactttct	atcattacaa	atcgctattt	ttatatcatt	360
gctaatttaa	ataataaagt	aaattatgaa	gaggaatcat	tggttgcaag	tcaccatggg	420
agtttagtcc	ctgtgaaaa	ataaaagcatt	taaaataatt	gtattctttt	accatttttt	480
attacatctc	tttaattttt	gtcacttgaa	tatattagga	tgatgatgat	actataatca	540
ctggaaacaaa	gacatttgct	tggacatctt	ttcttttttc	ccccattttt	gttctgttaa	600
taatttttaa	ctatagcttt	tcctttcttg	tccttatctg	tcctttatcg	atcatagata	660
gtttcactac	tatttttaag	tttttattgt	taaattgaag	atgaatctgt	acagttactt	720
gtgaattaag	atgcagctaa	gttaaaaatca	agtataattt	tgaagctgat	tttacattta	780
actagatgat	taaatatatt	ttttcagggtg	cttcttcaat	ttaaatcaag	ttttatgggt	840
tcagcaaaat	ttagaaaata	tgtactttac	ctaaaaaactt	ttcttttagt	gctttggata	900
tatacagaag	cttaaatgag	tagagtatcc	caaacatcca	gatgcttctc	aaaatagcat	960
ttccggccgg	gcgcgggtgc	tcacgcctgt	aatcccagca	ctttggggagg	ccgaggcggg	1020
cggatcacga	ggtcaggaga	tcgagaccat	cccggctaaa	acggtgaaac	cccgtctcta	1080
ctaaaaatac	aaaaaattag	ccgggcgtag	tggcgggcgc	ctgtagtccc	agctacttgg	1140
gaggctgagg	caggagaata	gcgtgaaccc	gggagggcga	gcttgcaagt	agccgagatc	1200
ccgccactgc	actccagcct	gggcgacaga	gcgagactcc	gtctcaaaaa	aaaaaaaaaa	1260
aaaactcgag						1270

<210> 14
 <211> 1237
 <212> DNA
 <213> Homo sapiens

<400> 14
 tcgacccacg cgtccgggca gccatggagt ctctgggata tttatgaaat atgatctcag 60
 ttctcttatg gtgacagtta ctgaggagca catgccattc tggcagtttt ttgtaagact 120
 ctgtgggtatt gttggaggaa tcttttcaac aacaggttaa caaccatttc ctttttgtct 180
 aatttctgaa agtgttgcaat atacttaagt tgcttcttct caaaggggca agaagtatac 240
 agattttcat gtttcgggtgt ttaatagctt ttgctttaat tacaaaactc caaaattata 300
 tggactaacc agtaaacata actaatttca ttgtattcaa tgatgtaagg tagattatat 360
 aatgggtgagt tggaaagatc ctgggtgtta acatcagatt gaagtagaat tgaatgtaag 420
 ttctgtcatt tacttgggtg tagcttggaa tagatcacct accttttctg aggttttcta 480
 atcagtaaaa atagcaataa taatacctaa tttgcaagtg tgctatagga ttaaatatga 540
 aaatgcctag aaggcattta agacattttt aactgtacag tatgtaaaat catatgttat 600
 agtactttga attatgcaat acatgaaact agatttgtaa tcagtaacat gtttatgatt 660
 tttgtcctga gatcctggaa ttcgctaaga ttatttgctg aattgtaatg atgaaaattg 720
 ggagttaagt ccatagagaa aaaggaaaca atcctatttt caccttcagt ccttattcag 780
 tattaatgga gctgggggat ttattatact tagaatcata tttttaaatg aatgaatagc 840
 tttcttcgaa attcttggtta gtgctcattt catctattta aatttggtgtg gttgactcat 900
 tattccaaat gtttgggtgg aactgaaaag attgtgttta ggcccgggtg agtggctcat 960
 gcctatatcc caacactttg ggaggccaag gctggcggtt caacttgagg ccagaagttc 1020
 cagatcagcc tggccaacat ggctaaaccc cgtctctact aaaaaataca aaattaccgc 1080
 gttatggtgt gcgcatttgt actgttagct actcgggagg ctgaggttgg ggaatcgctt 1140
 gaacctggga ggtagagatt gcagttagcc aagatcatgc cactgtactc cagcctgggc 1200
 aacagggtga gactctgtct caaaaaaaaa aaaaaaa 1237

<210> 15
 <211> 2182
 <212> DNA
 <213> Homo sapiens

<400> 15
 ccacgcgtcc gaaagaaggc ccttggctgt ggccgccatgt gaaaaggatg aagacctcca 60
 ggcccttctc cctctgagtc tccctcccc tgatgacct ctggaagcct gctggctcct 120
 cctcaccctc actcacactt caactcccag ttggattggc ctgtggacct acctgctgcg 180
 tctcagtagg agagaaataa tccagacctc aggaacttga cctcacagct ccagggaatt 240
 caccacgtgg gcgaacgggt agagtagaag atgctcagtg aacatgcgca ctgaggtggg 300
 cgcccaaaga ccatgcgcag tgagatgtgt gcttgctta ggggctgtgg tgtccctcct 360
 tgttccccct acccctgctc tttcttccat ccttctctag gaccccacta aggactttgg 420
 aatccatcct cccttggtgt ttttttttat gcctctgaga ctcaaatac tcaatatcac 480
 cgttcaaaac tcaactctgt ttcacctgac cctcctgccc tctatggccc ttgtcctccc 540
 ttgtctgggc ccctcaaggg agcaagtgc tgggtggtgt gctgacttct agtagaagga 600
 tgaggatctc tatcaggccg tggaccaagt ggcccaaccc atcgaaagt gctcactttc 660
 cctcatgttc actcacactc aacttctggg aggaactgat tatggacct tctgatgtgt 720
 tatagtttagc aagaaagaag tcacaacatt tctctccaca gctctgcagg gacagaaggc 780
 agagagcatg gcccacaggg aacaggaatt tgcataggaa gggacatgca cattgagcca 840
 gggactttca gggaatgcca gagttttccc tctgtcacca tgatagcagc agccactgcc 900
 atcatactgg ctgcagcagg gaagcccagc cagagctgca tgctctgtgg agccagcaaa 960
 agccagggac aagtgggatc cccacctttt acaagttggg gagggagccc ctgggtgccc 1020
 ctgcagccac ccaaaactgca gttgaagacc cagacttctg gctctatgga gcaggcagga 1080
 tccctgcctc cctgggtgca gctgtagcca ctggatccat ggctgcagac ccaggagctg 1140
 gggacaagtg ggagcccaaa cccttcagag ttggcggtgc aggagctcct tgggtgcagc 1200
 tgcaacttcc cttcaagggt caggaccag gtgtgtctgt agcctgcaat ctctgaagcc 1260
 tgggaaggcc cccactgtcc ctggggagca gggaaacagg gacactgtcc ctggggagca 1320
 ggctcagagg tgtctgtccc cactacctgg tctctccctg ctcccagcac ccactatgat 1380
 ttcagagcag gttgtgggct gagccctgc actctcacag ctcatgagg cttgcacatg 1440

ggcaggtcag	ccctggaatg	ccagccccc	gccacctcag	acccctccag	aatttgggtg	1500
ccaagaaaca	tgagagggga	agccaagggg	gtgctgaggg	cagctgggta	gtgctctgca	1560
ggtccgagca	gcctgggcac	catggactgc	agtgggaggg	agacagggtc	cagagcagaa	1620
gggggtggtc	ctaggttaagg	tcccaccttc	aggccagggg	tgggccaggg	tgccaatccc	1680
agagaccaga	gtatggactt	gtgtgcctt	ttctaggccc	acccatggac	taatgtacat	1740
gcactttctc	ccctctgagg	tccgtaaatg	cctgggactc	agccagagca	gggcagagga	1800
tgggagcaat	gggacaacca	gctgcagaga	ggagctaccc	tctccagggc	ctcctctctg	1860
ctgagagctg	cagatgttgg	aaagacctgc	ctgcagagag	gagacacact	cttcaggggc	1920
tcctctctgc	tgagagctga	acacttgacc	tgacgacctg	cctaaagagg	agctactgac	1980
tgtggatctc	ctctgagctg	ttctaact	caataaagct	ccacttgttt	gcataacctta	2040
ttcttcccag	atgcattaac	aagaacttga	acaaagggtg	caccagacac	agaggtttcc	2100
agccagaaaa	ttgactgccc	aaagatccca	tataaccctg	acccacatcc	acagggcatt	2160
ttttagtaaa	aaaaaaaaaa	aa				2182

<210> 16

<211> 1585

<212> DNA

<213> Homo sapiens

<400> 16

ggcacgaggg	tgggcgctct	ttctttttct	cttagaagag	ggtttagcac	aggttttttc	60
gttctcactt	ccacaccacc	ttaccgcctc	ccgaccccc	ctctccccct	ccccacctat	120
cgtcatgacg	gcctctccgg	attacttggt	ggtgcttttt	gggatcactg	ctggggccac	180
cggggccaag	ctaggtctcg	atgagaagga	gttgatcctg	ctgttctgga	aagtcgtgga	240
tctggccaac	aagaagggtg	gacagttgca	cgaatctagt	tagaccggat	cagttggaac	300
tgacggagga	ctgcaaagaa	gaaactaaaa	tagacgtcga	aagcctgtcc	tcggcgctgc	360
agctggacca	agccctccga	cagtttaacc	agtcagtgag	caatgaactg	aatattggag	420
tagggacttc	cttctgtctc	tgtactgatg	gggcagcttc	atgtcaggca	aatcctgcat	480
cctgaggctt	ccaagaagaa	tgtactatta	cctgaatgct	tctattcctt	ttttgatctt	540
cgaaaagaat	tcaagaaatg	ttgccctggt	tcacctgata	ttgacaaact	ggacgttgcc	600
acaatgacag	agtattttaa	ttttgagaag	agtagttcag	tctctcgata	tggagcctct	660
caagttgaag	atatggggaa	tataatttta	gcaatgattt	cagagcctta	taatcacagg	720
ttttcagatc	cagagagagt	gaattacaag	tttgaaagtg	gaacttggtg	agtgcctgag	780
tactatttat	ttgagctttt	taacttgttt	tttttttttt	tgtctgtttg	tttgtttttg	840
agacagaatc	ttgctctgtc	gcccaggctg	gagtgcagtg	gcacgatctc	agctcactgc	900
aagctccgcc	tcccgggttc	atgccattct	cctgcctcag	cctcccaggt	agctgggact	960
acaggctccc	gctaccatac	ctggctaatt	tttttgtagt	tttagtagag	atggggtttc	1020
accatattag	ccaggatggt	ctcaatctcc	tgacctcgtg	atctgcccgc	ctcgctcccc	1080
aaagtgtctg	gattacaggc	gtgagccacc	tcgcccggcc	tttaacttgt	ttttgttcca	1140
taattgtgcc	tcttaattct	tgttatattt	gagaaacttt	actaatcctt	ttagctatcc	1200
tttcttgctg	ttcggtcatc	tgtaaaagaa	ggttgtatta	cttagagctt	gatattggga	1260
ataaaatgta	atgacttact	ggcatcttta	gtcacccctga	ccttaagtat	attatatgct	1320
catatctgtg	attgttattt	tggctctccc	aaactatcca	atctttcatt	tagaaaattt	1380
ccaaaggaga	aattgtaggc	tttaatatag	ttcacaaatt	ttactgagat	aaaattttac	1440
gtacattcta	taagtacatt	tatttattta	tttattttag	ttttgagaca	cttgctctgt	1500
tgcccagctg	gaatatcgca	gtgagctgag	atcgcgccac	tgcactccag	cctgggtgaga	1560
gagcaagact	ccatcttaaa	aaaaa				1585

<210> 17

<211> 1888

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (37)

<223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1475)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1477)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1879)
 <223> n equals a,t,g, or c

<400> 17
 gggggggaaa tttgagggcc cccggcccgt ttagganaaa ttttggggga gttttggaat 60
 tttttttttt ttttttaaaa aaaagctgga gttggtggct taggccatca cccttccctt 120
 ggctggaact actggacaga cccttttgag atgtgcctgt ggtgctgtgg agatgtgtgt 180
 agtgggtctta gctctttgtt gagcttgtgt gtgtgtgtgt tagtcttagc tgtatgctga 240
 aattggggcgt gtgttgagg gcttcttagc tctttggtga gattgtatct ctatgtgttt 300
 gtatcagctg aatgttgctg gaaataaaac cttggtttgt caaggctcyt ttttgtggga 360
 agtaagtagg ggaaaaggct tttgaggggt cctaggctcc tttgtacaac aggaaaatgc 420
 ctcaaagcct tgcttcccag caacctgggg ctggttccca gtgcctgggc ctgccccttc 480
 ctggttctta tctcaaggca gagcttctga atttcaggcc ttcattccag agccctcttg 540
 tggccaggcc ttcctttgct ggaggaaggt acacagggtg aagctgatgc tgtacttggg 600
 ggatctcctt. ggcctgttcc accaagtga agaagggtact tactcttgta cctcctgttc 660
 agccagggtgc attaacagac ctccctacag ctgtaggaaac tactgtccca gagctgaggc 720
 aaggggattt ctcagggtcat ttggagaaca agtgctttag tagtagttta aagtagtaac 780
 tgctactgta tttagtgggg tggaattcag aagaaatttg aagaccagat catgggtggt 840
 ctgcatgtga atgaacagga atgagccgga cagcctggct gtcattgctt tcttccctcc 900
 catttggacc cttctctgcc cttacatttt tgtttctoca tctaccacca tccaccagtc 960
 tatttattaa cttagcaaga ggacaagtaa agggccctct tggcttgatt ttgcttcttt 1020
 ctttctgtgg aggatatact aagtgcgact ttgccctatc ctatttgga atccctaaca 1080
 gaattgagtt ttctattaag gatccaaaaa gaaaaacaaa atgctaata agccatcagt 1140
 caagggtcac atgccaataa acaataaatt ttccagaaga aatgaaatcc aactagacaa 1200
 ataaagtaga gcttatgaaa tgggttcagta argatgagtt tgttgttttt tgttttgttt 1260
 tgttttgttt ttttaaagac ggagtctcgc tctgtcacyc aggtgaggat gcagtgggat 1320
 gatcttggct cactgtaacc tccgctccc ggggtcaagc cattctctg cctcagcttc 1380
 ctgagtagct gggattgcgg gtgcgtgcca ccatgcctgg ctaatttttg tgtttttagt 1440
 agagacaggg tttcaccatg kggctcgggt ggtcnanaac tccygaccyc ytgatccgcc 1500
 tgccytggcc tcccaaagt atgggattac agatgtgagc caccctggcc tagccaagga 1560
 tgagattttt aaagtatgtt tcagttctgt gtcattggtg gaagacagag taggaaggat 1620
 atggaaaagg tcatggggaa gcagaggtga ttcattggctc tgtgaatttg aggtgaatgg 1680
 ttctttattg tctaggccac ttgtgaagaa tatgagtcag ttattgccag ccttggaatt 1740
 tacttctcta gcttacaatg gaccttttga actgaaaaac acctgtctg cattcacttt 1800
 aaaatgtcaa aactaatttt tataataaat gtttattttc acattgaaaa aaaaaaaaaa 1860
 tttaaaaact cgggggggnc ccggtacc 1888

<210> 18
 <211> 1380
 <212> DNA
 <213> Homo sapiens

<400> 18
 gggaaaggaa gggatggtgg gccaggtggc tctctagatg ggaggtgtcc gggaacttgc 60
 aggtctcaag cctgggtgac taggaggatg gtgcgcaaaa caggaaaggc aggacgcggc 120

tgctgggttc	ctttctcgag	tgcacgcagg	gctgaaagga	ggggagctga	gatgagaacg	180
gcccttttcc	ccactgaatg	ctgcctgccc	atgtgtgtcg	tcttagctgt	tttctatttg	240
cccacgtgtg	ttagtagaat	aattgaatct	gcagacagtt	ttgactagtc	catcttgctt	300
ctcactccac	cccgtgcct	ctcgtgcttt	ctctctctct	tccttacctg	cctgctgcca	360
gctccttgcc	tcccccttga	ttactgcgcc	cccgaataa	ctcactgttt	gatcttccac	420
atacgggaac	tcgaaaccca	gctactgtct	gcccagcaag	gctgcagtgt	ccagggtgac	480
ccaggccatg	tcttgcactg	attgtaatcc	tcctctgcgc	ctaacacaga	gccttacgtg	540
tataccgagt	agaggagaag	gaaggatgtc	aaacatgtca	ctaccacccc	ccagtgcattg	600
ttggctctcc	tcacgttgga	ctgtggcagg	agtcttccaa	aactgctctc	agtgcctcat	660
cccctctgtg	tgcaatcata	tcgttgctta	cttaaccaac	cattcatctc	ctagggcctg	720
agttctgtta	cccagcctcc	tcagaatctt	cagcagttcc	tcatttccat	aggggaaagc	780
cagctgttta	tttcttttac	ttatgcaacg	aataagtcag	tgtcagatag	tatttttgtt	840
gataaagccw	cagcggmgag	caaaacattt	tggtcctgct	tcctgtgagc	tgactttctg	900
caaggggagag	agatgataaa	tgcacatata	atatagttga	gagtgtacag	tgctgcaagg	960
aaaagcagag	ctgaggaagg	agcaaattgtt	ggagagggag	gagagggagt	ggtgctggcc	1020
tagacgggtca	aagggttgctg	tggttaagggg	acactggagt	taagatctga	gtgaggctgg	1080
gtgcgggtggc	tcatgcctgt	aatcccagca	ctttggggagg	atgagggtggg	cggatcactt	1140
gaggtcagga	gttcaagacc	agctcgggca	acatggctaa	tccccatctc	tactaaaagt	1200
acaaaaatta	gcctggcatg	gtgggtatgca	cctgtaattc	cagctacttg	ggaggctgag	1260
gcaggagaaat	tgcttaagcc	cgggagggga	aggttgacgt	gagccgagat	cacaccgctg	1320
cactccagcc	tgggcaacag	agtgagactc	tgtcacaaaa	taaaatataa	ataaaaaaaa	1380

<210> 19

<211> 1048

<212> DNA

<213> Homo sapiens

<400> 19

gccgtcctgc	aggtgggttc	catcgcgccc	ttcaccaggt	agctacggac	acccgggaat	60
acccacact	ggggccctcc	tcctgggcct	gaccagtcct	ccagctgtca	cctccccatt	120
cctggacagg	aagggcactt	ttcctagtga	actggccata	gatggttttg	gatggttcca	180
tctgttcttg	caggagtggg	agcaggagcc	agggcagaac	aaactgctgg	aggccctggt	240
gttgggaaca	gctgcgggga	gggtagggac	cagacagaac	tgcttcaag	atgagtccca	300
ggagcgcaca	ctcagccctg	tcagtggggt	ctggcttttag	cagccaggcc	tccacagacc	360
cccatgggcc	cccagggccc	agagggagga	cagagccctt	cagaacagag	gcctcatctc	420
actgcatccc	ccatcacccc	ctagttcccc	aatggctcta	atgtgtgttc	tgagatccca	480
gtttactcgg	tgccaggccc	ccacctgtgt	ttccaagtcg	ggctggagac	gcaggatggg	540
gtaggccttg	tgctctgagc	aacccagctg	ctgcctcaca	ggcaggcagg	cccggtgcaa	600
gagtggaact	tgggttccta	aagcaataaa	tgcaacaag	ccaacagctc	tgctgcctag	660
caatttccat	cttagccaca	cttctccctt	caggggcttc	ggaggagagg	tcagggtcta	720
ggccggggat	gagactgcag	gagagagagc	agcggagggc	cacattcgga	gcctccgtcc	780
actccagttt	tatcagcttt	tgctttttgc	acggagtgtc	aaacaaattc	tagctctgtg	840
tttttttccc	attcccagat	ttactatcag	ttctccttaa	aaagtatcta	agctgttaca	900
gtagcttttc	cttcacttga	ttctatttgt	tgttttctat	gtttggaata	attacacca	960
aatatctaga	tattttctct	tcaccgcatt	ttgtaataaa	agagatgtgt	atgccwmmmw	1020
raaaaaaaaa	aaaaaaaaag	gcggccgc				1048

<210> 20

<211> 1882

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1407)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1412)

<223> n equals a,t,g, or c

<400> 20

gaattcggca	cgaggtaa	atgtgtgttc	tcctagctgt	gaactgtgtc	ctaatacagga	60
tggaattttc	aaggagacag	atgctggaag	atgggttcat	attgtttgtg	ccctgtatgt	120
tcctggagta	gcctttggag	atattgacaa	attacgacca	gtaacactaa	cggaatgaa	180
ctattccaaa	tatgggtgcca	aggagtgtag	cttttgtgaa	gacctctgct	ttgctagaac	240
tggggtttgc	attagctgtg	atgcagggat	gtgcagagcc	tatttccatg	tgacctgtgc	300
tcaaaaggaa	ggtctgcttt	cagaggcagc	ggcggaaagag	gatatagcag	atccattctt	360
gcttattgta	agcaacatgc	agatagggtta	gacagaaagt	ggaagagaaa	aaactacttg	420
gctctacagt	cctattgtaa	aatgtctttg	caagagagag	agaagcaact	atcaccagaa	480
gcacaggcaa	ggatcaatgc	ccggcttcag	cagtatcgtg	ccaaagcaga	actagctcga	540
tctaccagac	cccaggcctg	ggttccaagg	gaaaaattgc	ccagaccact	caccagcagt	600
gcttcagcta	ttcgtaaa	tatgcggaaa	gcagaactca	tggggatcag	tacagatata	660
tttccagtgg	acaattcaga	tactagtctt	agtgtggatg	gaaggagaaa	acataagcaa	720
ccagctctca	ctgcagattt	tgtgaattat	tattttgaga	gaaatatgcy	catgattcaa	780
attcaggaaa	atatggctga	acaaaagaat	ataaaagata	aattagagaa	tgaacaagaa	840
aagcttccatg	tagaatataa	taagctatgt	gaatctttag	aagaactaca	aaacctgaat	900
ggaaaacttc	gaagtgaagg	acaaggaata	tgggctttac	taggcagaat	cacagggcag	960
aagttgaata	taccggcaat	tttgcgagca	cccaaggaga	gaaaaccaag	taaaaaagaa	1020
ggaggcacac	aaaagacatc	tactcttctt	gcagtacttt	atagttgtgg	gatttgtaag	1080
aagaaccatg	atcagcatct	tcttttattg	tgtgatacct	gtaaaactaca	ttaccatctt	1140
ggatgtctgg	atcctctctt	tacaaggatg	ccaagaaaga	ccaaaaacag	ttattggcag	1200
tgctcggaa	gtgaccaggc	agggagcagt	gacatggaag	cagatatggc	catggaaacc	1260
ctaccagatg	gaaccaaacy	atcaaggagg	cagattaagg	aaccagtga	atttgttcca	1320
caggatgtgc	caccagaacc	caagaagatt	ccgataagaa	acacgagaa	cagaggacga	1380
aaacgaagct	tcgttccctga	ggaaganaaa	cntgaggaaa	gagttcctag	agagagaaga	1440
caaagacagt	ctgtgttgca	aaagaagccc	aaggctgaag	atttaagaac	tgaatgtgca	1500
acttgcaagg	gaactggaga	caatgaaaat	cttgtcagggt	gtgatgaatg	cagactctgc	1560
taccattttg	gctgtttgga	tcctcctttg	aaaaagtctc	ctaaacagac	aggctacgga	1620
tggatatgtc	aggaatgtga	ttcttcatct	tccaaggaa	atgaaaatga	agctgaaaga	1680
aaaaatatat	ctcaggagct	caacatggaa	cagaaaaatc	caaagaaata	aaagattttc	1740
tgtagtgttt	ttgaaaagtt	tgcagcttat	gtaatagcag	ataaaatttc	taattgtaaa	1800
atgttaaatt	gtaaaatcta	atttgcaaaa	tgttctcaat	aaagtcattc	aaaatgaaaa	1860
aaaaaaaaaa	aaaaaactcg	ta				1882

<210> 21

<211> 1245

<212> DNA

<213> Homo sapiens

<400> 21

gtagaatgcc	atggagttaa	tagcttctgt	gacccatcat	gttccaagat	aactgcagca	60
gtccaaaaag	ccagtttctt	ttctggtgtt	tgtgggcata	cactttgttc	tgctcctgag	120
taagtcacac	tttgtcttcc	aggtcctcta	ggatccctgc	aatgttccat	ttgttgccctg	180
ggcattggag	taatagcagt	gcttgggtgt	acagaaatag	atggatggaa	gttgtggtta	240
ctgtgacacc	aaaaacttgt	cccctgagct	ccctactcct	ctttctccta	tatttttttg	300
taattggctc	tgtcattcac	ctcactgcag	gattcagaat	cctgggtactg	ggtcttgtat	360
ttctcttttt	cccttaccct	ccttatccaa	attgtcacca	agttctgctt	catgctctca	420
tgattttctca	cctgagttac	cctagtagct	tccaaatagg	gccctctgat	ttcaaccttg	480
gacactccca	ctatctttta	tattatggaa	agatctaate	atgttaccct	ccatttataaa	540
tccctcagag	agcactgcag	atacaattca	agccagttag	cttagtggtta	aggtttttaca	600
tgcatttctg	cagccatctg	cccctattct	tgcaccctaa	taatgccaaa	cttctttttg	660
gccttaattt	catcatctgc	aaaatgagga	taataaatag	tacctacttc	atatgattgt	720
aataaggsc	ctcaaaactg	tttcatgcct	cttttgccca	ctgcattagg	ctgttctcac	780

attgctataa	agaaatacct	gaggctgcgt	aatttataaa	gaaaagaagt	ttaattgact	840
cacatttmta	caggctatac	aggaagcatg	atgggtggcat	ctgcttggct	gctggggagg	900
gctcagaaaa	cttacagtca	gccgggcaca	gtgggtcact	cctgtaatcc	cagcacttgg	960
ggaggccgag	gtgggcagat	cacctaaggt	cagaagttcg	agaccagcct	gtccaacatg	1020
gtgaaacctc	atccctacta	aaaatacaaa	aattagccgg	gtgtggtggg	gcggcacctg	1080
taactccagc	tactcagaag	gytgaggcag	gagaatcact	tgaaccagg	aggtggagg	1140
tgcaagtgagc	caagattgag	ccactgcact	ccagcctgga	caacagagtg	ggactctgtc	1200
tcaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	ctcga		1245

<210> 22

<211> 810

<212> DNA

<213> Homo sapiens

<400> 22

gattactaac	atttttaata	tgacacaaat	tctgttttct	gttttgaaga	ttagcaccac	60
agacaggtga	tcattaatga	aatatggccc	ttaaaataca	cattacaaaa	gagaaactga	120
tggtaaaaat	gctggtgaag	ttacttttta	tcattttctc	actaattaaa	agttcagatt	180
ctgggatcac	atctctaagc	tgttcatatc	aaagagctat	tttttaaga	tcctgattat	240
aggcaacaaa	agcaaaaata	aacaaatagg	attacatcaa	aactgaaaag	cctctgcaca	300
gcaaaggaaa	caacagaatg	aagagccaac	ctacataatg	ggagaaaata	tttgtaaat	360
atacatctga	taagggttta	ataatcaaaa	tatataagga	actcaaagaa	tgcaatagta	420
agaaaacaac	ccaattaaaa	aacaggcaat	tccagcctgg	gcaacatggt	gaaaccctgt	480
ctctacaaaa	aatagataaa	attggccggg	cacggtgctc	acgcctgtaa	ccccagcact	540
ttggttgccc	gaggtgggtg	gatcgccctg	ggtcaggaga	tcgagaccag	cctggccaac	600
atggcaaaaac	cccacctgta	ctgraaatac	aaaaaattag	ccgggtgcag	tggtggggcg	660
ctgtaatccc	agctactcgg	gaggctaagg	caggagaatt	gcttgaaccc	gggaggcgga	720
ggttgccatg	agccgagttt	gcaccattgc	actccagcct	gggcaacaag	agcaaaattc	780
tgtttcaaaa	aaaaaaaaaa	aaaactcgag				810

<210> 23

<211> 1675

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (465)

<223> n equals a,t,g, or c

<400> 23

caccgcggtg	cggcgcgcct	ctagaactag	tgatccccc	gggctgcagg	aattcggcac	60
gagctgaaat	aagtattaat	acctaacatt	taatattaat	tctgtcctat	gtgcacttac	120
aaatacgtca	tataagtata	taaatgtact	ttacctatta	tatgcagaaa	ttgaaggggg	180
gaattttctgt	gtttctagct	ttcttggtta	tgtgaagggt	ggggcathtt	atgttttttc	240
aggattgcct	tattcaatga	agcaagctgg	gtttcccttg	ggaatattgc	ttttattctg	300
ggtttcatat	gttacaggta	aaatactata	taattttctta	tttctgcaac	ttcaactgtg	360
caataactac	acacatacac	acacacacac	acacacacat	gctgcaactg	aatttcctag	420
ttaattaaaa	agtgcatcaa	agaatcctaa	agaatttaag	catynatgcc	tgaggasaty	480
cacttttctt	actaatcctt	taaacagatt	wgaaaaagta	gaaaagcatt	atatattacc	540
aagcctaaat	ccttttcatg	tgcccttttc	actttttgca	gaaagtagta	gatgggggag	600
tcattttaaa	gcttcattaa	ggctaagaga	cgactgtgct	ctgaaagtgc	agatagcagg	660
gcttcgtggg	caggtgcgtg	tgaatgagca	accttattca	gctgttgwtt	gtggaggtag	720
aaatgaagct	ctgggtgatc	accagcaggg	ctcatcaagc	ctctccgcct	ggcttatgcc	780
tgcccaaaact	cgctgcctgc	tactgtcttt	aaatgcagca	ataagttgct	tctgtatcac	840
atctttctct	ctgcttcccc	ttcttcatgt	aaatagtcca	ttcacaccca	cgttttctca	900
ctctcccat	taaatgcagg	ctttacaamt	cataatcatc	tcctcttttt	gttgctcctg	960

tccccgcctt	gtcatccac	catctcacct	tatgacaaa	atggcgctct	ctctacctta	1020
ggatcactgt	gaaagaggtg	gcaatgatca	aaaacagaca	ccactcacag	gagttgctgc	1080
tgtggtggat	tagatgccct	tttaccagct	agtgcacaa	acctcagctg	ccctttgctc	1140
tggagtgttg	ccctgggcct	ccagggggct	tccttgctc	cacgggacca	atgtgtggta	1200
cagttggagc	tccagggctc	caccactgca	gtacttgctg	aactcttcc	cctgcctgt	1260
cctctcattc	cccttcttct	ggagcatttc	atccacagac	cccttgccca	agaatgtctg	1320
tctcagctct	gcttctagag	atcctccaag	atgccatccc	tcgtaaaacc	tcaggcttcc	1380
aagacctgcc	caacactcag	ctatttttct	tcaggctgac	gaagacagag	taaagcatga	1440
aatagttttc	aaattcaaag	ctagagaggc	attgagctcc	ctgccttctt	cctaccacct	1500
ccacctttaa	gacctaaact	gcttctagtt	attacagctc	ttaatttgta	acttaggacc	1560
cataaattag	cagcatgaga	cctaagtgtg	cttattaaga	gttgctgggtg	tttaaaaatt	1620
gcagtctact	tattggggca	tttattacac	taaaaaaaaa	aaaaaaaaac	tcgag	1675

<210> 24

<211> 1069

<212> DNA

<213> Homo sapiens

<400> 24

gttataaaagt	taccttgatg	acagagtcac	tgctatactt	gcaacttatt	ttattgtggg	60
ggatcagtg	aataccctct	agtaatactg	agatgtatag	aaaatgcccc	taaactaaat	120
gccccactg	ttttaagtta	aactgtattg	ttggcctggg	agcaagggtg	atgggtagtt	180
tttctctgta	gttaagcttt	gagctgtcat	ttcttatttt	agttattgta	ctgcctatga	240
aggctcttct	aattttttaa	ttcttaactc	gttttggtga	agtagatgaa	caaccaagtt	300
tattgaagct	ttaatcatag	ttgaacatgt	aattgagtc	ctgggatctg	cataaaagtt	360
tgcagatyct	gatatacagt	ctttatagga	gttagaatat	gaagattgta	gtagctattt	420
tcatacccca	tcagacttat	atgtttattc	agtagagctg	aaattattaa	atgtatgaat	480
attactggct	ttttcctgac	cattcacact	tcatgggtgat	ttcacaagag	aaggatatag	540
attctggttt	ccttgccagac	ttgtttttta	taatcacrtt	tattgaggct	taattttcat	600
acaataaatt	ttatatatat	tttaagttta	caatttgcca	ctcagatcaa	gatacggaaa	660
attctcatct	attggagaaa	gtttcctcat	acttctttgc	agccatcctc	ccsracctgc	720
cacttgcccc	aggcaatcac	taatctaatt	tttaacacta	cagattagtt	tgccacttca	780
tctaaataga	aacatatttt	atgtagtgtg	ttgtctggct	tttttccttc	aacaatgtct	840
gccataata	ttgcatttat	tgaagtttac	ttcattttta	ttgctgagta	gtaagtagtc	900
tattgtgtaa	tggataccac	agtttatcca	ttcgtctgtg	gatggacatt	tgggggtttt	960
acgcttttaa	gttgcaatga	acatgcatac	aagtattgct	gtgatcattg	tttttccttc	1020
tcttgaataa	ataactagaa	gtggaaaaaa	aaaaaaaaaa	aaactcgag		1069

<210> 25

<211> 1475

<212> DNA

<213> Homo sapiens

<400> 25

cacaggccag	gctccaccct	ctagtaaagg	ggaagaggct	gctggttatg	cccagragtc	60
tcaaagggag	gaggccagct	gagtaggcag	cctgggtgag	gggggcagg	gatgggcagg	120
agggtgggag	agtggatgag	gggtttctca	ctgtacatag	agtcactggc	atgatgccct	180
cgctccccca	tgccccccca	tcccagtggg	gcataactag	gggtcacggg	agagcagctc	240
cgtctcctgt	gtgtatgtgt	gtgagtgggt	ggcaggccag	tggcaggggc	ggccccagcc	300
cctgcatgga	ttccttgttg	cttttctgtc	ttttgctagc	ttcaccagtt	tctgttccct	360
gtgggatgct	gctctaggga	tactcagggg	gctcctgctc	tccttccctc	tccttctctg	420
cctcaccatt	cccctaggca	ggccctgcag	gtccacact	ctcccaggcc	ctaaacttgg	480
gcggccttgc	cctgagagct	ggtcctccag	cgaggccctg	tcagcgggtc	taggctcctg	540
cacatgaagg	tgtgtgcctg	tgggtgtgtg	gctgctctag	gagcagatac	aggctggtat	600
agaggatgca	gaaaggtagg	gcagtatgtt	taagtcagaa	cttggcacat	ggctagggat	660
actgctcact	agctgtggag	gtcctcagga	gtggagagaa	tgagtaggag	ggcagaagct	720
tccatttttg	tccttcctaa	gaccctgtta	tttgtgttat	ttcctgcctt	tccgagtcct	780

gcagtgggct	gcctgtacc	ctgaacctca	tgagcctcta	agggaaagga	ggaacaatta	840
ggacgtggca	atgagacctg	gcagggcaga	gtacaagccc	agcaccagct	gtcccagcct	900
tactgggtcc	ttaccctggg	ccaaacaggg	agggctgata	cctccttgct	cttccatgat	960
gccacacctc	tacaatctca	gccacaaagt	cctctccacc	ctagggggct	tgctgcatgg	1020
caataaactca	taatctgatt	tgagggtttg	ccctttacag	gggcagattt	tctgctcagt	1080
tcaacaatga	aatgaagagg	aactccctct	ttctacagct	cacttctatc	agaggcccag	1140
gtgcctcaga	gccacattga	gttgcctttt	ctgggatgag	gaagttaggt	taaaactccc	1200
agtttcctga	gggaggtctc	tgacaggtgc	cctttgtcag	accctaccac	agcctggata	1260
ggcagccaca	ttggtcctcg	cccttgctcg	gcactccgtg	gtggctcctg	ccttctccct	1320
gcatgcctgt	gggtctgctc	tgggtgtgta	aggtcgggtg	gttaactgtg	tgccctactga	1380
acctgggcaa	taaacatcac	cctgcaaaagc	caaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1440
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaa			1475

<210> 26

<211> 931

<212> DNA

<213> Homo sapiens

<400> 26

ggcagagact	gcctcggcct	cctgagtagc	tgggattaca	ggtgtgcgcc	actacaccca	60
gctaattttt	gtatttttat	tagagacgtg	gtttaccat	gtcagccagg	atgtttctca	120
tctcttgaca	cgtgtctccc	tccagcttct	gcccttattt	acctgcctgt	tggtctttaa	180
aggcattttt	ggttgagact	tttgcattga	aaataagaac	tttgccatct	ttggattccc	240
ccatgtttgt	ttgtttgttt	ttaataaata	atatttaata	ttaaaaggag	ctgtggtttt	300
tttctctcta	aagagcagga	aaggacagag	actggctcgt	ctctgcagtc	acacttgarg	360
tgaagaaacc	atgggataga	attagcygtt	agttgagtc	cyaggttcmg	aggragaaag	420
aagaccatac	cacctggtag	ggagtgcgaa	ggaggttcca	gggactgac	catagaaggg	480
tktcagamca	acttcmttaa	twaaggaktg	ccttaattty	cttgggtcaag	gggaaacttc	540
ctgtgtgcct	ttctatcctg	atgacacccc	ctcactgaaa	tcctgggtgt	gtttccacag	600
agctgtctgg	ccttttgtcc	ttgatccttg	gttaaggaaa	tgaccaacca	ggtaagacct	660
gtgttgaagg	gaaaaacatc	aattgggtctc	tttgccaagt	tcaagtccag	taggttttct	720
ggatgtgtag	tcaagaaact	agcatctcat	tcttgcccgg	ctcctaaaga	gctgggtgac	780
cctgggtacc	tagtcaccac	agtgttaggt	gggactagtg	aatgcaaat	actgagagga	840
ggattgggtc	atccaagtct	ttaccacaat	ttagttagta	atagaagaag	cttaaaagat	900
gttgtacaaa	aaaaaaaaaa	aaaaactcga	g			931

<210> 27

<211> 911

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (265)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (327)

<223> n equals a,t,g, or c

<400> 27

ggcagagacc	acgcccggct	aattttttgt	atttttgggtg	gagactgggt	ttcacctgtg	60
tggccgggat	ggtcacgatc	tcctgatctc	atgatccgcc	cgcctcagcc	tcccaaagtg	120
ctgggattac	aggcttgagc	caccgcgccc	ggcctgtcag	atgctttttt	gcatctgttg	180
tgatgatcat	atggtttttg	cccttcactt	tgcttgatg	gtttatcaca	tttatagatt	240
tgtttatgtt	gaaccacctt	tgtantcctg	ggataaatct	cacttgatca	tggtgaatgc	300

ttcttttatg	ggctgttgaa	ttggttngtt	agtatttttgk	tgaggatttt	kgcatattkg	360
ttcatcaggg	atatcgacct	gtaattttct	tgtagtgtcc	ttgtctcgct	ttggatcag	420
ggtaatgccg	acgtcgtaaa	atgagtttgg	aagtgtatct	ggaagtattc	gtcgtctttg	480
atttttggga	agagtttgag	aagaattgg-	actagtttta	ccttaagtgt	ttggcagaat	540
tcttctggtc	tcttgatgtt	ttcattgcct	tgctgagcat	agatccaggt	acttatgagc	600
aaaattctac	tcagtcctgac	aactctgctt	agaattatga	atgtgattaa	atgcagtggt	660
cactctacct	ttctaaggta	gttcagctca	agttacagcg	atccagtcct	gatagagctt	720
tgaaacctca	agtctattat	ataacgtaa-	gaaaaattgg	cttggtgagg	tggttcacac	780
ctataatccc	agcactttgg	gaggctgagg	tgggtggatc	acttgagttc	ggagttcagg	840
accaggctgg	gcaacatggc	aaaacccac	ttctaccaa	aaaaaaaaa	aaaaaaaaa	900
ctcgtgccga	a					911

<210> 28

<211> 1697

<212> DNA

<213> Homo sapiens

<400> 28

ggaagaaaac	aatgctggcc	ccttcatcta	aattctgaga	attatttaac	acttagtacc	60
caactctcaa	gttgttatga	agattaaatc	acataatgtg	atgttcccgg	cacagtgtc	120
tgtaacatac	tccggagcac	atagtacctg	cttaataagc	attgcataag	tatatgtgta	180
catgttggtt	ttcagtgag	acttactcag	acgttggtgc	cttctcctgt	ctctgaagtt	240
aaagagctag	caaagaatgt	ggtttttcag	gatagagatc	gattttttat	ttgatcagaa	300
gtatttgtgt	tgtgatgagt	gatgagtgtg	agagtttgtt	ccatgcctgc	tttctctagc	360
taaatgctac	taatgatggg	tctggggaag	ctacatcagc	attgacagga	gatgtgttta	420
aaatgcactt	tcatggatgc	ttttaaaacc	tgacagawtca	cattmcatag	tgtaggacca	480
gggttaccaa	atgatttata	tgacactga	agtttgagag	scaatgttta	gctaagtggg	540
tcttggccca	ggcttcta	taagattcca	tgggccaggt	gcagaaatct	tttcaactgt	600
gcccttccc	caggctctgt	atattgggtg	gggtgggagc	atccttgttg	atataattaa	660
gtgcctcatg	tgactccagg	ttgaggccag	gggtcaaacat	gaggaattca	aaatacatc	720
atgagagttg	agtccaact	ttattccaaa	gggaggtcca	ttccaatggg	tggatttggt	780
agggacaagt	tagtgtggcc	catatcccca	ttgctgtagc	agaaattgtg	gcactctgtg	840
caggaaaaga	gaaagataaa	ttttgatctt	tgtggaggag	ctcactgtcc	ttgaatctca	900
cctgttataa	agaacataaa	tgagtgagca	ttttctgcat	gcctggatct	ttctacctgt	960
gtttgtgggtg	gtagcagggtg	aagagattgt	gctgattcct	ttaaaggcat	attcccaaga	1020
tgacaggtgtg	acttgtccag	agaatatcac	ctgagaataa	atcctagaga	aggacgatga	1080
agagaaaaat	ggctttttct	cagggtgactg	tgtctcagac	caggaacagt	gttcaactctg	1140
cctyctggaa	tgccatatgt	ttagaactta	caaacctgta	cttcttgact	ttatgtgkt	1200
tctccctata	agtttgktta	aacacttttt	cttctcatga	tagtcaaaaca	actctgaaaa	1260
aatatttatt	tctatacact	agagtcttct	cgacattctc	ttcatcttgg	cttcttctct	1320
gctatgcaga	attctcatca	ttaatttatg	actcataata	ttaaaaatat	tccctttggc	1380
tgggcgcggt	ggctcatgct	tattatccca	gcattttgag	aggccgatgt	gtgtggatga	1440
cctgaggtca	ggagttcgag	accagcctgg	ccaacatggt	gaaaccctgt	cactactaaa	1500
aatagaaaaa	atagctgggc	atgggtgggtg	gtgcctgtaa	tcccagctac	ttgggaggct	1560
gaggcaagag	aatcacttga	acccaggagg	tggaggttct	ggaggttgca	gtgagcctac	1620
atcgtgccgc	tgactccag	cctgggcaac	agagagagac	tccatctcca	aagaaaaaaa	1680
aaaaaaaaa	aactcga					1697

<210> 29

<211> 1142

<212> DNA

<213> Homo sapiens

<400> 29

gaggcaatag	gtcggggaag	gtgatgaatg	ttctgtgggg	catgtcaaat	tgggtggaac	60
ctctggggcc	ttctgtggga	ratgcccagg	gagcacagat	ttaggagatg	ggagcaacta	120
gtgtgatggt	ggtgagggct	ggttgaaacc	ctggggagta	tgtggagctc	atctgtgttt	180

ccacagagct	tatctcccag	gagatagcca	tcgggagtg	cttgccctggc	atgttccccc	240
gctgaggctc	gttaccacag	agcctgcaga	cacaaagagc	aggctggtaa	tgctgagaag	300
cgaacattca	gtacctgtca	ccagaaccca	gcatgggtgt	tcaacactat	ctggtgactc	360
tgtgagaaga	ccctatgtct	aggggatgaa	gtgtgttgct	tgtgcaagag	ggatggagag	420
agagtgtttt	ccaagtatat	gtgtgtgtgc	atgtgtgtgt	accaggtgg	aaccctcctg	480
catgctcaca	tatgccttta	tgaatactgg	aatctctaaa	cctaccatca	tgcatctcgt	540
cttagcttcc	tacctctctc	tttctacccc	tgcaacagcc	atgttattgc	cagtaacaca	600
tgagaagagt	gagggagacc	tgtctgtaga	caagctcagt	gtgctgctaa	ggaagcaggc	660
agcagttctg	tcctcatgcg	ttcccattgt	gccctgtcct	gggatggcaa	atgcaaggcc	720
agacaggctc	tgggstctct	ggtctgacca	ctaatagcac	cttctcctcc	cgctaggctg	780
accagcctcc	aaggcaggac	tctgacacca	gggttataaa	tgcatctgtc	tgggcacatt	840
atctaaattg	ttatgtatca	ccctgggtaa	tggcaaaagt	aaaaaccgct	gttagctcag	900
tgaataaattc	cttggtgctg	atcaatcatt	gcacgacata	gactctttta	ataggcacia	960
tttacacaga	ggcttggcag	actgcttctg	cttctaattg	ctgatggaaa	atggatgccg	1020
agctctgctg	tgccgtaaaa	atgtaaacata	taaatgactt	aaaaacttgt	gtgctccctt	1080
ctccaccag	cactcatttt	aaccttttat	ttagaaacaa	aaaaaaaaaa	aaaaaactcg	1140
ag						1142

<210> 30

<211> 2322

<212> DNA

<213> Homo sapiens

<400> 30

ctcgtgccga	attcggcacg	agcggcacga	gggagacggt	tgggagaacc	gttgtggcga	60
gcgctacacg	aggcaaacga	cttctccctt	ctttgaaactg	gaccccgcca	gcaccagagt	120
cggcgtaact	atcgccctgac	aggcatttaa	atcaaacggt	attgagatgg	attgggttat	180
gaaacataat	ggtccaaatg	acgctagtga	tgggacagta	cgacttcgtg	gactaccatt	240
tggttgcagc	aaagaggaaa	tagttcagtt	ctttcaaggg	ttggaaatcg	tgccaaatgg	300
gataacattg	acgatggact	accaggggag	aagcacaggg	gaggccttcg	tgcatgttgc	360
ttcaaaggag	atagcagaaa	atgctctggg	gaaacacaag	gaaagaatag	ggcacaggta	420
tattgagatc	ttcagaagta	gcaggagtga	aatcaaaagg	ttttatgac	caccaagaag	480
attgctggga	cagcgaccgg	gaccatatga	tagaccaata	ggaggaagag	ggggttatta	540
tggagctggg	cgtggaagtt	atggaggttt	tratgactat	ggtggctata	ataattacgg	600
ctatgggaat	gatggccttg	atgacagaat	gagagatgga	agaggtatgg	gaggacatgg	660
ctatggtgga	gctgggtgatg	caagttcagg	ttttcatggt	ggtcatttcg	tacatatgag	720
agggttgcct	tttctgtcaa	ctgaaaatga	cattgctaatt	ttcttctcac	cactaaatcc	780
aatacgagtt	catattgata	ttggagctga	tggcagagca	caggagaagc	agatgtagag	840
tttgtgacac	atgaagatgc	agtagctgcc	atgtctaaag	ataaaaataa	catgcaacat	900
cgatatattg	aactcttctt	gaattctact	cctggaggcg	gctctggcat	gggaggttct	960
ggaatgggag	gctacggaag	agatggaatg	gataatcagg	gaggctatgg	atcagttgga	1020
agaatgggaa	tggggaacaa	ttacagtggg	ggatatggta	ctcctgatgg	tttgggtggg	1080
tatggccgtg	gtggtggagg	cagtggaggt	tactatgggc	aaggcggcat	gagtggaggt	1140
ggatggcgtg	ggatgtactg	aaagcaaaaa	caccaacata	caagtcttga	caacagcatc	1200
tgggtctacta	gactttctta	cagatttaatt	ttcttttgta	ttttaagaac	tttataatga	1260
ctgaagggaat	gtgttttcaa	aatattatatt	ggtaaagcaa	cagatttgtga	tgggaaaatg	1320
ttttctgtag	gtttatttgt	tgcatacttt	gacttaaaaa	taaattttta	tattcaaacc	1380
actgatgttg	atacttttta	tatactagtt	actcctaaag	atgtgctgcc	ttcataagat	1440
ttgggttgat	gtattttact	attagttcta	caagaagtag	tgtgggtgtaa	ttttagagga	1500
taattggttca	cctctgcgta	aactgcaagt	cttaagcaga	catctggaat	agagcttgac	1560
aaataaattag	tgtaactttt	ttcttttagt	cctcctggac	aacactgtaa	atataaagcc	1620
taaagatgaa	gtggcttcag	gagtataaat	tcagctaatt	atttctatat	tattattttt	1680
caaattgtcat	ttatcaggca	tagctctgaa	acattgatga	tctaagaggt	attgatttct	1740
gaatattcat	aattgtgtta	cctgggtatg	agagtgttgg	aagctgaatt	ctagccctag	1800
atthtggagt	aaaaccctt	cagcacttga	ccgaaatacc	aaaaatgtct	ccaaaaaatt	1860
gatagttgca	ggttatcgca	agatgtctta	gagtagggtt	aaggtttctca	gtgacacaa	1920
aattcagtat	taagtacata	ggtattttact	atggagata	attctcacaa	ttgtattttc	1980
agttttctgc	ccaatagagt	ttaaataact	gtataaatga	tgacttttaa	aaaatgtaag	2040

caacaagtcc	atgtcatagt	caataaaaaac	aatcctgcag	ttgggttttg	tatctgatcc	2100
ctgcttgagg	ttttagttta	aagaatctat	atgtagcaag	gaaaagggtgc	tttttaattt	2160
taatcccttt	gatcaatatg	gcttttttcc	aaattggcta	atggatcaaa	atgaaacctg	2220
ttgatgtgaa	ttcagttatt	gaacttggtta	cttggttttg	ccagaaatgt	tattaataaa	2280
tgtcaatgtg	ggagataata	aaaaaaaaaa	aaaaaaaaaa	aa		2322

<210> 31
 <211> 658
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (565)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (571)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (589)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (596)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (621)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (643)
 <223> n equals a,t,g, or c

<400> 31	
ttcggcacga	gtatacacia cattttggtt tttttttgca aatactctac tgaatatttc 60
cccattctat	ttaatatatt atgatctttc atactttatg aaactctaaa actgtaaaat 120
aatttttggg	agggagagaa gagttctatt gcaaaaaaaaa atgctttatg cacataattt 180
ttttatgcta	aacaatttcc ttggaataaaa cttgcaggca tggacatcta gattaagtw 240
gcaatttctt	ttgacatttg ctacatattg ctatgcta at tccaaaaga actgtactca 300
gtaagacaat	tacacatttc agcctccgca ctgtaactct gtcagcattt gtgtgtgcac 360
acataattac	acatagagtt gacacagaca ttttgccaag ataaaaaaaa aaaaaaaaaa 420
aactcgaggg	ggggcccggt acccaattcg ccctatagtg agtcgtatta caattcactg 480
gccgtcgttt	tacaacgtcg tgactgggaa aaccctggcg ttacccaact taatcgctt 540
gcagcacatc	cccctttcgc cagcnggcgt naatagcgaa gaggcccgna ccgatngccc 600
ttcccaacag	ttgcgcacct ngaaatggcg aatggcgaat tgnaagcggt aaaaattt 658

<210> 32
 <211> 1437
 <212> DNA

<213> Homo sapiens

<400> 32

ggcagcagaa	atattcttcc	tgagggttaat	ggaacataat	tttccacagc	caatagcatt	60
caatagtcaa	gactgctttt	aatgattttc	cagtgcgtgc	cgcttcttaa	tttgcaaata	120
tggtggatgt	tataattata	taaccaatat	gtatgtatta	gttaaacaga	tattggaggg	180
ataactaggg	aatctaacct	taacctctaa	taccatgaga	aaatcaattg	caaattaagt	240
tctgagatag	aagctgtttg	caaactctgt	tatggagaga	gcaacatgaa	aacacaaaat	300
cactgtattt	tttgcattgt	tattttattt	tctacttcag	tgccaccttt	aatttggtcg	360
tggcagtgtg	tttccgtcca	ttctttattt	taaatagaga	agtcatttat	ttggctcatg	420
gttctggagg	ctgagcagtc	caagatgtag	tggtgcgcat	tggtgagggc	ctttgtgctg	480
caccatagca	tggcagaagg	gccagcaagc	ccacgagaca	gagaaaatgg	gagccaaact	540
tacctttttg	tcaggaaccc	actcccttga	taactaacac	gctcctatga	tagtgggtatt	600
aatccagtcg	taagggtctt	gctctcaaga	tctaataacc	tcttaaaggc	ccaacctccc	660
aacctccttt	ttggcctgtc	ttttgtgtgt	gcaggcgcat	gtgtgcaaat	aaaatcacat	720
cagggttaagc	ttgtcaaagt	agggagcagc	tggttttaag	ataaactctc	tcattccacac	780
atattttccc	cacccaagc	acagctgcct	cttaactgct	gttggaccat	aactccaagt	840
gaagtgtgtc	tccctccccc	atctccacaa	atagcaggaa	aagtaatgtt	gtaatttaca	900
aagttaactta	ctccctgcc	tttcagagag	aagatggagt	ataggaaagc	cctcccaccc	960
actgtccttg	tgtgatgtga	cacaacttgc	tccctcagtc	ttggaataca	gcctcatgtg	1020
gtccttggcc	agaggcagag	aaagggcctt	catctctctc	acagctgaag	ggtgggaaac	1080
atggtcttca	ttccgtgtaa	ccacgtgtct	agctagagat	cagaggttct	gtcataaat	1140
tataaaggag	aagagagatt	tggggatgat	tagcagcctc	tgacataggg	gcatctcccc	1200
cagtgaggcg	tgggcagatt	attaaaggaa	tggtactggg	aataaaagtg	gctgaggata	1260
aatttttaaat	tctcatatta	cttcttcaaa	aaattctaat	ttttaaatca	agtcgtataa	1320
tttttaagaa	taggtcttca	attgatttct	agatggcaaa	taatttatat	aaacaaaaac	1380
aatggagcct	tctccaaaaa	tgaatactca	attaaaaaaa	aaaaaaaaaa	actcgag	1437

<210> 33

<211> 1968

<212> DNA

<213> Homo sapiens

<400> 33

gcgggtctgc	gaggtggggt	aggcgggcaa	ggcgggcgcc	gaggtttgca	aaggctcgca	60
gcggccagaa	acccggctcc	gagcggcggc	ggcccggtct	ccgctgcccg	tgagctaagg	120
acggtccgct	ccctctagcc	agctccgaat	cctgatccag	gcgggggcca	ggggcccytc	180
gcctccctct	tgaggaccga	agatgagctt	cctcttcagc	agcgcctctt	ctaaaacatt	240
caaaccaaag	agaatatatc	ctgaaggatc	tcattcagat	gaactcttaa	aacatgcaga	300
agcaactcta	ggaagtggga	atctgagaca	agctgttatg	ttgcctgagg	gagaggatct	360
caatgaatgg	attgctgtga	acactgtgga	ttcttttaac	cagatcaaca	tgttatatgg	420
aactattaca	gaattctgca	ctgaagcaag	ctgtccagtc	atgtctgcag	gtccgagata	480
tgaatatcac	tgggcagatg	gtactaatat	taaaaagcca	atcaaatgtt	ctgcacaaaa	540
atacattgac	tatttgatga	cttgggttca	agatcagctt	gatgatgaaa	ctctttttcc	600
ttctaagatt	ggtgtcccat	ttcccaaaaa	ctttatgtct	gtggcaaaag	ctattctaaa	660
gcgtctgttc	agggtttatg	cccatattta	tcaccagcac	tttgattctg	tgatgcagct	720
gcaagaggag	gccacctcca	acacctcctt	taagcacttt	atcttctttg	ttcaggagtt	780
taatctgatt	gataggcggt	agctggcacc	tcttcaagaa	ttaatagaga	aacttggatc	840
aaaagacaga	taaatgtttc	ttctagaaca	cagttacccc	cttgcttcat	ctattgctag	900
aactatctca	ttgctatctg	ttatagacta	gtgatacaaa	ctttaagaaa	acaggataaa	960
aagataccca	ttgcctgtgt	ctactgataa	aattatccca	aaggtaggtt	ggtgtgtag	1020
tttccgagta	agaccttaag	gacacagcca	aatcttaagt	actgtgtgac	cactcttggt	1080
gttatcacat	agtcatactt	ggttgtaata	tgtgatgggt	aacctgtagc	ttataaattt	1140
acttattatt	cttttactca	tttactcagt	catttcttta	caagaaaatg	attgaatctg	1200
ttttaggtga	cagcacaatg	gacattaaga	atttccatca	ataatttatg	aataagtttc	1260
cagaacaaat	ttcctaataa	cacaatcaga	ttggttttat	tcttttattt	tacgaataaa	1320
aaatgtattt	ttcagtatcc	ttagagattta	gaacatctgt	gtcacttcag	ataacatttt	1380
agtttcaagt	ttgtatggta	gtgtttttat	agataagata	cgtctatatt	ttcaaaattc	1440

atgattgcag	tttaaactcat	catatgacgt	gtgggtggga	gcaaccaaag	ttattttttac	1500
agggaacttta	ttttttgatc	tttattttgag	attgtttttca	tatctatcta	aattatttagg	1560
agtgtgtgta	tcagaagtaa	ttttttaatg	tcttctaagg	atggctcttc	aggcttttaa	1620
actgaaaagc	ttaattcaga	tagtagcttt	tggctgagaa	aaggaatcca	aaatattaat	1680
aaatttagat	ctcaaaacca	ctatttttat	tatttcatta	tttttcagag	gccctaaaaat	1740
tctggataag	agaatggagg	raaatactca	gagtactga	ttawtttawt	tcctttttatt	1800
aaaaaattac	ttctatgttt	ttattgtctc	ttgagcctta	gttaagagta	gtgtagaaat	1860
gcatgaactt	matcctaata	aggataaaac	ttaaggaaaa	ccacaataaa	ccatgaaggt	1920
gtacacatct	taaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaa		1968

<210> 34
 <211> 754
 <212> DNA
 <213> Homo sapiens

<400> 34	
ggcacgagga	aatttggggg aacgggtgttc caggcatagg gaatagcaga tgtaaaggcc 60
gtgatttggg	aataaacttg gtgtgatgga ggaatggcag agagggcaga acagagcaag 120
agggcaagat	ttgtaggaga tgaggctatc aggggccttg caggccatgg tgggggtgtg 180
gattctatct	ttagtgctg tggaaagtca aggcagggtt ttagcagagc aaagatgcaa 240
cctggcttgg	gctttataaa gctccccctg gctgcatgga gagaaataaa atgtaggcag 300
caaaagtggg	agaggagagg cagctgggtgc actaatccag gtgagaggta aagatggatg 360
ggtagggctg	aaggatgggt gggcagggtg tgagaagtga cttgggtctg gagacatatg 420
aaggaagatg	gtcaggcagg ccgggcacag tggctcatgc ctgtaatccc agcaatttta 480
gaggctgagg	tgggaggatt gcttgagctc aggagcttga gaccagcctg ggctacatag 540
caaaacctcc	tctctacaaa taaaaaaaaa tagtcgattg tgggtggcata tgctgtagt 600
cccagctact	gggaggcaga gataggagga ttgcttgacc ccaggaggtc gaggctgcag 660
tgagccaaga	ttgcaccact gcactccagc ctgggtgaca gagccagacc ctgtcttaaa 720
aagctaaagc	aaaaaaaaaa aaaaaaaaaa aaaa 754

<210> 35
 <211> 1324
 <212> DNA
 <213> Homo sapiens

<400> 35	
ccccgggct	gcaggaattc ggcacgagct ttgctatgaa gtggcaaatt acatgtagag 60
tgtctccttc	cttttcagag aacagttaat caaggcaaat cagcaagccc ccaaagtgtc 120
gtaatttaac	atcatgatta ccaccttcga agctatatat tttgcatact ttaaaatcac 180
ctaacttggg	ctgcttgaat tacattggct tttagaaccg aaattgtaac tatgtattgt 240
atttcatggg	aggtatattt tatgagcttt ttggctttct tttttccac agcaactgcc 300
aatgaaggat	gaatcccctt tttaaaaagt tgttgtgtt gttgttattt gatttttagt 360
taggagggat	aatagagaag tccattttaa aattattttt agaagctaaa gaaagtaatt 420
atgcttcctg	tgaattgtct tttactggca tctttgtttt cctctttgat gttagttaat 480
ttggtgtaat	acgtggggct tccatatttc aaagtggag ctttcttctc tgaagtcat 540
atatggtttt	gaattactag agctttgggc agtatttctt tccctatatg tcacagaggg 600
caccactgag	aactgcgtgc ataggacctt aaaatacaaa attagcaggg cctcacagtc 660
agcttcctca	tggctagttt ttccccctta tattacaatt tttgttttat aagtcatttt 720
tttctgata	tttccaccac ttttcagagt cctctacaaa atttttcttt cctcaagaaa 780
agagtccctt	ttgccttatt ccttatgcct tccccactgg tattgagggt ttgataataa 840
attggtagga	aaaaaaagta cctcctagaa ggaagccttc cccaccattt ccagggtcca 900
actgctaagc	agatatattc caaaaatggt aactgtcatg tgcacactgt tggttatttt 960
taataagcct	cttccacta gaacatttta ttttcttctg tcaccatata atcatgtact 1020
ctttaacaga	aattgctttt aaaaaatata tggaactatc tttaaaaaaa ctttattaat 1080
aatcatgtat	ttttactgat cacattttga aatgcctaaa agactttatt gttctaatta 1140
tccagatgta	cctttgtaaa atagctcttt tatgaattag ctgataaggc tgtatgtttc 1200
tggacaacaaa	tattggctcat ctaaaaactt tctgttttct ggggtctggg aaaatagaaa 1260

ataagatttc aaatattaaa taagcttaaa ggaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1320
 aaac 1324

<210> 36
 <211> 1099
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1051)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1073)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1076)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1087)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1093)
 <223> n equals a,t,g, or c

<400> 36
 ggagtatatt tcctgaataa tatctgtttt ggagacttgg acaaagttaa cttttttgct 60
 tttttaaaag ttgctgttta aattaacttc ctgcatttct aatgtagaaa aaatatggca 120
 cagtgatttg aattttgttt atggtttatt atcttcttaa attatcagct ctttaaaata 180
 tgggtctctg gcctgtatac catctgataa attaggttgg gtaaattttt cacctgaaaa 240
 aattcattct tttgaccag gttgtttggc ttggaaaaaa aaaatcacat actcattgca 300
 tgattaaact tgtccatcag attgtgattt tgtgcgttat gaggattgta gctggggtaa 360
 ttttaaaatg ttggtatttg gatagaactg ccagcccagg attttgataa agatcaaaat 420
 atatactgta tctaaagttt cttttttaaa agttatttca cttataatca aaagggttaa 480
 ataagtttag tgtatatatt atgattagta ttattttgta tgcattcaga gagaggaaaa 540
 ctgcattccc atagacaggg agacttgggtg cattaatatc caaagcttag ttttaagctgg 600
 tgatgattag aaaagtggct ttcatttggg ttctctggaa gattctcagt agtcctgtgg 660
 gcatgtgaac aagagcatgt gtaatcttca taatgtatgt cttgttagca gaaatgtctg 720
 aggcattgct gagatgtagg atgagctgag gtactgggtt tgtctttcat ggttccctat 780
 tatgtttttt gagaaactga gcttttctct acagtgttta gtttttcttg gctattttact 840
 aatgctatta atagtaacag tttccattat ggagcctcag taggttcttg acatacatta 900
 acccattgct attatgtaat tttctaataa aatgatgtga taaaacatat tttctgtaat 960
 atactcatag aatatgtgat tataagtaaa taaatagatg ttgggggtaaa aaaaaaaaaa 1020
 aaaaaaaaaa aagggcggcc gcccaaagga nccccgaggg gccagctaag cgncancgaa 1080
 gcaagcncnc ccnaaaggg 1099

<210> 37
 <211> 1379
 <212> DNA

<213> Homo sapiens

<400> 37

```

cccgggtcga cccacgcgtc cgcttctctca ggtccaagag aatgggagga gggtcattgtt      60
gaagtgtagc cactggaact ttcttgcatt tatggagtgt ctttttcttt cccaaggaaa      120
ctgatgtttg cctgtccgct ttatctttgt agtacatgaa cagttcagcc ttagactatg      180
taactgtttt ctcatcctta gctgaaaatg aggggcctac tgtattgcga gactgttcag      240
gggtaggggt ggaggggggt gtcccttaat ggccctgaa gatgttgat gtgtttctca      300
aaagctgctt tgtctcttct ctgagtttaa tagtgaaact actaaacatt aatagatttg      360
cacagccaca aagaatgaga gttgataata ccgaagaagt gatgcaaaaa caaaaaatca      420
cattactgat cattgatagt attacaaata aatgtctctt cctttctctt cctcccttcc      480
tccccctgcc ttccctctaa cctatgtgct catccttgct acttgaggct gttatttccc      540
tccgagtatt taaggagccc aaacaccttg gtcttcctgg gtgggggcat aattaaggga      600
agggagtgtg taaggaagga aacctcatac cctccattcc catccctgga tatattgcct      660
tttcagcagc ctcggtttca gtgtgcttgg ggtcaggagt gccaggttcc caagagcagc      720
gtaaaacatc cctgtacccc ttgacagtta taagcatttc tgcgttaaac ttgaagattc      780
cagagattcc ccacgacctt atgatctaag aatgcagatt ggattctttg atgttcaaatt      840
ttctcattta cttatgaaaa tccctaatta tatagtttta tataatgtgt atacagagta      900
ggattgttga tgaatttgag cggttggaac accctcatgg aacactggca acatggaatg      960
tagagagctg atgtcttccc cctcatagag gccattggct tcctttgtat aaggagaggg      1020
agaagtgatt ctggaaggag aagtgggtat gtctagcttc attgcgggccc ctcgggctac      1080
ccagcaagag gattctgcat caaggaaact gacgagccgc taccctaaact gccaccatct      1140
ttactcttta caaaatggac ccacgcagaa tggtgaaaag cttggaagta tcacttttga      1200
aaaaaaaaaa aattattttg cattcagcat ggactcgacc aggcattctat ggagattatt      1260
tttttgcttc attttataaa gttgtattta gaaaagtctt aagtattgtg ctttgtaaaag      1320
aagatgatta aaatgaaatt ttgtgagaat aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      1379

```

<210> 38

<211> 581

<212> DNA

<213> Homo sapiens

<400> 38

```

gaaggatatg gactattgca atacatttct tccttcaaatt cctgccactg ttttgttggc      60
ccacaactaa taggacctca aaataagcca tgctgctttg cacacacact agccttcttt      120
tgtacttttc attctggatg ggcttggcca aaacaggctc aggccaaaga cctcccaagc      180
tgtatgtact tccagtatcc tgaaacagtg tttggtgaca taatgccaaag ggtaaacaaag      240
cctgatttag gcaactgctt atccaggggc ttcacccatg aaattaataa aacttatctg      300
agtcacttga aacttggttc ccagaaaaca catttctggt ttataatctc cttttatgct      360
cacctgacat taattatcta tccttgatga tgtgttttaa ctgagtagca gaaaacagag      420
gccacacttt ctgggaaatt ttaaaggaag aaaccatttt taatgagatg aaaatattta      480
acgaatttaa aaagctaatt acaattttga gaaaaggttt gggatgtata ttgctatgta      540
atttaataaaa ctgattttat ggatataaaa aaaaaaaaaa a      581

```

<210> 39

<211> 1284

<212> DNA

<213> Homo sapiens

<400> 39

```

cccacgcgtc cgcgagagaca ggacactctt cctgaagcgg ggcgagatc agaggcagaa      60
gaggaggagg ccaggaccat cagagtgaca cctgtcaggg gccgagagag gctcaatgag      120
gaggagcctc caggtgggca agacccttgg aaattgtctga aggagcaaga ggagcggaag      180
aagtgtgtca tctgccagga ccagagcaag acagtgttgc tcctgccctg ccggcatctg      240
tgctgtgccc aggcctgcac tgaaatcctg atgcgccacc ccgtctacca ccgcaattgc      300
ccgtctgccc gccggggcat cctgcagacc ctcaatgtct acctctgaag cctccttccc      360
tgctgcccc cccctccatg ctccacgcag gcactcacgc taggacagca ttaacacctc      420

```

20

```

atctccgggt cctgggtctga atccccctct acccctgtgg ccatacctgcc atacatccag 480
gacattgagt tgaagacta tgatctgggt gggggcagga taacatggct tctctttacc 540
cagtgggtcc ctctgatgct gaggggtggg agtatgtcac tatgcaaggg cctcgagact 600
atttgctgtg ggctctcctc cagcctgccc agggcccacc cagatgcctc tggggttacc 660
cctgtctgct tctgggtttt ctgttggaga tctataggtc cttttcctgc ctctctcaca 720
tttctcccc agctttttgc gccacaacac atcagtgtca tttgggtgtt ttggcaactc 780
aggggccttc ggatgatctt aaacctttgt gttagccag agccctgtg ccctggtagg 840
cgttgggggt agtatctctc ggggtgccctc agagccacct ctgcctgtga tcgtctgatg 900
aggtccctc ccaacctgat ccaaaagcca gtctcaggag tttaccctg ggatggggga 960
tgcatctgca cctgactttg gggccacgtg ccctgtggca ccccagctca ctgggagtct 1020
caggagggat aaccggattt ctgctcttcc ccctgtcact cccacatcac acagaaaaat 1080
ggcattcttc tctgtctctc cctggcatgg agagggcaga ctgtgcacat ttactaggg 1140
tccaaataca gaagggccca gggcccaggg gcttgagct tcgtgagggg tctctggccc 1200
agtttccaat gaataaagt ctcttgacag ctmaaaaaaa aaaaaaaaaa aaaaaaaaaa 1260
aaaaaaaaaa aaaaaaaaaa tcga 1284

```

<210> 40
 <211> 792
 <212> DNA
 <213> Homo sapiens

```

<400> 40
cagacatggc tgaaatccag tcccgctgg cctacgtgtc ctgtgtgagg cagctagagg 60
ttgtcaagtc cagctcctac tgcgagtacc tgcgcccgc catcgactgc ttcaagacca 120
tggacttttg gaagtctgac cagatctatg atgtgggcta ccagtacggg aaggcgggtgt 180
ttggaggctg gagccgtggc aacgtcattg agaaaaatgct cacagaccgg cggctctacag 240
accttaatga gagccgcgt gcagacgtgc ttgccttccc aagctctggc ttactgact 300
tggcagagat tgtgtcccg attgagcccc ccacgagcta tgtctctgat ggctgtgctg 360
acggagagga gtcagattgt ctgacagagt atgaggagga cgccggaccc gactgctcga 420
gggatgaagg ggggtcccc gagggcgcaa gcccagcac tgcctccgag atggaggagg 480
agaagtcat tctccggcaa cgacgtgtc tgcccagga gccgcccggc tcagccacag 540
atgcctgagg acctcgacag gggtcacccc ctccctccca ccctggact gggctggggg 600
tggccccgtg ggggtagctc actccccctc ctgctgctat gcctgtgacc cccgcccgc 660
acacactgga ctgacctgcc ctgagcgggg atgcagtgtt gcactgatga cttgaccagc 720
ccctccccca ataaactcgc ctcttggaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 780
aaaaaaaaaa aa 792

```

<210> 41
 <211> 1351
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (864)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (876)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (883)
 <223> n equals a,t,g, or c

<400> 41

ctttgagccc	ctctcattcc	acttttagcaa	tcttttttgg	aagaactctt	aaagccaaaa	60
gtctgtctgaa	aagatttgct	gattattagt	ttaaaaaatct	tgtaacactc	agcagtgcta	120
ttttgagtca	tcccagtttc	ctgaaagtaa	tgcccagctc	tcctgaatcc	tccttaatag	180
cagaaccttg	gtgattttgt	tggctcatat	gaatgcttgt	catggatatg	ttaacaattt	240
agtgtttgac	attgcttcct	ctgccacaaa	gacaatactc	tggtgacaca	tgtctagacc	300
cagcacaggc	tgtaggccca	ggagtgcactc	aaaggagtgt	ttccctcttt	ctacagggtc	360
aaagggtgacc	ctgggtgggtg	ccagagcagt	aatgcttgtt	tgatgctctt	catggctcat	420
ctgctttctca	gaaccacccc	gttgagtttg	tgggtaacca	gcaggcaggc	caaagactgg	480
tgctttttcat	ttcatccttt	agagggatga	aacagttatt	tccgtctgat	gagcattcgg	540
tagaattttt	gaagtgcgat	tttatgaagt	caaaggggac	tttacacaga	tctcgacctg	600
ctttgaaacc	tagagggtgg	cctttgattt	gtgcgtgtcc	ttgccctctg	gacaacttaa	660
tattttcaagt	aatcgaatac	caacttcctc	gccagcccac	ctgccttccg	ccccgcttgt	720
gtaacagtcc	tgttttgttg	agttgctgct	attgcaactgc	cagtgcagcc	cacaccaa	780
cacaacccaa	gatactcaga	taggaagact	ccttcctctc	ccagtaactt	accaaaggaa	840
ccccgcag	gaccacatg	gggnccacgt	gttggnccag	ggnaatcagc	ctgtgcaggc	900
tggggatctc	aggctgatca	gtaggggcca	gctttggagc	cagccaagct	gaatcccaca	960
ctccaggtct	gtgctcaaga	gaccagatgg	tgtatttcca	aatggscttc	tctgggatgg	1020
gcaataggca	agctcctggg	gtctggttat	gtggaagatt	cttagtggtg	gttccgcctg	1080
gttagctggg	tctcttcaga	gaatataaag	tgaatgcctt	taggggtagc	tctgaaagag	1140
aaacccaa	acttcattcc	tagccatgaa	agtagcacga	tcataattgta	ctgtattgtt	1200
attgtaaaat	gaytatttgc	catgtcatga	gtaggtagat	gttttgccac	aaatatgaat	1260
gtgtttgttg	ttcctgactt	taagcaatga	agattgagac	aataaatagc	actcagagaa	1320
tgaaaaaaaa	aaaaaaaaaa	tgaccctcga	g			1351

<210> 42

<211> 2812

<212> DNA

<213> Homo sapiens

<400> 42

aaagttcatg	ttgttgatct	aaaggcagaa	tctgtagctg	ctcctataac	tgtycgtgct	60
tactttaaatc	agacagttac	agaattcaaa	caactgattt	caaaggccat	ccattttacct	120
gctgaaacaa	tgagaatagt	gctggaacgc	tgctacaatg	atttgcgtct	tctcagtgct	180
tccagtaaaa	ccctgaaagc	tgaaggattt	tttagaagta	acaagggtgt	tgttgaaagc	240
tccgagactt	tggattacca	gatggccttt	gcagactctc	atttatggaa	actcctggat	300
cggcatgcaa	atacaatcag	attatattgt	ttgtactctg	aacaatcccc	agtatcttat	360
tccaaaagga	cagcatacca	gaaagctgga	ggcgattctg	gtaatgtgga	tgatgactgt	420
gaaagagtca	aaggacctgt	aggaagccta	aagtctgtgg	aagctattct	agaagaaagc	480
actgaaaaac	tcaaaagctt	gtcactgcag	caacagcagg	atggagataa	tggggacagc	540
agcaaaagta	ctgagacaag	tgactttgaa	aacatcgaat	cacctctcaa	tgagagggac	600
tcttcagcat	cagtggataa	tagagaactt	gaacagcata	ttcagacttc	tgatccagaa	660
aattttcagt	ctgaagaacg	atcagactca	gatgtgaata	atgacaggag	tacaagtcca	720
gtggacagtg	atattcttag	ctccagtcac	agcagtgata	ctttgtgcaa	tgcagacaat	780
gctcagatcc	ctttggctaa	tggacttgac	tctcacagta	tcacaagtag	tagaagaacg	840
aaagcaaatg	aagggaaaaa	agaaacatgg	gatacagcag	aagaagactc	tggaaactgat	900
agtgaatatg	atgwgagtgg	caagagtagg	ggagaaatgc	agtacatgta	tttcaaagct	960
gaaccttatg	ctgcagatga	aggttctggg	gaaggacata	aatggttgat	ggtgcatgtt	1020
gataaaagaa	ttactctggc	agctttcaaa	caacatttag	agccctttgt	tggagttttg	1080
tcctctcact	tcaaggtctt	tgcagtgtat	gccagcaatc	aagagtttga	gagcgtccgg	1140
ctgaatgaga	catcttcac	attttctgat	gacaataaga	ttacaattag	actggggaga	1200
gcacttaaaa	aaggagaata	cagagttaaa	gtataacagc	tttttggtcaa	tgaacaagag	1260
ccatgcaagt	ttctgtctaga	tgctgtgttt	gctaaaggaa	tgactgtacg	gcaatcaaaa	1320
gaggaattaa	ttcctcagct	cagggagcaa	tgtggtttag	agctcagtat	tgacagggtt	1380
cgtctaagga	aaaaaacatg	gaagaatcct	ggcactgtct	ttttggatta	tcataatttat	1440
gaagaagata	ttaatatattc	cagcaactgg	gagggtttcc	ttgaagtctt	tgatggggta	1500
gagaagatga	agtcctatgc	acagcttgca	gttttgtcaa	gacggtggaa	gccttcagag	1560
atgaagttgg	atcccttcca	ggaggttgta	ttggaaagca	gtagtgtgga	cgaattgcga	1620

gagaagctta	gtgaaatcag	tgggattcct	ttggatgata	ttgaatttgc	taagggtaga	1680
ggaacatttc	cctgtgatat	ttctgtcctt	gatattcatc	aagatttaga	ctggaatcck	1740
aaagtttcta	ccctgaatgt	ctggcctcct	tatatctgtg	atgatggtgc	ggtcatattt	1800
tatagggata	aaacagaaga	attaatggaa	ttgacagatg	agcaaagaaa	tgaactgatg	1860
aaaaaagaaa	gcagtcgact	ccagaagact	ggacatcgtg	taacatactc	acctcgtaaa	1920
gagaaagcac	taaaaatata	tctggatgga	gcaccaaata	aagatctgac	tcaagactga	1980
ctctgatagt	gtagcatttt	ccctggggga	gttttggttt	taattagatg	gttcactacc	2040
actgggtagt	gccatttttg	ccggacatgg	ttggggtaac	ccagtgcac	cagcactgat	2100
tggactgccc	tacaccaatc	agaagctcag	tgcccaatgg	gccactgttt	tgactcggaa	2160
tcatgttggt	cactatagtc	aaatgtactg	taaagtga	agggatgtgc	aaaaaaawar	2220
araaaaacaa	caaraaragc	taaccttcta	ttasawaagg	ggacagggga	atgagtatrac	2280
ttcttttatt	gcggacaaat	gtgcacatag	ccgctagtaa	aactagcctc	aaacaggatg	2340
ctcatagctt	aataataaaa	gctgtgcaaa	ggccatgaat	gaatgaattt	cctgtttatt	2400
tcaactgatgc	acacattacc	tcattgaaca	attcagaagt	aaatccaacg	tgtgttgact	2460
cttggaagc	agcaaaarca	ggagctgaag	aaaagaaatt	cttggaacca	gccgtaaccc	2520
agtaaggaat	tgtgaagttg	tgtttttatt	ttgtttcatt	ttttgcagag	tattaagaac	2580
attattcttg	aacatcagaa	cgtttccctt	agaccgatcc	cagcaggtgg	cagctcagat	2640
tgctgcagtg	ttgtaattat	aactgattgt	acttaagtta	tggatgtaga	gaatatgttt	2700
cattcattta	ttcagcatgt	aaataaaaatt	gacctctgtg	agttatcata	attgcagttc	2760
aactatctgc	cmtgggttatt	cttttcacgt	atcatttcatt	ctgtacattt	gg	2812

<210> 43

<211> 1145

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (251)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (901)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1142)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1145)

<223> n equals a,t,g, or c

<400> 43

gccgcgctcc	tgctcctgc	cccagcaggc	aggaagaatg	ggggctgacc	tctacctcg	60
tgctcaagag	agaggcccca	gctggcaggg	accagaaga	gcctggagat	gttgggtgctg	120
gagaccccaa	ctctgatcag	ggactccctg	tgctgatgac	tcagggaaca	gaggacctaa	180
agggccagg	acaaagggtg	gagaatgagc	cactgctgga	ccctgttggc	cctgagcctc	240
tggggcctga	nagtcagtca	gggaaggagg	acatggtgga	gatggccaca	cggtttgggt	300
ccaccctgca	gctagacctg	gaaaagggaa	ggagagtctg	ttggagaaga	ggctggtggc	360
agaggaggaa	gaggacgaag	aggaggtgga	agaggatggc	cccagcagct	gctcggagga	420
cgattacagt	gagctgctgc	aggagatcac	agacaacctg	acgaagaagg	agattcagat	480
agagaagatc	catttgagaca	crtcctcctt	crtggaggag	ctgcctggag	agaaggacct	540
tgcccacgtg	gtagagatct	atgactttga	accagcgctc	aagacggagg	acctgctggc	600
aacgttttct	gagttccaag	agaagggggt	caggattcag	tgggtggatg	atactcacgc	660

actcggcattc	tttccctgcc	kggcctcagc	tgcggaagcc	ctgacccggg	agttctcggt	720
gctcaagatc	cggccctca	crcagggaa	caagcagtc	aagctcaaag	ccttgccagag	780
gccaaaactc	ctgcgtctgg	tgaaggagag	gccacagaca	aatgcgactg	tggcccgggc	840
gctgggtggc	cgggccctgg	gactccaaca	caaaaagaaa	gagcggcctg	ctgtccgggg	900
ntccgctgcc	gccctgaggg	ctggagaccc	aactggcctg	gatctgcgtc	ccgacgtagc	960
tggcgccccc	aacaccataa	gccttcacag	acgccagagc	agccccgcac	caccctcgag	1020
cttcaccatg	gggtgtggtg	ggcttttagt	tagtcccaga	aatggagaaa	aaataaaaaa	1080
tcacgttggt	ctaattgtgaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaagggggg	1140
gnccn						1145

<210> 44
 <211> 1509
 <212> DNA
 <213> Homo sapiens

<400> 44						
ggcacgagta	actgcctact	atccaatgtc	agttaattgg	tgtcttcccc	cctcatttgc	60
tctcttccct	aaaatgtgtc	ccagatgcct	tcatttgctg	ttttacttct	atgttctgct	120
tttctctctc	tctttgttcc	cttctgtctc	atccattgag	tttatgaaat	ggaagagtta	180
actgcatgca	ctagtgtttg	gaggggtgtg	tgttttgtct	ttctaattag	gtgtatagcc	240
tattcacttt	cctagaataa	atctcttaac	ctaaatttga	gtagtctgca	ttttggcaac	300
tcctctagca	gcttggtagc	ctagtacagg	ttgttttttt	aaaaaaggaa	aagcaggaa	360
gaggagtga	ttttattaac	atgtttgcca	aatgtattga	gatttggcct	ctgaagaaca	420
ctttttcagt	gttaagtttc	tttaccttaa	gattcagaaa	tacttttaga	tattattaat	480
tttaagtcc	gtctttacat	ccttttggaa	aacttgtatt	accatgagtt	tggaaaaagg	540
acaacgaaag	gcttttcatg	taaagataag	atcttttagc	atctctaacc	ctgtcctttt	600
ttcactgcat	tttttctagt	tttgcttcat	tgtcttatcat	taggatatgg	taagtgaagt	660
ttgctatgct	gctagcatcc	taagatgata	cctttgttga	aagaattgtg	aatagcatga	720
ttcatttcta	gcagaggctg	agtttaggac	agcagcttcc	attgagaagt	ctttctgtgt	780
cgtgaatagc	attttaatga	cctcttggct	cacataagca	aacaacatag	ggacgtatct	840
gctatgaaaa	tcacaaaatt	tttcagatag	tgccttaaaa	acaattttat	atgcctcact	900
ggttgttatt	cttaggttat	tcccacactt	gactttatca	ttgtttacta	ctagtaaaaa	960
gcagcattgc	caaataatcc	ctaattttcc	actaaaaata	taatgaaatg	atgttaagct	1020
ttttgaaaa	tttaggttaa	acctactgtt	gttagattaa	tgtatttgtt	gcttcccttt	1080
atctggaatg	tggcatttag	ttttttat	taaccctctt	taattcttat	tcaattccat	1140
gacttaaggt	tggagagcta	aacactggga	tttttggata	acagactgac	agttttgcat	1200
aattataatc	ggcattgtac	atagaaagga	tatggctacc	ttttgttaaa	tctgcacttt	1260
ctaaatatca	aaaaagggaa	atgaagtata	aatcaatttt	tgtataatct	gtttgaaaca	1320
tgagttttat	ttgcttaata	ttagggcttt	gccctttttc	tgtaatgtct	ttgggatcct	1380
gtgtagaagc	tgttctcatt	aaacaccaa	cagttaagtc	cattctctgg	tactagctac	1440
aaattcgggt	tcataattcta	cttaacaatt	taaataaaact	gaaatatttc	taaaaaaaaa	1500
aaaaaaaaa						1509

<210> 45
 <211> 1857
 <212> DNA
 <213> Homo sapiens

<400> 45						
ggcacgagca	aaaaataatt	cttttaagaa	aaaatgtaaa	aatgtttatt	ctaaaaagct	60
gcattaaagg	gacaacctat	aaaaagtttt	gctagctcat	ctttagaagg	aagaaagaat	120
attagcttgg	gtgatgttta	atttgggtgg	cgatagtttc	tgtaggctaa	acttgatgag	180
aaaagtgtac	ctactctata	aaggtaataa	atgtaaaacc	tcttgctgtt	attgaggaag	240
ctcttcaact	accctaaatt	tcacaaatgt	aacttataac	actatgaaaa	gattgaccaa	300
caattttacgt	ttgctgtgtg	cttagttttt	gttttaagcat	attctttgct	gaattctgtg	360
ttcatgagag	ttaggtgttt	tatgctctga	actaatttat	aacatattta	atatattacc	420
agtttaagata	taaaatcatt	tgtacatagc	gaattgtaaa	gcagctatta	aagtaggtga	480

aataaagtat	atattttgccg	gttatccata	tcttttagaa	gtcctgacag	aacaaccagt	540
ttattttgcac	ataggttagct	tctgtttgaa	ggaaggtaaa	gttataagga	aactcaaata	600
ctataagatg	tgtcaaggta	tttctccaga	attaattgca	aagctagtgc	tgaaggattt	660
taatcagctt	ctaaaatttt	cttctcaata	aggcatatgt	tttgattact	tagggaagat	720
tcctcathtt	tattttgccct	ttatgcattt	aatccacatg	ataggacatt	aaaaattaat	780
ataaagaaaa	atcgtgctca	tactgtacat	ctgtttctgt	gcttggaact	acttgtaaat	840
agtttttatc	gaagctgtca	gcaataaggg	acataaaact	gctgtattat	acattgtgga	900
attgaataaa	cagcctaatt	ttttttttct	agtatagggt	acttaagcat	ttccactttt	960
ggaagaaaag	tgtattagta	ttttataattg	catttcattt	aaaaggacag	tttttttttt	1020
ttttttttgta	aatccattca	ttgaaatggt	ttctaaactg	tataatgtaa	tttggagcct	1080
atttagtaat	agaattaaat	gtcctatgta	gtgctacaat	ttttgaatta	gaaagtgatc	1140
aaatgtaaga	aaaaaattta	aaaattcagc	ccagaaaaaca	aaatagtgt	ttaaattagt	1200
ttaattgtaa	aggaatttat	aagatttttt	tcctcaatat	agatacctca	cttgaagaaga	1260
aagcacagca	tacttaaagt	agttcttagta	aacatgtcct	agaaaacagt	tgctaaatgt	1320
aggacatctt	ttgaggaatt	agtttatgag	aaataaaatt	ttacttggtt	ttactatcct	1380
gttagaagta	tttgttttatc	ctgataattt	taagccaaca	tagtagtctt	aaattacttt	1440
tgaattccta	atctgtgaag	gcagtaaatg	aaatatctgt	tctgcaactg	ttgaaacaaa	1500
taattggcta	cattgacat	aattaaagt	aaaattttgc	caatgatgta	cagttttatg	1560
gttaaagttg	ctgtggttgg	ttgcattaca	tgacacagaa	aactgtcctc	tacctcacgt	1620
gaaataaata	ttttatatgg	ttttactaaa	aataagactc	atgtatctgg	tcacctagtt	1680
tacaaatttt	gaattatatt	tattgaaaca	tgacatactg	tgctctgagc	ttatacctca	1740
attgtatttt	gtgctgtttt	ccattttcat	gccttgtaaa	taacttgtat	agattgtgga	1800
tcaaatacta	aataaaaact	tttaatgcca	aaaaaaaaaa	aaaaaaaaaa	aaaaaaa	1857

<210> 46

<211> 1810

<212> DNA

<213> Homo sapiens

<400> 46

cggcacgagc	tgtctctcag	ccaggtgtct	tgcaaatgtg	tggttttatc	cctatgggga	60
accccatggg	aacgatggac	atattggcaga	ctgaacagac	acaccccatc	actggagatc	120
ctgtgcagaa	atcatgagct	gtgctctcac	acacacagtt	ccctcgacta	ggtctgcttt	180
cttgtttctta	ctgattttgt	aagcttttca	gagctgatga	taaaatttgt	gcttatacca	240
ggaaaacaga	aaaggatgtt	gctcttaagt	cactggcaac	attctaatat	catgcactta	300
actggcctga	tctttttgtt	cttggtttct	catectaate	aagacccttg	gctgtcttgt	360
cagaaagaga	gcagcagaga	aaatagtgtc	cttgaatatt	aagacattgg	gcaagaaaaa	420
gatattcatc	caggcttctc	atataacagg	atgtctagac	taataccact	ttgttttatt	480
atgtccaata	ctaggaatct	ttgagggatt	aaaagagaaa	agttcacctt	ggcttctttt	540
ttaaaaattc	agaagattaa	acataaaaatt	ttaaccagtg	tttactgatt	ccttttcaat	600
tttatattat	gatcagttaa	ggtacaggag	agaaatcctg	agatccaaga	ggaatcaaga	660
gtagaaagag	aagaaagagg	caagaggaaa	ggagaaatgg	tgctaagaca	gaggaggttg	720
ccctggctga	gtgctgccta	aactcagcaa	ctgctcctca	tcccaccagt	catccccctc	780
agatctgctg	gactgacagg	actcttcctc	ttgctgcacc	tgggccccag	gtcctaattc	840
ggtttacctg	gttccctgcc	aaaaattctt	aaagcagtgt	tcaggcctcc	tccagcatgt	900
gtccacagg	accaccccat	cactgagaac	tgttgctcca	tgtgctctta	gtggaagtcc	960
cacgtgcctt	ttttcttctc	cagtgtaaac	tttctctctc	gcccccgagt	gtcccttggt	1020
catgttggtg	tgtatttttg	tgtgtggtta	tgagatgatt	aatgtttgca	tcttccacc	1080
tctgtccatc	gttcccagg	cttcccttga	gagaggagaa	gagtgggtcc	caaataccat	1140
ttaagcacta	gtgatagaga	caaagtctct	gtcagactat	ggcaaaatga	gaaaaataaa	1200
ggggaacata	gaatatggaa	acacatactg	cattgtttat	aagtgcata	gtgtatgaaa	1260
cctcattgg	ggaagcactc	tgaaaaacca	tgaaatgttg	tggaaactgtg	cattattgtt	1320
gttgtgtgtt	tttttttttt	aatctccatt	taaccttaga	gtcttgacag	tgccccagct	1380
aaccactaga	atgcaaggcc	tgtggctgcc	atcgcttccc	ttcctctcca	gcgcacaaac	1440
ttattttctgt	cagcatttcc	tcctggggaa	gaattgcctc	ttgcctgggc	cacacctgtt	1500
cagaggata	gcccatacaa	cttacagact	tggcctctaa	gaggacccaa	aagaagtatg	1560
attttaggaa	atttatacta	ctctgccttc	ttttatctta	gtgcagtagt	gttatctttc	1620
taagacttac	aagcatttct	tgtttcttgt	ttgggattgt	ttgaatggaa	ggcatgatcc	1680

cttccttacg	ttgcttacat	tccaaacgtt	ttatcgctct	tgtaagcaaa	caagacaatt	1740
tatggcattg	ccaaaaagtg	tccgtgtaag	ctttaaaaatt	acttacatgt	tcaaaaaaaaa	1800
aaaaaaaaaa						1810

<210> 47

<211> 1879

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (41)

<223> n equals a,t,g, or c

<400> 47

agacctttga	taacataacc	attagcagag	aggctcaggg	ngaggtcctt	gcctcggact	60
caaagaccga	atgcacggcc	ttgtagggga	cgccccagat	tgtcagggat	kgggggatgg	120
tccttgaggt	tttgcattgt	ctcctccctc	ccacttctgc	accctttcac	cacctcgagg	180
agatttgctc	cccattagcg	aatgaaattg	atgcagtcct	acctaactcg	attccctttg	240
gcttggtggg	taggcctgca	gggcactttt	attccaaccc	ctggtcaytc	agtamtstkt	300
tactccagga	aggcacagga	tggtacctaa	agagaattag	agaatgaacc	tggckrgacg	360
gatgtctaat	cctgcrctta	gctgggttgg	tcagtagaac	ctattttcag	actcaaaaac	420
catcttcaga	aagaaaaggc	ccagggaagg	aatgtatgag	aggctctccc	agatgaggaa	480
gtgtactctc	tatgactatc	aagctcaggg	ctctcccttt	ttttaaacca	aagtctggca	540
accaagagca	gcagctccat	ggcctccttg	ccccagatca	gcctgggtca	ggggacatag	600
tgctattgtt	tggaaaactg	agacacaagg	tgtgggtcta	tcccacttcc	tagtgctccc	660
cacattcccc	atcagggtct	cctcacgtgg	amaggtktgc	tartccaggg	agttcacttg	720
cagtttccct	gtcctcatgc	ytcggggatg	ggagccmcmg	cygaactaga	gttcaggctg	780
gatacatgtg	ctcacctgct	gctcttgtct	tcctaagaga	cagagagtg	ggcagatgga	840
ggagaagaaa	gtgaggaatg	agtagcatag	cattctgcca	aaagggtccc	agattcttaa	900
tttagcaaac	taagaagccc	aattcaaaaag	cattgtgggt	aaagtctaac	gctcctctct	960
tggtcagata	acaaaagccc	tccctgttgg	atcttttgaa	ataaaaacgtg	caagttatcc	1020
aggctcgtag	cctgcatgct	gccaccttga	atcccaggga	gtatctgcac	ctggaatagc	1080
tctccacccc	tctctgcctc	cttactttct	gtgcaagatg	acttccctgg	ttacttccct	1140
tctttccatc	cacccacca	ctggaatctc	tttccaaaca	tttttccatt	ttcccacaga	1200
tgggctttga	ttagctgtcc	tctctccatg	cctgcaaagc	tccagatttt	tggggaaagc	1260
tgtacccaac	tggactgccc	agtgaactgg	gatcattgag	tacagtcgag	cacacgtgtg	1320
tgcattgggtc	aaaggggtgt	gttcccttct	atcctagatg	ccttctctgt	gccttccaca	1380
gcctcctgcc	tgattacacc	actgcccccg	ccccaccctc	agccatccca	attcttctctg	1440
gccagtgcgc	tccagcctta	tctaggaag	gargagtggg	tgtagccgtg	cagcaagatt	1500
ggggcctccc	ccatcccagc	ttctccacca	tcccagcaag	tcaggatata	agacartcct	1560
cccctgaccc	tcccccttgt	agatatcaat	tcccaaacag	agccaaatac	tctatatcta	1620
tagtcacagc	cctgtacagc	atttttcata	agttatatag	taaatgggtc	gcatgatttg	1680
tgcttctagt	gctctcattt	ggaaatgagg	caggcttctt	ctatgaaatg	taaagaaaga	1740
aaccactttg	tatatattgt	aataccacct	ctgtggccat	gcctgccccg	cccactctgt	1800
atatatgtaa	gttaaaccgg	ggyaggggct	gtggccgtct	ttgtactctg	gtgattttta	1860
aaaattgaat	ctttgtact					1879

<210> 48

<211> 556

<212> DNA

<213> Homo sapiens

<400> 48

tgacctgtct	gggcccagca	tgttgagat	gtgtatttat	gagcaatgg	atgcataatc	60
ctgtgtgact	gtcagtggtg	caagctggct	ggatccaacc	atctcttctg	aaataatgca	120
tccaaagggt	tgatattctg	ggggagggtc	ctgcagaagg	atggaactga	cctttattcc	180

ccagtgggca	gttactgagc	tttctctctc	agagccatgc	tggcagccct	gggacagaga	240
acgggtgtggc	tttggctgcc	tctgcatgga	atcttgcccc	ggactcctga	agactgcaca	300
aggaatgagg	aagatcaggg	acaacctggg	aactgaataa	ctttcaaagc	cagtgtctcag	360
cttctctgct	ccgtactagc	gtttacaggt	cttaattcaa	accagatgcc	tgtactagtt	420
tttagacccc	aagtcaacct	ttctgagcca	cagcttcccc	ctgggaataa	tgatgcctgc	480
cctatctacc	tcacagactt	gttatgagga	taaagtgaga	ttaaactgcc	tcaaagtgaa	540
aaaaaaaaaa	aaaaaa					556

<210> 49
 <211> 607
 <212> DNA
 <213> Homo sapiens

<400> 49	
ggcacgagtg	ggcctggaat
acctctcttg	catccattct
ggtatggagg	caaaggctta
aggggtttgt	tcttggtctt
gtttttgaca	tgagtgtact
tgccctcccc	actgtgagtg
tctgtttcct	ccttctttcc
cagaactcac	cctggggtcg
ttggcagctg	gcctaggtgg
tgacttccct	ctccttggtt
aaaaaaaa	

<210> 50
 <211> 596
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (564)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (569)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (571)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (578)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (580)
 <223> n equals a,t,g, or c

<400> 50

cagctatgac	ccatgattac	gccaaagctcg	aaattaaccc	tcactaaagg	gaacaaaagc	60
tggagctcca	ccgcggtggc	ggccgctcta	gaactagtgg	atccccggg	ctgcaggaat	120
tcggcacgag	aattggggaa	aagggtattc	aataatttatt	aagtaacaat	gagaaatgca	180
acaaacttcc	ttattttatgc	cttatgaata	aaagagtgtg	gaatgtaagg	tgaaatttta	240
tgtgcaagat	cctgaaggaa	tgggtattct	tgaaggcagg	gactgtcttt	tctatgtttg	300
ttctgtacag	ctctcagcac	actcttgggtg	cttgataaat	gttatgatgt	tatataatac	360
caataactaa	gcacattttt	agatcttttt	tcaaatggct	tgtgtaaaat	ttgggttaatg	420
tacaatgggt	ggtttgaagc	tatcatgtaa	aattggcctc	tccaaatata	atcagaaata	480
aaccgaaaaa	aataataaaa	aaaaaaaaaa	aaaaactcga	ggggggggccc	ggtacccaat	540
tcgcctcata	gtgagtcgta	tacnctaant	nctttttntn	cctatagtga	gtctta	596

<210> 51
 <211> 284
 <212> DNA
 <213> Homo sapiens

<400> 51						
ggcacgagat	tttcttcaaa	tatataatgg	caattttcag	atatctcacc	ttaccatatac	60
tttctctatt	ttcactgcat	gcatttaatc	actgtattac	ttaatgtttg	atttgtttatt	120
atgggcattt	caaataggca	agcattgaat	tgtaatgaca	aaaaggctat	tttatatttaa	180
ggatatatgc	atttgtattt	cacacaccag	agatgatatt	aaacactgat	tatttttatgc	240
tgctgtttat	taaaaatggt	tactataaaa	aaaaaaaaaa	aaaa		284

<210> 52
 <211> 1615
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (591)
 <223> n equals a,t,g, or c

<400> 52						
ctttctactt	ttctttggca	ctcttactgc	ctgtaaggag	tagaactggt	agggcacact	60
gttgctatac	agtttaactc	ccattttcat	gttttgtctt	tcttttccca	tttctggggc	120
ttacctcttg	atacctgctt	actttctgga	agtagtgggc	aagtaagatt	tggctcttgg	180
tttctaattt	ttaaatctct	gaatactgcc	ctagtctgaa	cttggccttt	atagattaat	240
ctttgcttca	catttttagt	gttgtattta	aactatttta	taatttaaaa	atagattcta	300
atctgaagat	acttttcaag	aaatattatt	aactgatgtc	atcctcatcc	cagcagctca	360
tctgttagga	atgaagttga	gatgcttcta	ttccatgttt	ttgtatttgg	gaaggattca	420
aagttgaagg	tttattgtcg	ttgggttttt	cagatggtga	catgtaaact	caggatagca	480
aaccctaata	ttcacacagt	gctctgcctc	tgcactcagt	tgggatagtt	gtcccytttg	540
agtgtkttaa	tcacgtgata	actaatcgta	gtgycaagaa	gtycataatg	nkgtatgtag	600
ctaattgtcac	tgaaaaacag	tcctaccatt	taggtaagac	caaacagagt	ctctaaccce	660
aggacttggt	acacctgaca	acctatagta	tattttgctt	ttctcacaaa	atgaaaccce	720
ttttgccgaa	agctagctgg	gataatagga	tcatacacaag	ttgcagtttc	tataactaaa	780
attagattga	aatctcttct	gacctagaac	attttacttc	aggcattcag	cagatttcag	840
aaagaattac	cttattttta	gttagtttct	ttgttagttt	actgtgtgtc	tcttattcaa	900
taaaacaagca	gaatttgggt	cctgccttat	ccatgtctta	aagatgagaa	gttggatcca	960
ctgagttagt	ttcattgggg	cgggggaaag	aactgtaatt	aaacttgttt	aatccttatt	1020
ttgtattgta	gctatttttt	gtaaaagcaa	cttaaaatct	tttaaaaaat	ttatagtac	1080
attagagaca	atggtcatac	aaattatcac	ataaacatgg	acttgaaaaa	ttaggctttt	1140
cataaaacac	atcacatgtc	attgactgct	ttttagaaat	acacttccaa	ggcagtacat	1200
ctgtattgct	actgaaaagt	gccawttcac	agaacacaga	cttctttttg	cyccttgaca	1260
tcttgaaaac	atctgttttt	cttttttaat	acmaaaacttt	gtgctcaaga	cmaactcttac	1320
atgaaactct	cataaaccat	gaaaatgtag	ctggccttcg	ggccttaggc	atgaaataag	1380

catgaggaac	atattcccct	aactttctacc	cccagcccag	caagttatcc	tttaagaaat	1440
ctcctaggaa	ttctggagtt	tgaaaacaat	tgctctatgt	tattcctgct	tccagttctt	1500
aagtaacaag	ggcattttaa	agcatagtct	cttaagggtcc	actatagtgg	ttctttattt	1560
aaggaataac	tcagctgggt	gcagtgggtc	acgsctgtta	atcccagcac	tttta	1615

<210> 53

<211> 1961

<212> DNA

<213> Homo sapiens

<400> 53

ggggaaaaatg	aaagaaaaga	gatatgatgc	cagcaaaggg	atggaaagtc	tagaggacac	60
ctttgtatct	caagctaata	ctctacaaag	gaaaggccga	gcaggcggtg	ttgcatctgg	120
ggtctgcttc	cattttattca	ctagccatca	ctacaatcac	cagcttttaa	aacaacagct	180
accagaaata	caaagagtgc	cattggaaca	gctgtgtcta	agaattaaaa	ttttagagat	240
gttttagtct	cataatctcc	agtctgtgtt	ctctcggtc	attgaacctc	cacacaccga	300
ttctcttcgt	gcctcaaaaa	tacgattacg	agacttagga	gcattaactc	cagatgaaag	360
attgaccctt	cttgggtatc	atttggcctc	tctgcccgtg	gatgtgagaa	ttggcaaaact	420
aatgttgttt	gggtctatct	tccgctgttt	ggatctctgt	ctcaccattg	ctgccagttt	480
ggcttttaag	tcckcgtttg	tatctccctg	ggataaaaaa	gaagaagcta	accagaaaaa	540
gctggaattt	gcattcgcaa	acagtgatta	tctggccctt	ctacaagcgt	ataagggatg	600
gcagctaagt	acaaaaaga	gcgtgcgtgc	aagtataaat	tactgcagac	aaaacttctt	660
gtctggaaga	gttctgcagg	aaatggccag	cctcaaacga	caattcacgg	aactgttatc	720
ggatataggg	tttgaaggg	aagggtcag	agcaagggaa	attgagaaaa	gggcccaagg	780
aggagatggg	gtcttagatg	ccacaggaga	agaggcaaac	tcaaatgctg	agaaccccaa	840
gctgatatca	gcaatgctgt	gtgctgcttt	gtatccaaat	gtagtgcagg	tgaaaagccc	900
agaaggaaaa	tttcagaaga	ccagtactgg	agctgtcaga	atgcaaccaa	aatcagctga	960
gttgaagtgt	gtcaccaaga	acgatggata	tgtaacacatt	cacccttcat	cagtgaacta	1020
tcaggtgaga	cactttgaca	gcccctacct	gttgtaaccac	gagaagataa	aaactagtctg	1080
agtattcatc	cgagactgca	gcattggtgtc	tgtgtaccctg	ctggctctgt	ttggaggagg	1140
ccaagtgaat	gtgcagcttc	aaagaggaga	gttcgttgtc	tccctggatg	atggttggat	1200
ccgttttgta	gctgcttccc	atcagggtggc	tgaactggta	aaggagcttc	gttgcgaaact	1260
tgatcagctt	ctccaggata	aaattaaaam	cccaagcatt	gatctgtgta	cgtgtcctcg	1320
aggatcccg	atcatcagca	caattgtgaa	acttgtcacc	acacaatrra	aagcagcttt	1380
aragagtgt	tgctactcac	ctgcttctag	ctcacctggg	aaataacagc	agaacctcta	1440
cctcgaacta	aagacctatt	ggggctggcc	ctgggtggagg	agcccagggc	atgaagccca	1500
aggcagctga	ggcagtgtat	atacccttag	ggccatttct	aacaaagcct	tggccactcc	1560
cagcacaatt	tggagtgtca	agggtgagag	cctaaaaccc	agcttgccctg	tctttgtctc	1620
tgtgattgtt	ctggagtga	ttaagttcac	ctgataactc	aaaagtgaat	gtataataca	1680
attctgtttt	aatctgtgta	ttctttttct	cctacttttt	actgggggtga	gaggggcatg	1740
aagagaaata	cgcttttttt	tttttctttt	cctgtcgcca	aggctcgact	gagagaagtc	1800
agaacagaga	aggggaaaaa	aaacccaaaa	ttatgtgaac	aagcaaaatt	aaaatttcat	1860
tttaggctat	tggctactga	gtaaacttga	cttgtgaggg	gtttttattt	ttactcatta	1920
aaagtcaact	taaaaaaaaa	aaaaaaaaaa	aaaaactcga	g		1961

<210> 54

<211> 1357

<212> DNA

<213> Homo sapiens

<400> 54

ggcacgagtg	acttaaatca	tggctgtatt	atttcatttt	taaagaaaat	aaagtataaa	60
ataatacatt	taaaatacct	gtcaaagttt	taaaatataa	gatagaacct	tctttttttg	120
ccttcttaca	catgaatgta	cttaaagtat	tgttatgtga	tcttgggata	cttattttatt	180
tttgaaattt	ttgtatatat	agcatttctg	aacttagcaa	ataatatgtg	taaaggaatt	240
aacccaaaaat	gaaagaactg	gcatttttcat	atgggatata	tatttgctta	aactaaataa	300
aataacttag	attttattta	atcaggaata	tttacgttgt	tgatcatttt	taaagtatat	360

ttgttcaa	atccta	att	tg	tttt	cag	cacact	tg	ta	ag	tt	ct	420
atactac	agc	gt	tata	tg	aa	ta	at	gt	tt	ta	aa	480
tca	ctgc	ata	ac	aa	att	ga	a	ac	ca	at	gt	540
ctac	ag	tt	tc	aa	at	tc	at	ct	ct	tt	ct	600
gg	aca	agg	at	gt	tt	at	tt	ag	tt	at	gt	660
ag	ag	ta	tt	cc	tt	at	tg	aa	at	gc	ta	720
tt	ct	ac	ga	tg	ca	gg	ct	ga	at	tt	ta	780
ca	tag	aaa	ac	ct	tg	ca	tt	tt	tc	tt	ta	840
cc	tt	tt	tt	tt	tt	tt	tt	tt	tt	tt	tt	900
gg	ta	ca	ta	tt	aa	tc	ag	aa	at	gt	ct	960
ct	gg	aa	at	gt	cg	aa	tc	at	tt	tt	tt	1020
tt	ga	ta	ca	aa	gt	ct	ct	at	tt	tt	tt	1080
tg	gg	aa	gg	tt	gc	aa	ta	aa	at	at	at	1140
ca	gt	tt	ct	ct	tg	ta	ct	tt	tt	tt	tt	1200
tt	tt	tt	tt	tt	tt	tt	tt	tt	tt	tt	tt	1260
gt	aa	gaaa	aa	ac	ct	gt	at	tt	gt	tt	aa	1320
tt	tt	tt	gt	aa	at	tt	gt	aa	at	tt	gt	1357

<210> 55
 <211> 785
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (9)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (22)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (39)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (44)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (774)
 <223> n equals a,t,g, or c

ca	att	gg	anc	g	ca	ac	cg	g	ca	an	tt	aa	at	gg	tt	anc	cc	ant	ca	att	ag	gc	ac	cc	ca	60
gg	ct	tt	ta	ca	ct	tt	cg	ct	gt	ta	gg	tt	gt	gg	aa	tt	gt	gg	gc	gg	aa	ca	aa	tt	gg	120
tt	ca	cc	ac	ag	ct	aa	gc	ta	tg	ac	ca	tg	at	gc	aa	gc	tc	ga	aa	tt	aa	cc	ct	ca	ct	180
ag	gg	ga	ac	aa	aa	ag	ct	gg	ag	ct	cc	ac	cg	cg	gt	gg	cg	cg	ct	ct	ag	aa	ct	ag	tg	240
gg	gt	gc	ag	aa	tt	cg	gc	ac	ga	gt	gt	gg	gc	ac	ta	gg	tt	ct	ta	ag	tt	ta	ag	aa	tt	300
at	ga	ac	aa	aa	aa	ta	ta	at	tt	at	tt	at	tt	at	tt	at	tt	at	tt	at	tt	at	tt	at	tt	360
tc	at	ag	tc	aa	aa	ag	tc	ag	tc	aa	aa	ag	tc	ag	tc	aa	aa	ag	tc	ag	tc	aa	aa	ag	tc	420
tt	at	ag	ct	tt	gt	gg	at	tt	ct	tt	at	tt	at	tt	at	tt	at	tt	at	tt	at	tt	at	tt	at	480
ac	cg	tt	gt	gt	gc	gc	tc	ac	tg	ta	ac	ca	aa	aa	gt	ta	at	gc	ac	ca	gc	cc	tt	gt	gc	540

tttctcctga	ttttgtggat	ttaaattgtcc	aaatgcaaac	ctttgtgact	tccttttgag	600
gacttggcag	cacagcatgc	ccccgtgacc	tgcttgcgtg	ggtatgagct	atgaccaaga	660
gcaggcttcc	tgctccatgg	agtcctgagt	tgctctgggg	caggggatta	cgttatgaaa	720
actaaccatg	tgtaacaata	aatctacctt	agcagaaaaa	aaaaaaaaaa	aaanaaaaaac	780
tcgag						785

<210> 56

<211> 2440

<212> DNA

<213> Homo sapiens

<400> 56

tacggctgcg	agacgacaga	aggggccttc	tagcagaaat	ggcggctgcg	gcggctcgag	60
tggtgttgtc	atccgcggcg	cgcggcgcc	ctggggtttc	agcgagagtc	ttctaataccg	120
agggcgtgcg	ggacgggtcat	tatatgttgg	agagaacaga	ttaagaagta	cacaggctgc	180
tacccaagtt	gttctgaatg	ttcctgaaac	aagagtaaca	tgtttagaaa	gtggactcag	240
agtagcttcg	gaagactctg	ggctctcaac	atgcacagtt	ggactctgga	ttgatgctgg	300
aagtagatac	gaaaatgaga	agaacaatgg	aacagcacac	tttctggagc	atatggcctt	360
caagggcacc	aagaagagat	cccagttaga	tctggaactt	gagattgaaa	atatgggtgc	420
tcattctcaat	gcctatacct	ccagagagca	gactgtatac	tatgccaaaag	cattctctaa	480
agacttgcca	agagctgtag	aaattcttgc	tgatataata	caaaacagca	cattgggaga	540
agcagagatt	gaacgtgagc	gtggagtaat	ccttagagag	atgcaggaag	ttgaaaccaa	600
tttacaagaa	gttggttttg	attatcttca	tgccacagct	tatcaaaaata	ctgcacttgg	660
acggacaatt	ttgggaccaa	ctgaaaatat	caaatctata	agtcgtaagg	acttagtgga	720
ttatataaac	acacattata	aggggccaag	aatagtgtct	gctgctgctg	gaggtgtttc	780
ccatgatgaa	ttgcttgact	tagcaaagtt	tcatttcggt	gactctttat	gcacacacaa	840
aggagaaata	ccagctctgc	ctccctgcaa	attcacagga	agtgagattc	gtgtgaggga	900
tgacaagatg	cctttggcgc	accttgcaat	agctgttgaa	gctgttggtt	gggcacatcc	960
agatacaatc	tgtctcatgg	ttgcaaacac	gctgattggc	aactgggatc	gctcttttgg	1020
gggaggaatg	aatttatcta	gcaagctggc	ccagctcact	tgctatggca	atcctttgcca	1080
tagctttcag	tctttcaaca	cttcctacac	agatacagga	ttatggggac	tgtatatggt	1140
ttgtgaatca	tccactgttg	cagacatgct	acatgttggt	caaaaagaat	ggatgcgact	1200
ctgtacaagt	gtcacagaaa	gtgaggttgc	acgagccaga	aatcttctga	aaacaaacat	1260
gttgttgcag	cttgatggtt	caactccaat	ttgtgaagat	attggtaggc	aaatgttatg	1320
ctataataga	aggattccca	tccctgagct	tgaagcaaga	attgatgctg	tgaatgctga	1380
gmcaattcga	gaagtatgta	ccaaatacat	ttataatagg	agtccagcta	ttgctgctgt	1440
tggattcttt	cttcttagga	tataatcaca	gaagtgaact	tcatgaatgg	aaatggaaca	1500
agttattttc	caaaaggcaa	actatttcat	actcctacgt	gaacatcctt	ttaccacagc	1560
ctcagccaca	gtacgtctaa	ttatttataa	tttgtgatta	tcgctgggtg	tcaacaattt	1620
ttttgttttt	catcctttta	ctggaaaaag	gaggggctgt	ctcagttttt	cttctgactc	1680
tgtgtgtcac	ttacaattaa	taatgctagc	tggttaacatc	tacatagcag	ttgacatgtg	1740
ccaggcctgt	ttaccagtta	atcttctcca	tgatcctatg	aggaaagtgc	tattgctgtc	1800
tccatttcat	agatgaggaa	aatgaggcac	agaggagacg	ttatgtagcc	actaccactg	1860
caacttgctc	aaacttccgg	ccaagtccgg	tctagtccag	acagcctgac	tcctcagcct	1920
gcgtctgtat	gctgcctctc	ctaattcatt	atgtttatta	ataatttttc	cccgttttgt	1980
taacacttat	gtttcaaaaa	cagtcactct	tatttacatt	gactgatcat	ttcttttgta	2040
atttcttcta	gtacttacaa	tagttctagt	ttcatataca	tttcctatag	actgaaaaaa	2100
ttttttaatc	tttttggaat	tttaatatag	tcaagaaagt	atctaaactt	ctcatttttc	2160
aaaatcttac	tgcattttaa	taatecttcc	cttttccact	gawwwgtgac	actataatag	2220
taaattttac	aagggtttgt	tttggttact	tattcttgcc	ctggggttat	ctttaaactg	2280
accacagytt	tctaatatat	ttgatcgtaa	cttccaaaaa	ctgtgttaatt	tttgcttatt	2340
tgtcttgcac	ctagtcactt	aactctcttt	tgcttttcta	ggcagatcct	atattatcta	2400
caaataatat	atttattttc	ttctttccaa	aaaaaaaaaa			2440

<210> 57

<211> 810

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (22)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (26)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (43)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (54)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (59)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (88)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (806)

<223> n equals a,t,g, or c

<400> 57

ggaangagcg	cccccaattac	gnaaaanccgg	ctttttccccc	ggngggggttg	gccnggatnc	60
attaatgccca	gctggcacgg	acaggttncc	cggactggaa	aagccgggcc	agtgagcgca	120
acgcaattaa	tgggggggttg	gctcacttca	ttaggcaccc	caggctttac	actttatgct	180
tccggctcgt	atgttgtgtg	gaattgtgag	cggataacaa	tttcacacag	gaaacagcta	240
tgaccatgat	tacgccaagc	tcgaaattaa	ccctcactaa	aggggaacaaa	agctggagct	300
ccaccgcggg	ggcgcccgct	ctagaactag	tggatccccc	gggctgcagg	aattcggcac	360
gagccgagaa	ggcccttaac	tcaaagtagc	ttatttatcc	aaaatgttct	ggatgcatca	420
tctccaacca	aggacccttt	atttatcatg	cctttgttct	cttttccctc	agatgtatat	480
ttctttaaaa	ataattttcc	taataacaaa	acttatctt	aaaacagctt	aaaaattcaa	540
agaaaaaccc	caaacactga	cattacctac	acttccacta	cccaaagaca	aaatgtgccc	600
actgtgtgct	tttgagtgtg	ttttctttta	gtttgttttt	tggtgggtgc	atatttatga	660
taataacaat	gatggacttc	aattgtactc	actgttctat	tggtgggttt	aattagcagc	720
aagttgtgat	cactttccca	ggtgaataaa	tcatttcaaa	gcaaaaaaaaa	aaaaaaaaaaa	780
aaaaaaaaaa	aaaaaaaaaa	aaaaantcga				810

<210> 58
 <211> 484
 <212> DNA
 <213> Homo sapiens

```

<400> 58
ggcacgaggg gagacaataa tgagggactt tcagttttac tttacataat tttcttttaa      60
gtattggaat ttaggtgatt tttcctttgg ggttttctgt attttccaat cacaataaat      120
aaaataagtt ataaatatatt gttgcatgaa tgaaatgtat aaacccattt atgtatgtat      180
ttttttaaaa ttagtatatt attaagtcta tacaatatta gtatattggt atgtatgtat      240
aagcttttta acatgaagtt tgcagaatat agtacttctt ccaaactcta tgacatgggg      300
ggaactgaag tatggggata tcttgtacca gtgtaagaat tcaagaagag accgtgtgtg      360
gtggctcatg cctatagtcc cagcactttg ggatgccaaa gcaggatgat ctcttggagc      420
taggcgttca agaccagcct gggcaacata tcaagacccc atctctaaaa aaaaaaaaaa      480
aaaa                                         484
  
```

<210> 59
 <211> 431
 <212> DNA
 <213> Homo sapiens

```

<400> 59
ggacgctggg ttcattaatt acctttaaac cgttccttat tttttttaag attttaaatt      60
gtattttggc ttttgcctcc agtatccttt ctgggtgctc tggtttgaat taagttccta      120
ttatgctgca gcacatatca accttcccta agtaaccatt tcctggaatg tgaagcatcg      180
gtgccattag cagaccatat gcagaaatgt cgtgtacttg catttctttt ttgtgcactc      240
tataaggctg gttgtgactc agatcagctt aactttttat attatgttat ttcactaact      300
gtacacgtca aaatgatcaa atctttgtac aatagaaaaa tatttaaatt ttatttttct      360
actgacattt ctaattctag tgtaaatgtt tatcaataaa aaattacttt caaaaaaaaaa      420
aaaaaaaaaa a                                         431
  
```

<210> 60
 <211> 38
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (38)
 <223> Xaa equals stop translation

```

<400> 60
Met Ile Leu Lys Gln Gly Leu Ile Cys Thr Trp Gln Val Leu Leu Leu
  1             5             10            15

Ala Ser Ala Leu Glu Met Leu Val Phe Ile Cys Ala Met Glu Cys Leu
          20             25             30

Thr Gln Phe Gln Val Xaa
          35
  
```

<210> 61
 <211> 6
 <212> PRT
 <213> Homo sapiens

<220>
<221> SITE
<222> (6)
<223> Xaa equals stop translation

<400> 61
Met His Ile Ile Gln Xaa
1 5

<210> 62
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (45)
<223> Xaa equals stop translation

<400> 62
Met Asp Thr Trp Ile Phe Leu Leu Val Thr Lys Ile Phe Lys Leu Phe
1 5 10 15

Val Tyr Thr His Thr His Thr His Thr His Val Ser Val Pro
20 25 30

Arg Asn Val Tyr Arg Gly Gly Gln Phe Ser Glu Asp Xaa
35 40 45

<210> 63
<211> 39
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (39)
<223> Xaa equals stop translation

<400> 63
Val Leu Leu Ile Leu Lys Leu Leu Leu Lys Gly Ala Arg Ser Ile
1 5 10 15

Gln Ile Phe Met Phe Arg Cys Leu Ile Ala Phe Ala Leu Ile Thr Lys
20 25 30

Leu Gln Asn Tyr Met Asp Xaa
35

<210> 64
<211> 39
<212> PRT
<213> Homo sapiens

<220>
<221> SITE

34

<222> (39)

<223> Xaa equals stop translation

<400> 64

Met Arg Thr Glu Val Gly Ala Gln Arg Ala Cys Ala Val Arg Cys Val
1 5 10 15

Leu Ala Leu Gly Ala Val Val Ser Leu Leu Val Pro Pro Thr Pro Ala
20 25 30

Leu Ser Ser Ile Pro Ser Xaa
35

<210> 65

<211> 53

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (53)

<223> Xaa equals stop translation

<400> 65

Met Thr Ala Ser Pro Asp Tyr Leu Val Val Leu Phe Gly Ile Thr Ala
1 5 10 15

Gly Ala Thr Gly Ala Lys Leu Gly Ser Asp Glu Lys Glu Leu Ile Leu
20 25 30

Leu Phe Trp Lys Val Val Asp Leu Ala Asn Lys Lys Val Gly Gln Leu
35 40 45

His Glu Ser Ser Xaa
50

<210> 66

<211> 19

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (19)

<223> Xaa equals stop translation

<400> 66

Val Leu Cys Ser Leu Ser Cys Met Leu Lys Leu Gly Val Cys Trp Arg
1 5 10 15

Ala Ser Xaa

<210> 67

<211> 39

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (39)

<223> Xaa equals stop translation

<400> 67

Met Arg Thr Ala Leu Phe Pro Thr Glu Cys Cys Leu Pro Met Cys Val
1 5 10 15

Val Leu Ala Val Phe Tyr Leu Pro Ile Val Phe Ser Arg Ile Ile Glu
20 25 30

Ser Ala Asp Ser Phe Asp Xaa
35

<210> 68

<211> 57

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (57)

<223> Xaa equals stop translation

<400> 68

Gly Trp Phe His Leu Phe Trp Gln Glu Trp Glu Gln Glu Pro Gly Gln
1 5 10 15

Asn Lys Leu Leu Glu Ala Leu Val Leu Gly Thr Ala Ala Gly Arg Val
20 25 30

Gly Thr Arg Gln Asn Cys Leu Gln Asp Glu Ser Gln Glu Arg Thr Leu
35 40 45

Ser Pro Val Ser Gly Val Trp Leu Xaa
50 55

<210> 69

<211> 34

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (34)

<223> Xaa equals stop translation

<400> 69

Met Val Pro Arg Ser Val Ala Phe Val Lys Thr Leu Ala Leu Leu Glu
1 5 10 15

Leu Gly Phe Ala Leu Ala Val Met Gln Gly Cys Ala Glu Pro Ile Ser
20 25 30

Met Xaa

<210> 70
 <211> 98
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (98)
 <223> Xaa equals stop translation

<400> 70
 Met Glu Val Val Val Thr Val Thr Pro Lys Thr Cys Pro Leu Ser Ser
 1 5 10 15

 Leu Leu Leu Phe Leu Leu Tyr Phe Leu Val Ile Gly Ser Val Ile His
 20 25 30

 Leu Thr Ala Gly Phe Arg Ile Leu Val Leu Gly Leu Val Phe Leu Phe
 35 40 45

 Phe Pro Tyr Pro Pro Tyr Pro Asn Cys His Gln Val Leu Leu His Ala
 50 55 60

 Leu Met Ile Ser His Leu Ser Tyr Pro Ser Ser Phe Gln Ile Gly Pro
 65 70 75 80

 Ser Asp Phe Asn Leu Gly His Ser His Tyr Leu Leu Tyr Tyr Gly Lys
 85 90 95

Ile Xaa

<210> 71
 <211> 36
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (36)
 <223> Xaa equals stop translation

<400> 71
 Met Val Lys Leu Leu Val Lys Leu Thr Phe Ile Ile Ser Pro Leu Ile
 1 5 10 15

 Lys Ser Ser Asp Ser Gly Ile Thr Ser Leu Ser Cys Ser Tyr Gln Arg
 20 25 30

 Ala Ile Phe Xaa
 35

<210> 72

37

<211> 18
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (18)
<223> Xaa equals stop translation

<400> 72
Met Gln Lys Leu Lys Gly Gly Ile Ser Val Phe Leu Ala Phe Leu Leu
1 5 10 15

Met Xaa

<210> 73
<211> 32
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (32)
<223> Xaa equals stop translation

<400> 73
Met Thr Glu Ser Leu Leu Tyr Leu Gln Leu Ile Leu Leu Trp Gly Ile
1 5 10 15

Ser Glu Ile Pro Ser Ser Asn Thr Glu Met Tyr Arg Lys Cys Pro Xaa
20 25 30

<210> 74
<211> 17
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (17)
<223> Xaa equals stop translation

<400> 74
Met Gln Lys Gly Arg Ala Val Cys Leu Ser Pro Asp Leu Ala His Gly
1 5 10 15

Xaa

<210> 75
<211> 12
<212> PRT

38

<213> Homo sapiens

<220>

<221> SITE

<222> (12)

<223> Xaa equals stop translation

<400> 75

Met Phe Val Cys Leu Phe Leu Ile Asn Asn Ile Xaa
1 5 10

<210> 76

<211> 35

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (28)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (35)

<223> Xaa equals stop translation

<400> 76

Met Ile Ile Trp Phe Leu Pro Phe Thr Leu Leu Val Trp Phe Ile Thr
1 5 10 15

Phe Ile Asp Leu Phe Met Leu Asn His Pro Cys Xaa Pro Gly Ile Asn
20 25 30

Leu Thr Xaa
35

<210> 77

<211> 6

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (6)

<223> Xaa equals stop translation

<400> 77

His Ala Cys Phe Leu Xaa
1 5

<210> 78

<211> 33

<212> PRT

<213> Homo sapiens

<220>

39

<221> SITE
<222> (33)
<223> Xaa equals stop translation

<400> 78
Met Phe Cys Gly Ala Cys Gln Ile Gly Trp Asn Leu Trp Gly Leu Leu
1 5 10 15
Trp Glu Met Pro Arg Glu His Arg Phe Arg Arg Trp Glu Gln Leu Val
20 25 30

Xaa

<210> 79
<211> 25
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (25)
<223> Xaa equals stop translation

<400> 79
Val Met Glu Val Leu Met Thr Met Val Ala Ile Ile Ile Thr Ala Met
1 5 10 15
Gly Met Met Ala Leu Met Thr Glu Xaa
20 25

<210> 80
<211> 40
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (40)
<223> Xaa equals stop translation

<400> 80
Met Leu Asn Asn Phe Leu Gly Ile Asn Leu Gln Ala Trp Thr Ser Arg
1 5 10 15
Leu Ser Xaa Gln Phe Leu Leu Thr Phe Ala Thr Tyr Cys Tyr Ala Asn
20 25 30
Phe Gln Lys Asn Cys Thr Gln Xaa
35 40

40

<210> 81
<211> 36
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (36)
<223> Xaa equals stop translation

<400> 81
Met Lys Thr Gln Asn His Cys Ile Phe Cys Ile Val Ile Leu Phe Ser
1 5 10 15
Thr Ser Val Pro Pro Leu Ile Trp Ser Trp Gln Cys Val Ser Val His
20 25 30
Ser Leu Phe Xaa
35

<210> 82
<211> 6
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (6)
<223> Xaa equals stop translation

<400> 82
Met Asn Gly Leu Leu Xaa
1 5

<210> 83
<211> 40
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (40)
<223> Xaa equals stop translation

<400> 83
Met Arg Ser Ser Gly Ala Trp Gln Ala Met Val Gly Val Trp Ile Leu
1 5 10 15
Phe Leu Ser Ala Val Glu Ser Gln Gly Arg Val Leu Ala Glu Gln Arg
20 25 30
Cys Asn Leu Ala Trp Ala Leu Xaa
35 40

<210> 84
<211> 27

```
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> SITE  
<222> (27)  
<223> Xaa equals stop translation
```

<400> 84
Met Tyr Cys Ile Ser Trp Glu Val Tyr Phe Met Ser Phe Leu Ala Phe
1 5 10 15

Phe Phe Pro Thr Ala Thr Ala Asn Glu Gly Xaa
20 25

```
<210> 85
<211> 36
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (36)
<223> Xaa equals stop translation
```

```
<400> 85
Met Ile Lys Leu Val His Gln Ile Val Ile Leu Cys Val Met Arg Ile
  1             5             10            15
```

Val Ala Gly Val Ile Leu Lys Cys Trp Tyr Leu Asp Arg Thr Ala Ser
20 25 30

Pro Gly Phe Xaa
35

```
<210> 86
<211> 73
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> SITE  
<222> (73)  
<223> Xaa equals stop translation
```

```
<400> 86
Met Leu Asp Val Phe Leu Lys Ser Cys Phe Val Ser Phe Leu Ser Leu
 1             5             10            15
```

Ile Val Lys Leu Leu Asn Ile Asn Arg Phe Ala Gln Pro Gln Arg Met
20 25 30

Arg Val Asp Asn Thr Glu Glu Val Met Gln Lys Gln Lys Ile Thr Leu
35 40 45

Leu Ile Ile Asp Ser Ile Thr Asn Lys Cys Leu Phe Leu Ser Leu Pro
50 55 60

Pro Phe Leu Pro Leu Pro Ser Ser Xaa
65 70

<210> 87
<211> 38
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (38)
<223> Xaa equals stop translation

<400> 87
Met Leu Leu Cys Thr His Thr Ser Leu Leu Leu Tyr Phe Ser Phe Trp
1 5 10 15

Met Gly Leu Ala Lys Thr Gly Ser Gly Gln Arg Pro Pro Lys Leu Tyr
20 25 30

Val Leu Pro Val Ser Xaa
35

<210> 88
<211> 18
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (18)
<223> Xaa equals stop translation

<400> 88
Met Pro Leu Gly Leu Pro Leu Ser Ala Ser Gly Phe Ser Val Gly Asp
1 5 10 15

Leu Xaa

<210> 89
<211> 46
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (46)
<223> Xaa equals stop translation

<400> 89
Met Arg Ala Ala Val Gln Thr Cys Leu Pro Ser Gln Ala Leu Ala Ser
1 5 10 15

Leu Thr Trp Gln Arg Leu Cys Pro Gly Leu Ser Pro Pro Arg Ala Met

43

20 25 30

Ser Leu Met Ala Val Leu Thr Glu Arg Ser Gln Ile Val Xaa
 35 40 45

<210> 90
 <211> 36
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (36)
 <223> Xaa equals stop translation

<400> 90
 Met Leu Phe Met Ala His Leu Leu Leu Arg Thr His Pro Leu Ser Leu
 1 5 10 15

Trp Val Thr Ser Arg Gln Ala Lys Asp Trp Cys Phe Ser Phe His Pro
 20 25 30

Leu Glu Gly Xaa
 35

<210> 91
 <211> 103
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (72)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (103)
 <223> Xaa equals stop translation

<400> 91
 Met Thr Gly Val Gln Val Gln Trp Thr Val Ile Phe Leu Ala Pro Val
 1 5 10 15

Ile Ala Val Ile Leu Cys Ala Met Gln Thr Met Leu Arg Ser Leu Trp
 20 25 30

Leu Met Asp Leu Thr Leu Thr Val Ser Gln Val Val Glu Glu Arg Lys
 35 40 45

Gln Met Lys Gly Lys Lys Lys His Gly Ile Gln Gln Lys Lys Thr Leu
 50 55 60

Glu Leu Ile Val Asn Met Met Xaa Val Ala Arg Val Gly Glu Lys Cys
 65 70 75 80

Ser Thr Cys Ile Ser Lys Leu Asn Leu Met Leu Gln Met Lys Val Leu

44

85

90

95

Gly Lys Asp Ile Asn Gly Xaa
100

<210> 92

<211> 37

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (16)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (37)

<223> Xaa equals stop translation

<400> 92

Met Ser His Cys Trp Thr Leu Leu Ala Leu Ser Leu Trp Gly Leu Xaa
1 5 10 15

Val Ser Gln Gly Arg Glu Thr Trp Trp Arg Trp Pro His Gly Leu Gly
20 25 30

Pro Pro Cys Ser Xaa
35

<210> 93

<211> 45

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (45)

<223> Xaa equals stop translation

<400> 93

Leu Ile Gly Val Phe Pro Pro His Leu Leu Ser Ser Leu Lys Cys Val
1 5 10 15

Pro Asp Ala Phe Ile Cys Cys Phe Thr Ser Met Phe Cys Phe Ser Ser
20 25 30

Ser Leu Cys Ser Leu Pro Val Tyr Pro Leu Ser Leu Xaa
35 40 45

<210> 94

<211> 17

<212> PRT

<213> Homo sapiens

<220>

45

<221> SITE
<222> (17)
<223> Xaa equals stop translation

<400> 94
Glu Lys Ile Asp Gln Gln Phe Thr Phe Ala Val Cys Leu Val Phe Val
1 5 10 15

Xaa

<210> 95
<211> 13
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (13)
<223> Xaa equals stop translation

<400> 95
Asn Trp Leu Asp Leu Phe Val Leu Gly Phe Ser Ser Xaa
1 5 10

<210> 96
<211> 54
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (54)
<223> Xaa equals stop translation

<400> 96
Met Gly Gln Arg Gly Val Phe Leu Leu Ile Leu Asp Ala Phe Ser Val
1 5 10 15

Pro Ser Thr Ala Ser Cys Leu Ile Thr Pro Leu Pro Pro Pro His Pro
20 25 30

Gln Pro Ser Gln Phe Phe Leu Ala Ser Ala Leu Gln Pro Tyr Leu Gly
35 40 45

Lys Glu Glu Trp Val Xaa
50

<210> 97
<211> 38
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (38)

<223> Xaa equals stop translation

<400> 97

Met Leu Gln Met Cys Ile Tyr Ala Gln Trp Tyr Ala Tyr Leu Cys Val
1 5 10 15

Thr Val Ser Val Ala Ser Trp Leu Asp Pro Thr Ile Ser Ser Glu Ile
20 25 30

Met His Pro Lys Gly Xaa
35

<210> 98

<211> 24

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (24)

<223> Xaa equals stop translation

<400> 98

Met Ser Val Leu Leu Leu Ser Ser Ser Cys Gly Ala Ala Phe Ala Val
1 5 10 15

Leu Cys Pro Pro His Cys Glu Xaa
20

<210> 99

<211> 4

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (4)

<223> Xaa equals stop translation

<400> 99

Gly Tyr Ser Xaa
1

<210> 100

<211> 11

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (11)

<223> Xaa equals stop translation

<400> 100

Met His Leu Ile Thr Val Leu Leu Asn Val Xaa
1 5 10

<210> 101
 <211> 26
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (26)
 <223> Xaa equals stop translation

<400> 101
 Met Phe Cys Leu Ser Phe Pro Ile Ser Gly Ala Tyr Leu Leu Ile Pro
 1 5 10 15
 Ala Tyr Phe Leu Glu Val Val Gly Lys Xaa
 20 25

<210> 102
 <211> 335
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (290)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (316)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (321)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (335)
 <223> Xaa equals stop translation

<400> 102
 Met Leu Phe Gly Ser Ile Phe Arg Cys Leu Asp Pro Ala Leu Thr Ile
 1 5 10 15
 Ala Ala Ser Leu Ala Phe Lys Ser Pro Phe Val Ser Pro Trp Asp Lys
 20 25 30
 Lys Glu Glu Ala Asn Gln Lys Lys Leu Glu Phe Ala Phe Ala Asn Ser
 35 40 45
 Asp Tyr Leu Ala Leu Leu Gln Ala Tyr Lys Gly Trp Gln Leu Ser Thr
 50 55 60
 Lys Glu Gly Val Arg Ala Ser Tyr Asn Tyr Cys Arg Gln Asn Phe Leu

48

65		70		75		80
Ser Gly Arg Val Leu Gln Glu Met Ala Ser Leu Lys Arg Gln Phe Thr						
	85			90		95
Glu Leu Leu Ser Asp Ile Gly Phe Ala Arg Glu Gly Leu Arg Ala Arg						
	100		105			110
Glu Ile Glu Lys Arg Ala Gln Gly Gly Asp Gly Val Leu Asp Ala Thr						
	115		120			125
Gly Glu Glu Ala Asn Ser Asn Ala Glu Asn Pro Lys Leu Ile Ser Ala						
	130		135			140
Met Leu Cys Ala Ala Leu Tyr Pro Asn Val Val Gln Val Lys Ser Pro						
	145		150		155	160
Glu Gly Lys Phe Gln Lys Thr Ser Thr Gly Ala Val Arg Met Gln Pro						
		165		170		175
Lys Ser Ala Glu Leu Lys Phe Val Thr Lys Asn Asp Gly Tyr Val His						
	180		185			190
Ile His Pro Ser Ser Val Asn Tyr Gln Val Arg His Phe Asp Ser Pro						
	195		200			205
Tyr Leu Leu Tyr His Glu Lys Ile Lys Thr Ser Arg Val Phe Ile Arg						
	210		215			220
Asp Cys Ser Met Val Ser Val Tyr Pro Leu Val Leu Phe Gly Gly Gly						
	225		230		235	240
Gln Val Asn Val Gln Leu Gln Arg Gly Glu Phe Val Val Ser Leu Asp						
		245		250		255
Asp Gly Trp Ile Arg Phe Val Ala Ala Ser His Gln Val Ala Glu Leu						
	260		265			270
Val Lys Glu Leu Arg Cys Glu Leu Asp Gln Leu Leu Gln Asp Lys Ile						
	275		280			285
Lys Xaa Pro Ser Ile Asp Leu Cys Thr Cys Pro Arg Gly Ser Arg Ile						
	290		295			300
Ile Ser Thr Ile Val Lys Leu Val Thr Thr Gln Xaa Lys Ala Val Leu						
	305		310		315	320
Xaa Ser Ala Cys Tyr Ser Pro Ala Ser Ser Ser Pro Gly Lys Xaa						
		325		330		335

<210> 103

<211> 39

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (39)

<223> Xaa equals stop translation

<400> 103

Met Tyr Leu Lys Tyr Cys Tyr Val Ile Leu Gly Tyr Leu Phe Ile Phe
1 5 10 15

Glu Ile Phe Val Tyr Ile Ala Phe Leu Asn Leu Ala Asn Asn Met Cys
20 25 30

Lys Gly Ile Asn Gln Lys Xaa
35

<210> 104

<211> 12

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (12)

<223> Xaa equals stop translation

<400> 104

Met His Gln Pro Leu Cys Ile Tyr Cys Phe Ser Xaa
1 5 10

<210> 105

<211> 11

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (11)

<223> Xaa equals stop translation

<400> 105

Met Thr Arg Cys Leu Trp Arg Thr Leu Gln Xaa
1 5 10

<210> 106

<211> 6

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (6)

<223> Xaa equals stop translation

<400> 106

Ile Val Gly Phe Asn Xaa
1 5

<210> 107

50

<211> 54
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (54)
<223> Xaa equals stop translation

<400> 107
Met Tyr Phe Phe Lys Ile Ser Ile Leu Leu Ser Leu Tyr Asn Ile Ser
1 5 10 15
Ile Leu Leu Cys Met Tyr Lys Leu Phe Asn Met Lys Phe Ala Glu Tyr
20 25 30
Ser Thr Ser Ser Lys Leu Tyr Asp Met Gly Gly Thr Glu Val Trp Gly
35 40 45
Tyr Leu Val Pro Val Xaa
50

<210> 108
<211> 67
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (67)
<223> Xaa equals stop translation

<400> 108
Met Gln Lys Cys Arg Val Leu Ala Phe Leu Phe Cys Ala Leu Tyr Lys
1 5 10 15
Ala Gly Cys Asp Ser Asp Gln Leu Asn Phe Leu Tyr Tyr Val Ile Ser
20 25 30
Leu Thr Ala Thr Val Lys Met Ile Lys Ser Leu Tyr Asn Arg Lys Leu
35 40 45
Phe Lys Phe Tyr Phe Ser Thr Asp Ile Ser Asn Ser Ser Val Asn Val
50 55 60
Tyr Gln Xaa
65

<210> 109
<211> 70
<212> PRT
<213> Homo sapiens

<400> 109
Phe Phe Phe Phe Phe Glu Thr Glu Ser Cys Ser Val Ala Glu Ala Gly
1 5 10 15

Val Gln Trp Cys Asp Leu Gly Ser Leu Lys Ser Pro Pro Pro Gly Ser
 20 25 30
 Ser Asp Ser Pro Ala Ser Ala Ser Arg Val Ala Gly Ile Thr Gly Met
 35 40 45
 His His His Thr Gln Leu Ile Phe Val Phe Leu Val Glu Thr Gly Ser
 50 55 60
 His Met Gln Leu Ser Asp
 65 70

<210> 110
 <211> 71
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (44)
 <223> Xaa equals stop translation

<400> 110
 Phe Phe Phe Phe Phe Glu Thr Glu Ser His Pro Val Ala Gln Ala Gly
 1 5 10 15
 Val Gln Trp His Asp Leu Gly Ser Leu Gln Ser Leu Pro Pro Arg Phe
 20 25 30
 Lys Arg Phe Pro Asn Leu Ser Leu Pro Ser Ser Xaa Gln Tyr Lys Cys
 35 40 45
 Ala His His Asn Arg Val Ile Phe Val Phe Leu Val Glu Thr Gly Phe
 50 55 60
 Ser His Val Gly Gln Ala Asp
 65 70

<210> 111
 <211> 95
 <212> PRT
 <213> Homo sapiens

<400> 111
 Thr Gln Thr Ser Pro Val Ala Asp Ala Pro Thr Gly Val Gln Trp His
 1 5 10 15
 Asp Phe Gly Ser Leu Gln Pro Leu Pro Pro Gly Phe Lys Arg Phe Ser
 20 25 30
 Cys Leu Ser Leu Pro Arg Ser Trp Asp Tyr Arg His Pro Pro Pro Arg
 35 40 45
 Pro Ala Asn Phe Glu Phe Leu Val Glu Thr Gly Phe Leu His Val Gly
 50 55 60
 Gln Ala Gly Leu Glu Leu Leu Thr Ser Gly Asp Leu Pro Ala Ser Ala

Ala Trp Val Thr Glu Gly Asp Ser Val Ser Lys Gln Asn Lys Thr Lys
65 70 75 80

<210> 114
 <211> 80
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (15)
 <223> Xaa equals stop translation

<220>
 <221> SITE
 <222> (34)
 <223> Xaa equals stop translation

<220>
 <221> SITE
 <222> (70)
 <223> Xaa equals stop translation

<220>
 <221> SITE
 <222> (76)
 <223> Xaa equals stop translation

<400> 114
 His Leu Arg Ser Gly Val Gln Asp Gln Leu Gly Gln His Gly Xaa Ser
 1 5 10 15
 Pro Ser Leu Leu Lys Val Gln Lys Leu Ala Trp His Gly Gly Met His
 20 25 30
 Leu Xaa Phe Gln Leu Leu Gly Arg Leu Arg Gln Glu Asn Cys Leu Ser
 35 40 45
 Pro Gly Gly Glu Gly Cys Ser Glu Pro Arg Ser His Arg Cys Thr Pro
 50 55 60
 Ala Trp Ala Thr Glu Xaa Asp Ser Val Thr Lys Xaa Asn Ile Asn Lys
 65 70 75 80

<210> 115
 <211> 393
 <212> PRT
 <213> Homo sapiens

<400> 115
 Ala Tyr Cys Lys Gln His Ala Asp Arg Leu Asp Arg Lys Trp Lys Arg
 1 5 10 15
 Lys Asn Tyr Leu Ala Leu Gln Ser Tyr Cys Lys Met Ser Leu Gln Glu
 20 25 30

Arg Glu Lys Gln Leu Ser Pro Glu Ala Gln Ala Arg Ile Asn Ala Arg
 35 40 45
 Leu Gln Gln Tyr Arg Ala Lys Ala Glu Leu Ala Arg Ser Thr Arg Pro
 50 55 60
 Gln Ala Trp Val Pro Arg Glu Lys Leu Pro Arg Pro Leu Thr Ser Ser
 65 70 75 80
 Ala Ser Ala Ile Arg Lys Leu Met Arg Lys Ala Glu Leu Met Gly Ile
 85 90 95
 Ser Thr Asp Ile Phe Pro Val Asp Asn Ser Asp Thr Ser Ser Ser Val
 100 105 110
 Asp Gly Arg Arg Lys His Lys Gln Pro Ala Leu Thr Ala Asp Phe Val
 115 120 125
 Asn Tyr Tyr Phe Glu Arg Asn Met Arg Met Ile Gln Ile Gln Glu Asn
 130 135 140
 Met Ala Glu Gln Lys Asn Ile Lys Asp Lys Leu Glu Asn Glu Gln Glu
 145 150 155 160
 Lys Leu His Val Glu Tyr Asn Lys Leu Cys Glu Ser Leu Glu Glu Leu
 165 170 175
 Gln Asn Leu Asn Gly Lys Leu Arg Ser Glu Gly Gln Gly Ile Trp Ala
 180 185 190
 Leu Leu Gly Arg Ile Thr Gly Gln Lys Leu Asn Ile Pro Ala Ile Leu
 195 200 205
 Arg Ala Pro Lys Glu Arg Lys Pro Ser Lys Lys Glu Gly Gly Thr Gln
 210 215 220
 Lys Thr Ser Thr Leu Pro Ala Val Leu Tyr Ser Cys Gly Ile Cys Lys
 225 230 235 240
 Lys Asn His Asp Gln His Leu Leu Leu Cys Asp Thr Cys Lys Leu
 245 250 255
 His Tyr His Leu Gly Cys Leu Asp Pro Pro Leu Thr Arg Met Pro Arg
 260 265 270
 Lys Thr Lys Asn Ser Tyr Trp Gln Cys Ser Glu Cys Asp Gln Ala Gly
 275 280 285
 Ser Ser Asp Met Glu Ala Asp Met Ala Met Glu Thr Leu Pro Asp Gly
 290 295 300
 Thr Lys Arg Ser Arg Arg Gln Ile Lys Glu Pro Val Lys Phe Val Pro
 305 310 315 320
 Gln Asp Val Pro Pro Glu Pro Lys Lys Ile Pro Ile Arg Asn Thr Arg
 325 330 335
 Thr Arg Gly Arg Lys Arg Ser Phe Val Pro Glu Glu Glu Lys His Glu
 340 345 350

Glu Arg Val Pro Arg Glu Arg Arg Gln Arg Gln Ser Val Leu Gln Lys
355 360 365

Lys Pro Lys Ala Glu Asp Leu Arg Thr Glu Cys Ala Thr Cys Lys Gly
370 375 380

Thr Gly Asp Asn Glu Asn Leu Val Arg
385 390

<210> 116
<211> 393
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (345)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (346)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (347)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (348)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (349)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (350)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (351)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (352)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (353)

<223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (354)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (355)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (356)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (357)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (358)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (359)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (360)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (361)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (362)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (363)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <400> 116
 Ala Tyr Cys Lys Gln His Ala Asp Arg Leu Asp Arg Lys Trp Lys Arg
 1 5 10 15
 Lys Asn Tyr Leu Ala Leu Gln Ser Tyr Cys Lys Met Ser Leu Gln Glu
 20 25 30

Arg Glu Lys Gln Leu Ser Pro Glu Ala Gln Ala Arg Ile Asn Ala Arg
 35 40 45
 Leu Gln Gln Tyr Arg Ala Lys Ala Glu Leu Ala Arg Ser Thr Arg Pro
 50 55 60
 Gln Ala Trp Val Pro Arg Glu Lys Leu Pro Arg Pro Leu Thr Ser Ser
 65 70 75 80
 Ala Ser Ala Ile Arg Lys Leu Met Arg Lys Ala Glu Leu Met Gly Ile
 85 90 95
 Ser Thr Asp Ile Phe Pro Val Asp Asn Ser Asp Thr Ser Ser Ser Val
 100 105 110
 Asp Gly Arg Arg Lys His Lys Gln Pro Ala Leu Thr Ala Asp Phe Val
 115 120 125
 Asn Tyr Tyr Phe Glu Arg Asn Met Arg Met Ile Gln Ile Gln Glu Asn
 130 135 140
 Met Ala Glu Gln Lys Asn Ile Lys Asp Lys Leu Glu Asn Glu Gln Glu
 145 150 155 160
 Lys Leu His Val Glu Tyr Asn Lys Leu Cys Glu Ser Leu Glu Glu Leu
 165 170 175
 Gln Asn Leu Asn Gly Lys Leu Arg Ser Glu Gly Gln Gly Ile Trp Ala
 180 185 190
 Leu Leu Gly Arg Ile Thr Gly Gln Lys Leu Asn Ile Pro Ala Ile Leu
 195 200 205
 Arg Ala Pro Lys Glu Arg Lys Pro Ser Lys Lys Glu Gly Gly Thr Gln
 210 215 220
 Lys Thr Ser Thr Leu Pro Ala Val Leu Tyr Ser Cys Gly Ile Cys Lys
 225 230 235 240
 Lys Asn His Asp Gln His Leu Leu Leu Leu Cys Asp Thr Cys Lys Leu
 245 250 255
 His Tyr His Leu Gly Cys Leu Asp Pro Pro Leu Thr Arg Met Pro Arg
 260 265 270
 Lys Thr Lys Asn Ser Tyr Trp Gln Cys Ser Glu Cys Asp Gln Ala Gly
 275 280 285
 Ser Ser Asp Met Glu Ala Asp Met Ala Met Glu Thr Leu Pro Asp Gly
 290 295 300
 Thr Lys Arg Ser Arg Arg Gln Ile Lys Glu Pro Val Lys Phe Val Pro
 305 310 315 320
 Gln Asp Val Pro Pro Glu Pro Lys Lys Ile Pro Ile Arg Asn Thr Arg
 325 330 335
 Thr Arg Gly Arg Lys Arg Ser Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 340 345 350

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Val Leu Gln Lys
 355 360 365

Lys Pro Lys Ala Glu Asp Leu Arg Thr Glu Cys Ala Thr Cys Lys Gly
 370 375 380

Thr Gly Asp Asn Glu Asn Leu Val Arg
 385 390

<210> 117

<211> 114

<212> PRT

<213> Homo sapiens

<400> 117

Lys Cys Gly Val Ser Pro Ser Cys Glu Leu Cys Pro Asn Gln Asp Gly
 1 5 10 15

Ile Phe Lys Glu Thr Asp Ala Gly Arg Trp Val His Ile Val Cys Ala
 20 25 30

Leu Tyr Val Pro Gly Val Ala Phe Gly Asp Ile Asp Lys Leu Arg Pro
 35 40 45

Val Thr Leu Thr Glu Met Asn Tyr Ser Lys Tyr Gly Ala Lys Glu Cys
 50 55 60

Ser Phe Cys Glu Asp Pro Arg Phe Ala Arg Thr Gly Val Cys Ile Ser
 65 70 75 80

Cys Asp Ala Gly Met Cys Arg Ala Tyr Phe His Val Thr Cys Ala Gln
 85 90 95

Lys Glu Gly Leu Leu Ser Glu Ala Ala Glu Glu Asp Ile Ala Asp
 100 105 110

Pro Phe

<210> 118

<211> 114

<212> PRT

<213> Homo sapiens

<400> 118

Lys Cys Gly Val Ser Pro Ser Cys Glu Leu Cys Pro Asn Gln Asp Gly
 1 5 10 15

Ile Phe Lys Glu Thr Asp Ala Gly Arg Trp Val His Ile Val Cys Ala
 20 25 30

Leu Tyr Val Pro Gly Val Ala Phe Gly Asp Ile Asp Lys Leu Arg Pro
 35 40 45

Val Thr Leu Thr Glu Met Asn Tyr Ser Lys Tyr Gly Ala Lys Glu Cys
 50 55 60

Ser Phe Cys Glu Asp Pro Arg Phe Ala Arg Thr Gly Val Cys Ile Ser
 65 70 75 80

Cys Asp Ala Gly Met Cys Arg Ala Tyr Phe His Val Thr Cys Ala Gln
 85 90 95

Lys Glu Gly Leu Leu Ser Glu Ala Ala Ala Glu Glu Asp Ile Ala Asp
 100 105 110

Pro Phe

<210> 119
 <211> 79
 <212> PRT
 <213> Homo sapiens

<400> 119
 Cys Gly Ile Cys Lys Lys Asn His Asp Gln His Leu Leu Leu Leu Cys
 1 5 10 15

Asp Thr Cys Lys Leu His Tyr His Leu Gly Cys Leu Asp Pro Pro Leu
 20 25 30

Thr Arg Met Pro Arg Lys Thr Lys Asn Ser Tyr Trp Gln Cys Ser Glu
 35 40 45

Cys Asp Gln Ala Gly Ser Ser Asp Met Glu Ala Asp Met Ala Met Glu
 50 55 60

Thr Leu Pro Asp Gly Thr Lys Arg Ser Arg Arg Gln Ile Lys Glu
 65 70 75

<210> 120
 <211> 78
 <212> PRT
 <213> Homo sapiens

<400> 120
 Cys Ala Thr Cys Lys Gly Thr Gly Asp Asn Glu Asn Leu Val Arg Cys
 1 5 10 15

Asp Glu Cys Arg Leu Cys Tyr His Phe Gly Cys Leu Asp Pro Pro Leu
 20 25 30

Lys Lys Ser Pro Lys Gln Thr Gly Tyr Gly Trp Ile Cys Gln Glu Cys
 35 40 45

Asp Ser Ser Ser Ser Lys Glu Asp Glu Asn Glu Ala Glu Arg Lys Asn
 50 55 60

Ile Ser Gln Glu Leu Asn Met Glu Gln Lys Asn Pro Lys Lys
 65 70 75

<210> 121

60

<211> 26
<212> PRT
<213> Homo sapiens

<400> 121
Glu Thr Glu Ser Cys Ser Val Ala Glu Ala Gly Val Gln Trp Cys Asp
1 5 10 15
Leu Gly Ser Leu Lys Ser Pro Pro Pro Gly
20 25

<210> 122
<211> 26
<212> PRT
<213> Homo sapiens

<400> 122
Glu Thr Glu Ser His Ser Val Val Gln Ala Gly Val Gln Trp Arg Asn
1 5 10 15
Leu Gly Ser Leu Gln Pro Pro Pro Pro Gly
20 25

<210> 123
<211> 17
<212> PRT
<213> Homo sapiens

<400> 123
Gly Ser Ser Asp Ser Pro Ala Ser Ala Ser Arg Val Ala Gly Ile Thr
1 5 10 15
Gly

<210> 124
<211> 17
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (11)
<223> Xaa equals stop translation

<400> 124
Gly Ser Ser Asp Ser Pro Ala Ser Xaa Phe Xaa Val Ala Gly Val Thr
1 5 10 15
Gly

<210> 125
<211> 26
<212> PRT
<213> Homo sapiens

<400> 125
Asp Ser Pro Ala Ser Ala Ser Arg Val Ala Gly Ile Thr Gly Met His
1 5 10 15
His His Thr Gln Leu Ile Phe Val Phe Leu
20 25

<210> 126
<211> 26
<212> PRT
<213> Homo sapiens

<400> 126
Asp Leu Pro Thr Ser Ala Ser Pro Ser Ala Gly Ile Thr Gly Val Ser
1 5 10 15
His Cys Ala Arg Leu Thr Val Ser Phe Leu
20 25

<210> 127
<211> 16
<212> PRT
<213> Homo sapiens

<400> 127
His His Thr Gln Leu Ile Phe Val Phe Leu Val Glu Thr Gly Ser His
1 5 10 15

<210> 128
<211> 16
<212> PRT
<213> Homo sapiens

<400> 128
His His Thr Arg Leu Ile Phe Val Phe Leu Val Gly Met Arg Phe His
1 5 10 15

<210> 129
<211> 48
<212> PRT
<213> Homo sapiens

<400> 129

Lys Lys Leu Ile His His Asp Gln Val Gly Phe Ile Pro Gly Met Gln
 1 5 10 15

Gly Trp Phe Asn Ile Arg Lys Ser Ile Asn Val Ile Gln His Ile Asn
 20 25 30

Arg Ala Lys Asp Lys Asn His Met Ile Ile Ser Ile Asp Ala Glu Lys
 35 40 45

<210> 130

<211> 48

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (15)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 130

Lys Arg Ser Ile His His Asp Gln Val Arg Phe Ile Pro Gly Xaa Gln
 1 5 10 15

Gly Trp Phe Asn Ile Asn Lys Ser Ile Asn Val Ile Asn His Thr Ser
 20 25 30

Lys Val Lys Gly Lys Asn His Met Ile Ile Thr Thr Asp Ala Lys Lys
 35 40 45

<210> 131

<211> 23

<212> PRT

<213> Homo sapiens

<400> 131

Leu Pro Asn Ser Phe Tyr Glu Ala Ser Ile Ile Leu Ile Pro Lys Pro
 1 5 10 15

Gly Arg Asp Thr Thr Lys Lys
 20

<210> 132

<211> 23

<212> PRT

<213> Homo sapiens

<400> 132

Leu Pro Asn Ser Phe Tyr Asp Val Gly Ile Thr Leu Ile Pro Lys Arg
 1 5 10 15

Asp Lys Asp Thr Thr Arg Lys
20

<210> 133
<211> 26
<212> PRT
<213> Homo sapiens

<400> 133
Thr Lys Lys Glu Asn Phe Arg Pro Ile Ser Leu Met Asn Ile Asp Ala
1 5 10 15

Lys Ile Leu Asn Lys Ile Leu Ala Asn Arg
20 25

<210> 134
<211> 26
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (14)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (20)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 134
Thr Leu Gln Glu Asn Tyr Arg Ser Ile Ser Leu Met Asn Xaa Tyr Ala
1 5 10 15

Lys Ile Leu Xaa Lys Ile Leu Thr Asn Gln
20 25

<210> 135
<211> 113
<212> PRT
<213> Homo sapiens

<400> 135
Glu Val Phe Lys Ser Asn Asn Val Glu Met Asp Trp Val Leu Lys His
1 5 10 15

Thr Gly Pro Asn Ser Pro Asp Thr Ala Asn Asp Gly Phe Val Arg Leu
20 25 30

Arg Gly Leu Pro Phe Gly Cys Ser Lys Glu Glu Ile Val Gln Phe Phe
35 40 45

Ser Gly Leu Glu Ile Val Pro Asn Gly Ile Thr Leu Pro Val Asp Phe
50 55 60

64

Gln Gly Arg Ser Thr Gly Glu Ala Phe Val Gln Phe Ala Ser Gln Glu
 65 70 75 80
 Ile Ala Glu Lys Ala Leu Lys Lys His Lys Glu Arg Ile Gly His Arg
 85 90 95
 Tyr Ile Glu Ile Phe Lys Ser Ser Arg Ala Glu Val Arg Thr His Tyr
 100 105 110

Asp

<210> 136
 <211> 110
 <212> PRT
 <213> Homo sapiens

<400> 136
 Gln Ala Phe Lys Ser Asn Gly Ile Glu Met Asp Trp Val Met Lys His
 1 5 10 15
 Asn Gly Pro Asn Asp Ala Ser Asp Gly Thr Val Arg Leu Arg Gly Leu
 20 25 30
 Pro Phe Gly Cys Ser Lys Glu Glu Ile Val Gln Phe Phe Gln Gly Leu
 35 40 45
 Glu Ile Val Pro Asn Gly Ile Thr Leu Thr Met Asp Tyr Gln Gly Arg
 50 55 60
 Ser Thr Gly Glu Ala Phe Val Gln Phe Ala Ser Lys Glu Ile Ala Glu
 65 70 75 80
 Asn Ala Leu Gly Lys His Lys Glu Arg Ile Gly His Arg Tyr Ile Glu
 85 90 95
 Ile Phe Arg Ser Ser Arg Ser Glu Ile Lys Gly Phe Tyr Asp
 100 105 110

<210> 137
 <211> 203
 <212> PRT
 <213> Homo sapiens

<400> 137
 Asn Gln Lys Thr Phe Arg Pro Lys Lys Ser Ala Pro Ser Gly Thr Lys
 1 5 10 15
 Gly Ala Glu Leu Arg Lys His Ile Asp Ala Thr Leu Gly Ser Gly Asn
 20 25 30
 Leu Arg Glu Ala Val Lys Leu Pro Pro Gly Glu Asp Leu Asn Glu Trp
 35 40 45
 Leu Ala Val Asn Thr Val Asp Phe Phe Asn Gln Val Asn Leu Leu Phe
 50 55 60

65

Gly Thr Leu Thr Glu Phe Cys Thr Pro Glu Asn Cys Ser Thr Met Thr
 65 70 75 80
 Ala Gly Pro Lys Tyr Glu Tyr Arg Trp Ala Asp Gly Val Gln Ile Lys
 85 90 95
 Lys Pro Ile Glu Val Ser Ala Pro Lys Tyr Val Glu Tyr Leu Met Asp
 100 105 110
 Trp Ile Glu Thr Gln Leu Asp Asp Glu Thr Ile Phe Pro Gln Lys Leu
 115 120 125
 Gly Ala Ala Phe Pro Pro Asn Phe Lys Glu Val Val Lys Thr Ile Phe
 130 135 140
 Lys Arg Leu Phe Arg Val Tyr Ala His Ile Tyr His Ser His Phe Gln
 145 150 155 160
 Lys Ile Val Ser Leu Lys Glu Glu Ala His Leu Asn Thr Cys Phe Lys
 165 170 175
 His Phe Ile Leu Phe Thr His Glu Phe Val Leu Ile Asp Lys Lys Glu
 180 185 190
 Leu Ala Pro Leu Gln Glu Leu Ile Glu Ser Ile
 195 200

<210> 138

<211> 203

<212> PRT

<213> Homo sapiens

<400> 138

Ser Ser Lys Thr Phe Lys Pro Lys Lys Asn Ile Pro Glu Gly Ser His
 1 5 10 15
 Gln Tyr Glu Leu Leu Lys His Ala Glu Ala Thr Leu Gly Ser Gly Asn
 20 25 30
 Leu Arg Gln Ala Val Met Leu Pro Glu Gly Glu Asp Leu Asn Glu Trp
 35 40 45
 Ile Ala Val Asn Thr Val Asp Phe Phe Asn Gln Ile Asn Met Leu Tyr
 50 55 60
 Gly Thr Ile Thr Glu Phe Cys Thr Glu Ala Ser Cys Pro Val Met Ser
 65 70 75 80
 Ala Gly Pro Arg Tyr Glu Tyr His Trp Ala Asp Gly Thr Asn Ile Lys
 85 90 95
 Lys Pro Ile Lys Cys Ser Ala Pro Lys Tyr Ile Asp Tyr Leu Met Thr
 100 105 110
 Trp Val Gln Asp Gln Leu Asp Asp Glu Thr Leu Phe Pro Ser Lys Ile
 115 120 125
 Gly Val Pro Phe Pro Lys Asn Phe Met Ser Val Ala Lys Thr Ile Leu

130 135 140
 Lys Arg Leu Phe Arg Val Tyr Ala His Ile Tyr His Gln His Phe Asp
 145 150 155 160
 Ser Val Met Gln Leu Gln Glu Glu Ala His Leu Asn Thr Ser Phe Lys
 165 170 175
 His Phe Ile Phe Phe Val Gln Glu Phe Asn Leu Ile Asp Arg Arg Glu
 180 185 190
 Leu Ala Pro Leu Gln Glu Leu Ile Glu Lys Leu
 195 200

<210> 139
 <211> 74
 <212> PRT
 <213> Homo sapiens

<400> 139
 Asp Arg Val Leu Leu Cys His Pro Gly Trp Ser Ala Val Val Gln Ser
 1 5 10 15
 Leu Phe Thr Val Ala Ser Thr Phe Leu Val Lys Gln Ser Ser Cys Leu
 20 25 30
 Gly Leu Pro Ser Ser Trp Asp Tyr Arg Arg Ile Pro Pro His Leu Ala
 35 40 45
 Asn Phe Ser Phe Phe Cys Arg Asn Lys Ser Leu Thr Met Leu Pro Arg
 50 55 60
 Leu Ile Leu Asn Ser Trp Pro Gln Val Ile
 65 70

<210> 140
 <211> 73
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (54)
 <223> Xaa equals stop translation

<220>
 <221> SITE
 <222> (61)
 <223> Xaa equals stop translation

<220>
 <221> SITE
 <222> (69)
 <223> Xaa equals stop translation

<400> 140
 Asp Arg Val Trp Leu Cys His Pro Gly Trp Ser Ala Val Val Gln Ser

	1	5	10	15
Trp Leu Thr Ala Ala Ser Thr Ser Trp Gly Gln Ala Ile Leu Leu Ser				
	20		25	30
Leu Pro Pro Ser Ser Trp Asp Tyr Arg His Met Pro Pro Gln Ser Thr				
	35		40	45
Thr Phe Phe Tyr Leu Xaa Arg Gly Gly Phe Ala Met Xaa Pro Arg Leu				
	50		55	60
Val Ser Ser Ser Xaa Ala Gln Ala Ile				
	65	70		

```
<210> 141
<211> 181
<212> PRT
<213> Homo sapiens
```

```

<400> 141
Asp Met Ala Glu Ile Gln Ser Arg Leu Ala Tyr Val Ser Cys Val Arg
 1          5          10          15
Gln Leu Glu Val Val Lys Ser Ser Ser Tyr Cys Glu Tyr Leu Arg Pro
          20          25          30
Pro Ile Asp Cys Phe Lys Thr Met Asp Phe Gly Lys Phe Asp Gln Ile
          35          40          45
Tyr Asp Val Gly Tyr Gln Tyr Gly Lys Ala Val Phe Gly Gly Trp Ser
          50          55          60
Arg Gly Asn Val Ile Glu Lys Met Leu Thr Asp Arg Arg Ser Thr Asp
          65          70          75          80
Leu Asn Glu Ser Arg Arg Ala Asp Val Leu Ala Phe Pro Ser Ser Gly
          85          90          95
Phe Thr Asp Leu Ala Glu Ile Val Ser Arg Ile Glu Pro Pro Thr Ser
          100          105          110
Tyr Val Ser Asp Gly Cys Ala Asp Gly Glu Glu Ser Asp Cys Leu Thr
          115          120          125
Glu Tyr Glu Glu Asp Ala Gly Pro Asp Cys Ser Arg Asp Glu Gly Gly
          130          135          140
Ser Pro Glu Gly Ala Ser Pro Ser Thr Ala Ser Glu Met Glu Glu Glu
          145          150          155          160
Lys Ser Ile Leu Arg Gln Arg Arg Cys Leu Pro Gln Glu Pro Pro Gly
          165          170          175
Ser Ala Thr Asp Ala
          180

```

<210> 142

<211> 181
 <212> PRT
 <213> Homo sapiens

<400> 142
 Asp Met Ala Glu Ile Gln Ser Arg Leu Ala Tyr Val Ser Cys Val Arg
 1 5 10 15
 Gln Leu Glu Val Val Lys Ser Ser Ser Tyr Cys Glu Tyr Leu Arg Pro
 20 25 30
 Pro Ile Asp Cys Phe Lys Thr Met Asp Phe Gly Lys Phe Asp Gln Ile
 35 40 45
 Tyr Asp Val Gly Tyr Gln Tyr Gly Lys Ala Val Phe Gly Gly Trp Ser
 50 55 60
 Arg Gly Asn Val Ile Glu Lys Met Leu Thr Asp Arg Arg Ser Thr Asp
 65 70 75 80
 Leu Asn Glu Ser Arg Arg Ala Asp Val Leu Ala Phe Pro Ser Ser Gly
 85 90 95
 Phe Thr Asp Leu Ala Glu Ile Val Ser Arg Ile Glu Pro Pro Thr Ser
 100 105 110
 Tyr Val Ser Asp Gly Cys Ala Asp Gly Glu Glu Ser Asp Cys Leu Thr
 115 120 125
 Glu Tyr Glu Glu Asp Ala Gly Pro Asp Cys Ser Arg Asp Glu Gly Gly
 130 135 140
 Ser Pro Glu Gly Ala Ser Pro Ser Thr Ala Ser Glu Met Glu Glu Glu
 145 150 155 160
 Lys Ser Ile Leu Arg Gln Arg Arg Cys Leu Pro Gln Glu Pro Pro Gly
 165 170 175
 Ser Ala Thr Asp Ala
 180

<210> 143
 <211> 414
 <212> PRT
 <213> Homo sapiens

<400> 143
 Gly Val His Arg Glu Met Arg Tyr Asn Ser Arg Arg His Leu Ser Arg
 1 5 10 15
 Leu Thr Asp Thr Phe Val Ser Lys Ala Asn Ala Lys Gln Arg Ser Gly
 20 25 30
 Arg Ala Gly Arg Val Gln Glu Gly Ile Cys Tyr His Leu Phe Ser Lys
 35 40 45
 Phe Lys His Asp Thr Gln Phe Leu Ser Tyr Gln Thr Pro Glu Ile Leu
 50 55 60

Arg Leu Asn Leu Gln Glu Val Val Leu Arg Val Lys Met Cys Gln Met
 65 70 75 80
 Gly Asp Val Gln Asp Val Leu Gly Lys Ala Leu Asp Pro Pro Ser Ser
 85 90 95
 Thr Asn Ile Ile Arg Ala Leu Glu Lys Leu His Gln Val Gly Ala Leu
 100 105 110
 Ser Glu Asn Glu Lys Leu Thr Lys Leu Gly Lys Phe Leu Ser Gln Leu
 115 120 125
 Pro Val Asp Ala Asn Leu Gly Lys Ile Leu Val Leu Gly Cys Phe Tyr
 130 135 140
 Lys Cys Val Asp Ala Ala Ser Ser Ile Val Ala Met Leu Thr Ile Gly
 145 150 155 160
 Ser Pro Phe Arg Lys Ser Val Asp Asn Glu Phe Ser Ala Asn Lys Ala
 165 170 175
 Arg Leu Ser Phe Ala Lys Glu Asn Thr Arg Ser Asp Leu Val Leu Met
 180 185 190
 Tyr Tyr Ala Tyr Cys Ala Trp Arg Glu Ile Cys Leu Ser Pro Leu Gly
 195 200 205
 Pro Asp Glu Asp Ser Phe Ala Lys Glu Lys Tyr Leu Asn Leu Glu Ala
 210 215 220
 Leu Ser Met Thr Glu Ser Leu Lys Ile Gln Leu Leu Ser Glu Leu Lys
 225 230 235 240
 Asp Met Lys Leu Leu Gly Ala Ser Asp Val Asp Thr Cys Lys Ser Leu
 245 250 255
 Lys Arg Ser Ile Cys Arg Arg Phe Ala Val Ile Pro Lys Glu His Asp
 260 265 270
 Ile Asn Ser Gly Asn Ala Glu Ile Leu Cys Gly Val Ile Ala Ala Ser
 275 280 285
 Leu Tyr Pro Asn Ile Leu Arg Tyr Asp Tyr Glu Lys Arg Gln Trp Ser
 290 295 300
 Thr Leu Ser Thr Asn Lys Arg Val Arg Ile Leu Asp Val Ser Val Asn
 305 310 315 320
 Asn Arg Ser Glu Leu Pro Asn Met Pro Ser Lys Phe Val Ala Tyr Thr
 325 330 335
 Asn Met Met Ser Ser Thr Arg Ala Ser Glu Tyr Val Asn Glu Thr Thr
 340 345 350
 Met Val Thr Leu Arg Gln Leu Leu Met Met Cys Gly Leu Lys Val Glu
 355 360 365
 Asn Arg Val Ser Val Gly Gln Ala Lys Leu Asp Asn Phe Thr Val Tyr

70

370 375 380
 Phe Glu Asn Val Tyr Val Ser Ala Ser Leu Ser Ile Leu Arg Arg Phe
 385 390 395 400
 Ile Glu Thr Ser Leu Asn Glu Phe Phe Ala Glu Pro Asp Lys
 405 410

 <210> 144
 <211> 429
 <212> PRT
 <213> Homo sapiens

 <400> 144
 Gly Lys Met Lys Glu Lys Arg Tyr Asp Ala Ser Lys Gly Met Glu Ser
 1 5 10 15
 Leu Glu Asp Thr Phe Val Ser Gln Ala Asn Ala Leu Gln Arg Lys Gly
 20 25 30
 Arg Ala Gly Val Val Ala Ser Gly Val Cys Phe His Leu Phe Thr Ser
 35 40 45
 His His Tyr Asn His Gln Leu Leu Lys Gln Gln Leu Pro Glu Ile Gln
 50 55 60
 Arg Val Pro Leu Glu Gln Leu Cys Leu Arg Ile Lys Ile Leu Glu Met
 65 70 75 80
 Phe Ser Ala His Asn Leu Gln Ser Val Phe Ser Arg Leu Ile Glu Pro
 85 90 95
 Pro His Thr Asp Ser Leu Arg Ala Ser Lys Ile Arg Leu Arg Asp Leu
 100 105 110
 Gly Ala Leu Thr Pro Asp Glu Arg Leu Thr Pro Leu Gly Tyr His Leu
 115 120 125
 Ala Ser Leu Pro Val Asp Val Arg Ile Gly Lys Leu Met Leu Phe Gly
 130 135 140
 Ser Ile Phe Arg Cys Leu Asp Pro Ala Leu Thr Ile Ala Ala Ser Leu
 145 150 155 160
 Ala Phe Lys Ser Pro Phe Val Ser Pro Trp Asp Lys Lys Glu Glu Ala
 165 170 175
 Asn Gln Lys Lys Leu Glu Phe Ala Phe Ala Asn Ser Asp Tyr Leu Ala
 180 185 190
 Leu Leu Gln Ala Tyr Lys Gly Trp Gln Leu Ser Thr Lys Glu Gly Val
 195 200 205
 Arg Ala Ser Tyr Asn Tyr Cys Arg Gln Asn Phe Leu Ser Gly Arg Val
 210 215 220
 Leu Gln Glu Met Ala Ser Leu Lys Arg Gln Phe Thr Glu Leu Leu Ser
 225 230 235 240

<213> Homo sapiens

Val	Val	Leu	Ser	Ser	Ala	Ala	Arg	Arg	Arg	Leu	Trp	Gly	Phe	Ser	Glu
1				5					10					15	
Ser	Leu	Leu	Ile	Arg	Gly	Ala	Ala	Gly	Arg	Ser	Leu	Tyr	Phe	Gly	Glu
			20					25					30		
Asn	Arg	Leu	Arg	Ser	Thr	Gln	Ala	Ala	Thr	Gln	Val	Val	Leu	Asn	Val
		35					40					45			
Pro	Glu	Thr	Arg	Val	Thr	Cys	Leu	Glu	Ser	Gly	Leu	Arg	Val	Ala	Ser
	50					55					60				
Glu	Asp	Ser	Gly	Leu	Ser	Thr	Cys	Thr	Val	Gly	Leu	Trp	Ile	Asp	Ala
65					70					75					80

Gly	Ser	Arg	Tyr	Glu	Asn	Glu	Lys	Asn	Asn	Gly	Thr	Ala	His	Phe	Leu
				85				90				95			
Glu	His	Met	Ala	Phe	Lys	Gly	Thr	Lys	Lys	Arg	Ser	Gln	Leu	Asp	Leu
				100				105				110			
Glu	Leu	Glu	Ile	Glu	Asn	Met	Gly	Ala	His	Leu	Asn	Ala	Tyr	Thr	Ser
				115				120				125			
Arg	Glu	Gln	Thr	Val	Tyr	Tyr	Ala	Lys	Ala	Phe	Ser	Lys	Asp	Leu	Pro
				130				135				140			
Arg	Ala	Val	Glu	Ile	Leu	Ala	Asp	Ile	Ile	Gln	Asn	Ser	Thr	Leu	Gly
				145				150				155			
Glu	Ala	Glu	Ile	Glu	Arg	Glu	Arg	Gly	Val	Ile	Leu	Arg	Glu	Met	Gln
				165				170				175			
Glu	Val	Glu	Thr	Asn	Leu	Gln	Glu	Val	Val	Phe	Asp	Tyr	Leu	His	Ala
				180				185				190			
Thr	Ala	Tyr	Gln	Asn	Thr	Ala	Leu	Gly	Arg	Thr	Ile	Leu	Gly	Pro	Thr
				195				200				205			
Glu	Asn	Ile	Lys	Ser	Ile	Ser	Arg	Lys	Asp	Leu	Val	Asp	Tyr	Ile	Thr
				210				215				220			
Thr	His	Tyr	Lys	Gly	Pro	Arg	Ile	Val	Leu	Ala	Ala	Ala	Gly	Gly	Val
				225				230				235			
Ser	His	Asp	Glu	Leu	Leu	Asp	Leu	Ala	Lys	Phe	His	Phe	Gly	Asp	Ser
				245				250				255			
Leu	Cys	Thr	His	Lys	Gly	Glu	Ile	Pro	Ala	Leu	Pro	Pro	Cys	Lys	Phe
				260				265				270			
Thr	Gly	Ser	Glu	Ile	Arg	Val	Arg	Asp	Asp	Lys	Met	Pro	Leu	Ala	His
				275				280				285			
Leu	Ala	Ile	Ala	Val	Glu	Ala	Val	Gly	Trp	Ala	His	Pro	Asp	Thr	Ile
				290				295				300			
Cys	Leu	Met	Val	Ala	Asn	Thr	Leu	Ile	Gly	Asn	Trp	Asp	Arg	Ser	Phe
				305				310				315			
Gly	Gly	Gly	Met	Asn	Leu	Ser	Ser	Lys	Leu	Ala	Gln	Leu	Thr	Cys	His
				325				330				335			
Gly	Asn	Leu	Cys	His	Ser	Phe	Gln	Ser	Phe	Asn	Thr	Ser	Tyr	Thr	Asp
				340				345				350			
Thr	Gly	Leu	Trp	Gly	Leu	Tyr	Met	Val	Cys	Glu	Ser	Ser	Thr	Val	Ala
				355				360				365			
Asp	Met	Leu	His	Val	Val	Gln	Lys	Glu	Trp	Met	Arg	Leu	Cys	Thr	Ser
				370				375				380			
Val	Thr	Glu	Ser	Glu	Val	Ala	Arg	Ala	Arg	Asn	Leu	Leu	Lys	Thr	Asn
				385				390				395			
															400

Met Leu Leu Gln Leu Asp Gly Ser Thr Pro Ile Cys Glu Asp Ile Gly
 405 410 415

Arg Gln Met Leu Cys Tyr Asn Arg Arg Ile Pro Ile Pro Glu Leu Glu
 420 425 430

Ala Arg Ile Asp Ala Val Asn Ala Glu Thr Ile Arg Glu Val Cys Thr
 435 440 445

Lys Tyr Ile Tyr Asn Arg Ser Pro Ala Ile Ala Ala Val Gly
 450 455 460

<210> 146

<211> 460

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (440)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 146

Val Val Ile Arg Gly Ala Arg Arg Leu Trp Gly Phe Ser Glu Ser Leu
 1 5 10 15

Leu Ile Arg Gly Ala Ala Gly Arg Ser Leu Tyr Phe Gly Glu Asn Arg
 20 25 30

Leu Arg Ser Thr Gln Ala Ala Thr Gln Val Val Leu Asn Val Pro Glu
 35 40 45

Thr Arg Val Thr Cys Leu Glu Ser Gly Leu Arg Val Ala Ser Glu Asp
 50 55 60

Ser Gly Leu Ser Thr Cys Thr Val Gly Leu Trp Ile Asp Ala Gly Ser
 65 70 75 80

Arg Tyr Glu Asn Glu Lys Asn Asn Gly Thr Ala His Phe Leu Glu His
 85 90 95

Met Ala Phe Lys Gly Thr Lys Lys Arg Ser Gln Leu Asp Leu Glu Leu
 100 105 110

Glu Ile Glu Asn Met Gly Ala His Leu Asn Ala Tyr Thr Ser Arg Glu
 115 120 125

Gln Thr Val Tyr Tyr Ala Lys Ala Phe Ser Lys Asp Leu Pro Arg Ala
 130 135 140

Val Glu Ile Leu Ala Asp Ile Ile Gln Asn Ser Thr Leu Gly Glu Ala
 145 150 155 160

Glu Ile Glu Arg Glu Arg Gly Val Ile Leu Arg Glu Met Gln Glu Val
 165 170 175

Glu Thr Asn Leu Gln Glu Val Val Phe Asp Tyr Leu His Ala Thr Ala

180	185	190
Tyr Gln Asn Thr Ala Leu Gly	Arg Thr Ile Leu Gly	Pro Thr Glu Asn
195	200	205
Ile Lys Ser Ile Ser Arg Lys	Asp Leu Val Asp Tyr Ile Thr Thr His	
210	215	220
Tyr Lys Gly Pro Arg Ile Val Leu Ala Ala Ala Gly Gly Val Ser His		
225	230	235 240
Asp Glu Leu Leu Asp Leu Ala Lys Phe His Phe Gly Asp Ser Leu Cys		
245	250	255
Thr His Lys Gly Glu Ile Pro Ala Leu Pro Pro Cys Lys Phe Thr Gly		
260	265	270
Ser Glu Ile Arg Val Arg Asp Asp Lys Met Pro Leu Ala His Leu Ala		
275	280	285
Ile Ala Val Glu Ala Val Gly Trp Ala His Pro Asp Thr Ile Cys Leu		
290	295	300
Met Val Ala Asn Thr Leu Ile Gly Asn Trp Asp Arg Ser Phe Gly Gly		
305	310	315 320
Gly Met Asn Leu Ser Ser Lys Leu Ala Gln Leu Thr Cys His Gly Asn		
325	330	335
Leu Cys His Ser Phe Gln Ser Phe Asn Thr Ser Tyr Thr Asp Thr Gly		
340	345	350
Leu Trp Gly Leu Tyr Met Val Cys Glu Ser Ser Thr Val Ala Asp Met		
355	360	365
Leu His Val Val Gln Lys Glu Trp Met Arg Leu Cys Thr Ser Val Thr		
370	375	380
Glu Ser Glu Val Ala Arg Ala Arg Asn Leu Leu Lys Thr Asn Met Leu		
385	390	395 400
Leu Gln Leu Asp Gly Ser Thr Pro Ile Cys Glu Asp Ile Gly Arg Gln		
405	410	415
Met Leu Cys Tyr Asn Arg Arg Ile Pro Ile Pro Glu Leu Glu Ala Arg		
420	425	430
Ile Asp Ala Val Asn Ala Glu Xaa Ile Arg Glu Val Cys Thr Lys Tyr		
435	440	445
Ile Tyr Asn Arg Ser Pro Ala Ile Ala Ala Val Gly		
450	455	460

<210> 147

<211> 53

<212> PRT

<213> Homo sapiens

<400> 147

Phe Phe Ile Phe Phe Phe Arg Asp Arg Val Leu Leu Cys His Pro Gly
1 5 10 15

Trp Ser Ala Val Val Gln Ser Leu Phe Thr Val Ala Ser Thr Phe Leu
20 25 30

Val Lys Gln Ser Ser Cys Leu Gly Leu Pro Ser Ser Trp Asp Tyr Arg
35 40 45

Arg Ile Pro Pro His
50

<210> 148

<211> 43

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (19)

<223> Xaa equals stop translation

<400> 148

Phe Phe Phe Phe Phe Phe Arg Asp Gly Val Leu Ile Cys Cys Pro Gly
1 5 10 15

Trp Ser Xaa Thr Pro Ser Ser Lys Arg Ser Ser Cys Phe Gly Ile Pro
20 25 30

Lys Cys Trp Asp Tyr Arg His Glu Pro Pro His
35 40